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ABSTRACT OF DISSERTATION 
 
 
FORMULATION OPTMIZATION FOR PORE LIFETIME ENHANCEMENT AND 
SUSTAINED DRUG DELIVERY ACROSS MICRONEEDLE TREATED SKIN 
 
Microneedle (MN) enhanced drug delivery is a safe, effective and efficient 
enhancement method for delivery of drug molecules across the skin. The “poke (press) 
and patch” approach employs solid stainless steel MN to permeablize the skin prior to 
application of a regular drug patch over the treated area. It has been previously shown 
that MN can be used to deliver naltrexone (NTX) at a rate that provides plasma 
concentrations in the lower end of the therapeutic range in humans. The drug delivery 
potential of this technique is, however, limited by the re-sealing of the micropores in a 
48-72h timeframe. The goal of the current research was to optimize the formulation for a 
7 day MN enhanced delivery system for NTX either by adding a second active 
pharmacological moiety or by optimizing formulation characteristics alone. Three 
different formulation strategies were explored: formulation pH optimization with NTX; a 
codrug approach with NTX and a nonspecific cyclooxygenase inhibitor, diclofenac (DIC); 
and a topical/transdermal approach with NTX and an enzyme inhibitor of the cholesterol 
synthesis pathway, fluvastatin (FLU). The results indicated that formulation pH cannot be 
used to extend micropore lifetime, although formulation optimization leads to enhanced 
transport and thus drug delivery across MN treated skin. The codrug approach was 
successful in extending the micropore lifetime and further screening of codrug structures 
and formulation optimization helped in selection of a codrug candidate suitable for 
evaluation in animal pharmacokinetic studies.  Local treatment with FLU helped to keep 
the micropores open and enabled delivery of NTX for an extended period. The pores re-
sealed on removal of treatment within a 30-45 minute timeframe, indicating that 
infection/irritation should not be a major issue, as in the case of other topical chemical 
enhancers. Thus, overall it can be concluded that different formulation strategies can be 
utilized to extend micropore lifetime and enhance delivery of drug molecules across the 
skin.  
KEYWORDS: microneedles, naltrexone, transdermal, formulation strategies, micropore 
lifetime 
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Chapter 1 
Statement of problem 
Oral and parenteral drug deliveries are the preferred routes for most 
therapeutically relevant drugs. Both the routes have advantages and disadvantages. 
Oral drug delivery is the easiest mode of treatment for any disease since it doesn’t 
require clinical supervision. The parenteral intravenous administration route is the fastest 
route to get drug into the systemic circulation. However, common disadvantages of oral 
drug delivery include reduced bioavaibility due to first pass effects and gastric irritation 
issues. The need for administration by trained healthcare professional in most cases and 
needlephobia are some of the disadvantages of the parenteral route. Transdermal drug 
delivery provides an alternative to pills and injections. Most of the above mentioned 
disadvantages of oral and parenteral delivery can be taken care of by using transdermal 
delivery. The stratum corneum (SC), the topmost layer of the skin is the most important 
barrier to delivery of drugs across the skin. 1 The molecules that can be delivered across 
the SC are limited by physicochemical properties like size, charge and hydrophobicity. 
Different enhancement techniques like iontophoresis, electroporation, microneedles 
(MN), ultrasound, chemical enhancers etc. open up transdermal drug delivery to a whole 
new class of molecules that are much larger in size, even protein and peptide 
therapeutics, for example. 2 Most of these systems enhance transport by permeabilizing 
the SC, either by physical or chemical methods. 
MN enhancement has been shown to be effective both in vitro as well as in vivo 
for a large number of molecules. Some examples include small molecules like 
naltrexone (NTX), docetaxel, calcein, and lidocaine, to peptides and proteins like insulin 
and a host of other biotherapeutics. 3-6  The “poke and patch” approach of MN 
application involves one time application of MN followed by application of a transdermal 
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patch over the permeabilized skin. It has been investigated over the past decade for a 
whole range of molecules. The research provided insight into formulation aspects of MN 
enhanced delivery that is completely different from passive transdermal delivery. 7 The 
first in-human trial of MN with the above technique further proved the efficacy of MN 
treatment. 4 Therapeutically relevant levels of naltrexone (NTX) were detected in the 
plasma using MN compared to no observed plasma concentrations for delivery across 
intact skin. One major disadvantage, however, was that drug could only be delivered for 
48-72h following one time application of MN. 8, 9 The drug delivery potential of the 
system is severely impaired by the resealing of the micropores or microchannels due to 
normal physiological processes of the skin. Thus, although the method is able to deliver 
drug in therapeutically relevant concentrations, reapplications of MN would be required 
every couple of days to maintain steady state plasma concentrations. 
Several mechanisms could be responsible for the healing of the micropores. The 
rate of pore closure in MN treated skin has been studied utilizing both direct and indirect 
techniques. Depending on the sensitivity of the technique, the type of skin, as well as the 
physical characteristics of the MN, the timeframe has been shown to vary anywhere 
between 30 minutes for unoccluded skin to 72 hours for occluded skin. 10-12 The 
underlying mechanism has not been studied in extensive detail yet. Recent studies from 
our laboratory suggest that up-regulation of cyclooxygenase (COX) enzymes in a wound 
model leads to local subclinical inflammation and a faster rate of micropore healing. 
Utilizing a nonspecific COX inhibitor, diclofenac (DIC) sodium, it has been shown that 
the rate of skin re-sealing can be decreased and NTX can be delivered over a 7 day time 
period. 8, 13, 14 
The main goal of this research project was to understand and optimize formulation 
characteristics for sustained transport across MN treated skin via the “poke and patch” 
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approach. The ideal transdermal drug delivery goal would be sustained delivery for 7 
days following one time application of the MN. The model compound for the project was 
NTX. It is a µ-opioid receptor antagonist and is approved for treatment of alcohol and 
opioid addiction. 15 NTX is an ideal transdermal candidate since it has bioavailability and 
gastric irritation issues related to the currently approved oral dosage form. 16 The 
recently approved extended release intramuscular injection form has issues with 
injection site reactions, and is difficult to remove if there is an emergency opiate 
requirement. 17 Since it has already been shown that NTX can be delivered for 2-3 days 
using MN, and development of a 7 day system for alcohol addiction would be ideal, NTX 
was chosen as the model compound for the current project. 
Various mechanisms were exploited for sustained delivery of the model compounds. 
Formulation pH is known to affect rate of skin recovery following SC removal via tape 
stripping or acetone treatment. 18 Therefore the role of pH was exploited as a potential 
pore lifetime enhancement technique in a MN treated skin model. The role of COX 
inhibitor, DIC as a micropore lifetime enhancer has been established in the literature. 
However, NTX and DIC are physico-chemically incompatible in coformulation. NTX is a 
weak base with a most acidic pKa of 7.5 and DIC is an acid with a pKa of 4.2. 19 As a 
result, it is impossible to formulate the two drugs in high concentrations into a single 
formulation around a pH of 5, the pH of the outer surface of the skin. 20 Precipitation of 
diclofenac on co-administration leads to a decreased flux across MN treated skin. 14, 21, 22 
A codrug approach was explored in order to solve the formulation issue. Codrugs or 
mutual prodrugs are formed when two active pharmaceutical moieties are linked 
together via a covalent linkage to solve a drug delivery problem. 23 Once inside the body 
they cleave back due to chemical and enzymatic hydrolysis to regenerate back the 
parent compounds. The third aspect was to explore the mechanism of local inhibition of 
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lipid synthesis pathways as a mode of delaying recovery of the SC barrier. The correct 
ratio of SC lipids is the most important factor regeneration of the SC barrier following 
insult. 24 It has been shown in the literature that enzymes of the lipid synthesis pathway 
are up-regulated following SC insult and local application of inhibitors led to delayed 
barrier recovery.25  Thus topical application of inhibitors was used in a MN treated skin 
model to evaluate its role in micropore healing. 
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Chapter 2 
Research hypotheses 
 The overall goal of the project was to optimize the formulation for development of 
a 7-day transdermal drug delivery system using microneedles (MN). Three different 
approaches were utilized to enhance micropore lifetime under occlusion following MN 
treatment. The current studies helped to provide a better understanding of MN-enhanced 
drug delivery and barrier recovery following MN treatment, as compared to other 
methods of stratum corneum (SC) disruption.  
The research was driven by the following hypotheses: 
Hypothesis 1: Formulation pH/ionization state can be utilized to enhance flux of 
naltrexone (NTX) and delay pore closure across MN treated skin  
A pH of 7.4 is known to delay barrier recovery following acetone treatment or 
tape stripping, as compared to the skin surface pH of 5.0. This is due to decreased 
activity of β-glucocerebrosidase, an important enzyme of the lipid biosynthesis pathway, 
at pH 7.4. NTX is a weak base with the most acidic pKa of 7.5. Therefore the drug is 
more than 99% ionized at pH 5.0 and almost 50% unionized at pH 7.4. Several 
physicochemical factors like molecular weight, charge/ionization state, hydrophobicity, 
solubility, etc. influence diffusion of drug across intact skin. The effect of ionization state 
of the molecule on transport and permeability has been well studied in case of passive 
transdermal delivery systems. Permeability of ionized molecules across intact skin is 
lower compared to unionized molecules, due to hydrogen bonding and repulsion of 
negatively charged molecules across the skin barrier. However, in case of MN enhanced 
transdermal drug delivery, the mechanism of drug movement is different. Higher 
solubility of ionized molecules in an aqueous media translates into higher flux, due to 
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increased driving force in case of MN treated skin. However, the effect of ionization state 
on movement across micropores has not been studied. It is hypothesized that there will 
be no significant difference in permeability of ionized molecules across MN treated skin, 
however higher solubility will translate into enhanced flux using the ionized form of NTX 
in the lower pH range. On the other hand, pH 7.4 will be effective in delaying micropore 
closure compared to pH 5.5, thus extending the drug delivery window. Therefore, pH 7.4 
will be beneficial for development of a 7-day transdermal system even with 
comparatively lower flux.  
Hypothesis 2: Codrugs of NTX and diclofenac (DIC) can be used for pore lifetime 
enhancement and sustained NTX delivery 
 NTX can be delivered transdermally using MN for 2-3 days from a single patch. 
DIC sodium, a non-steroidal anti-inflammatory drug has been shown to enhance 
micropore lifetime up to 7 days under occlusion, following one time application of MN, 
both in animal models and humans. However, NTX and DIC are physicochemically 
incompatible. NTX is a weak base with the most acidic pKa being 7.5 and DIC is a weak 
acid with a pKa of 4.2. Therefore at the preferred topical preparation skin surface pH of 
4.5-5.5, DIC has limited aqueous solubility and precipitation occurs on simultaneous 
application of both the compounds. Codrugs or mutual prodrugs are new chemical 
moieties synthesized by joining two active pharmacological ingredients. This helps in 
keeping them stable in formulation, and once inside the body, they convert back to 
parent drugs via enzymatic and chemical hydrolysis. It is hypothesized that synthesis of 
NTX-DIC codrugs will help solve the drug delivery issue. Once in the skin, local 
concentration of DIC will keep the micropores open and NTX will be delivered 
systemically. Structure design optimization will help in selection of a codrug with 
7 
 
optimum stability, solubility, transdermal flux of NTX and skin concentration of DIC for 
development of a 7-day drug delivery system for NTX via MN.  
Hypothesis 3: Lipid synthesis inhibitors can be used to delay resealing of 
micropores and sustain NTX delivery 
 The stratum corneum (SC) is the most important barrier to delivery of most drugs 
across the skin. It is formed of dead keratinized remains of once rapidly dividing 
epidermal cells bound together by a lipid matrix. The main lipids of the SC are 
ceramides, fatty acids and cholesterol. A 1:1:1 molar ratio of the SC lipids is crucial for 
its barrier properties and recovery of barrier function following insult. In a tape 
stripping/acetone treatment model of SC disruption, inhibitors of the lipid synthesis 
pathway have been shown to delay recovery of barrier function. MN is an alternate 
method of SC disruption where small micron-scale needles are used to permeablize the 
SC. It is hypothesized that local application of fluvastatin (FLU), an inhibitor of the 
cholesterol synthesis pathway, will delay micropore healing, similar to the tape stripping 
model and allow NTX delivery over a 7-day period. Since irritation of skin and recovery 
of the barrier function following removal of treatment are some of the concerns 
associated with use of biochemical enhancers, follow up studies will be conducted to 
evaluate these issues. It is hypothesized that on removal of occlusion, the increase in 
transepidermal water loss will lead to fast and efficient recovery of the SC barrier 
properties.  
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Chapter 3 
Research plan 
3.1 Method development and utilization of impedance spectroscopy to evaluate 
the effect of formulation pH on micropore healing in vivo in a Yucatan miniature 
pig model 
 Development of surrogate methods to monitor micropore lifetime in addition to 
pharmacokinetic studies are imperative for faster screening of drugs and development of 
delivery systems. Impedance spectroscopy (IM) is a fast, efficient, noninvasive and cost 
friendly method for measuring the resistance across the skin. Intact skin has the highest 
resistance with very limited flow of ions, microneedle (MN) treatment leads to formation 
of micropores and a significant drop in resistance of the skin. Thus, the rate of skin 
healing or micropore lifetime can be monitored by obtaining regular measurements using 
IM. The rate of skin healing under occlusion will be monitored at 3 different pH values: 
pH 5.5, pH 6.5 and pH 7.4 using 3% hydroethylcellulose gels of 0.1M citrate buffer. 
Three MN treated sites (100 MN pores per site) and one untreated control site will be 
used for each formulation per experiment. IM readings will be obtained immediately 
before, following treatment and every 24h up to 100h. Sites will be cleaned with gauze 
before each measurement, and occluded using an occlusive patch after re application of 
gel following measurements.  Care will be taken to limit the exposure of all sites to air 
between readings. The data will be analyzed using the following model to obtain 
micropore resistance.        
 
 
    
 
 
     
 
     
      
. Where Zskin will be obtained from the 
intact skin value under the same treatment condition at each time point, Zbox=200kΩ 
resistance box and Ztotal is the raw value obtained on the meter. Admittance 
(1/Impedance) values will be used to compare pore closure kinetics among formulations. 
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3.2 Evaluation of the effect of formulation pH/ionization state of NTX on solubility, 
flux and permeability in vitro and modeling of the permeability data across MN 
treated and untreated skin using the permeability of ionized and unionized form of 
the drug 
 Unionized molecules have higher permeability through intact skin compared to 
their ionized counterpart. However, the effect of ionization state on permeability is not 
well understood across MN treated skin. Saturated NTX solutions in 0.3M citrate buffer 
at 6 different pH values over a pH range of 5.5 to 8.5 will be evaluated to determine 
solubility, viscosity, and transdermal flux across MN treated and intact skin. Viscosity will 
be determined using a Brookfield DV-III LV programmable cone/plate rheometer and a 
CPE-40 spindle. Viscosity is quantified since across MN treated skin, high viscosity is 
known to decrease transdermal flux. Transdermal permeation studies will be carried out 
using a flow through diffusion cell system and Yucatan miniature pig skin. Drug 
concentration from solubility and permeation studies will be quantified using reverse 
phase HPLC. Steady state flux will be obtained from plotting cumulative permeation vs. 
time for both MN treated skin and intact skin. Total flux and intact skin values will then be 
used to determine microchannel pathway flux. Flux values across MN treated skin and 
untreated control will be used to compare formulation across the pH range. Permeability 
values will also be obtained for intact skin pathway and microchannel pathway. 
Permeability values for the ionized and unionized form of the drug across the two 
pathways will be then used to model the permeability data across the pH range. The 
model will enhance our understanding of differences in drug movement across MN 
treated skin compared to intact skin 
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3.3 Proof of concept to evaluate the effectiveness of naltrexone (NTX) diclofenac 
(DIC) codrugs for sustained drug delivery across MN treated skin 
 MN enhancement allows NTX to be delivered for 2-3 days across the skin after 
one time application. DIC helps in further enhancement of the micropore lifetime up to 7 
days. Since they are not compatible in formulation, codrugs of NTX and DIC will be 
synthesized to obtain formulation stability and delivery of NTX from a single patch for 7 
days across MN treated skin. A 3-O-ester linked codrug will be synthesized for proof of 
concept studies. The codrug will be evaluated for formulation stability in a 0.3M acetate 
buffer pH 5.0 to estimate the conversion in formulation due to chemical hydrolysis. 
Stability will also be determined in hairless guinea pig (HGP) plasma to evaluate 
enzymatic hydrolysis in addition to chemical hydrolysis. The codrug will be tested for 
transdermal flux of NTX and local skin concentration of DIC using a flow through 
diffusion cell system and Yucatan miniature pig skin. Steady state naltrexone flux will be 
quantified and compared with optimized NTX formulations for MN treated skin. Changes 
in skin concentration will be monitored over time and local skin concentration values will 
be used to correlate in vitro data with in vivo effect on micropore lifetime. The formulation 
will be optimized to obtain low viscosity formulations, and salt forms of the drug will be 
synthesized with the ultimate goal of maximizing solubility and transdermal flux. All in 
vitro diffusion samples will be quantified using reverse phase HPLC. Finally, a proof of 
concept pharmacokinetic study will be carried out in a HGP to evaluate the codrug 
approach as a drug delivery system for MN treated skin. The HGP will be stained with 
gentian violet/India ink at the end of the study to confirm presence/absence of pores on 
the skin. Both the dyes stain epidermis but not dead SC, so a grid will only be observed 
in the presence of micropores on the skin 
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3.4 Optimization of codrug structures based on physicochemical properties and 
flux of NTX/ naltrexol (NTXol) 
 Based on the results from the proof of concept study (3.4), the codrug structure 
will be optimized for stability in formulation, solubility of codrug, transdermal flux of NTX/ 
NTXol and local skin concentration of diclofenac. Since a secondary alcohol covalent 
link is more stable as compared to a phenolic link, due to resonance stabilization of 
phenol as a leaving group, the 6-O-position of NTXol, an active metabolite of NTX will be 
utilized to stabilize codrugs. NTXol has a longer half-life in the body and is known to be 
pharmacologically active in the treatment of alcohol addiction. In addition to ester 
linkages, carbamate and amide linkages will be explored to join the two codrugs for 
stability enhancement. Polyethylene glycol (PEG) will be used as the linker molecule to 
serve the dual role of solubility and stability enhancement. Stability, permeation and skin 
concentration data will be evaluated to determine a structure permeability relationship for 
NTX-DIC codrugs as well as selection of a candidate for further in vivo evaluation  
3.5 Formulation optimization for treatment with fluvastatin (FLU), a 3-hydroxy-3-
methyl-glutaryl-CoA (HMG CoA) reductase inhibitor in presence of NTX 
 Topical applications of inhibitors of the lipid biosynthesis pathway have been 
shown to delay barrier recovery following tape stripping. FLU is an inhibitor of the 
cholesterol synthesis pathway. FLU will be used in combination with NTX for micropore 
lifetime enhancement and development of a 7-day drug delivery system for NTX 
following MN treatment. NTX permeation and skin concentration of NTX and FLU will be 
quantified from four different formulations to determine the best method of FLU 
application for in vivo pharmacokinetic studies. NTX flux will be determined across MN 
treated Yucatan miniature pig skin using a flow through diffusion cell system. Both drugs 
will be quantified using reverse phase HPLC. Five different treatment groups will be 
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used with 4 different methods of FLU application and a NTX control. All cells will be MN 
treated (100 pores total) and 3% hydroxyethlycellulose gel of NTX will be applied either 
following FLU application or directly after treatment. Drug loading and amount for all 
vehicles of FLU will be constant; 40µl of 1.5% solution of FLU will be used per diffusion 
cell. The vehicles to be used for FLU are 200 proof ethanol, acetone, propylene glycol 
(PG): ethanol=7:3 and PG: ethanol: water=1:3:1. Steady state flux and skin 
concentration of FLU will be evaluated to choose the most appropriate formulation for in 
vivo pharmacokinetic studies.  
3.6 Pharmacokinetic analysis to study the effect of FLU on transport across MN 
treated skin over a 7 day period 
 Pharmacokinetic (PK) studies are required to establish the effectiveness 
of FLU in vivo as a micropore lifetime enhancement agent. Following the identification of 
a method for FLU deposition (3.5), in vivo pharmacokinetic studies will be carried out in 
a HGP model. Three different treatment groups will be used. A treatment group to 
evaluate the effectiveness of FLU as a pore lifetime enhancement agent, a vehicle 
control group to evaluate the effect of FLU vehicle on drug delivery, and a control group 
with only NTX. For all studies, HGP will be treated at 2 sites, 100 MN per site. The sites 
will be cleaned with ethanol pads and treated with MN. NTX gel will be applied either 
following FLU/vehicle or directly. The sites will be covered with occlusive patches and 
Bioclusive™ will be used to hold the patches in place. Blood samples will be obtained at 
regular intervals of time up to 7 days. Plasma will be separated from blood via 
centrifugation and stored at -80ºC until analysis. All plasma samples will be analyzed 
using LC/MS-MS consisting of a Waters Alliance 2695 Separations Module HPLC and a 
Waters Micromass® Quattro MicroTM API Tandem Mass Spectrometer. Multiple 
reaction monitoring (MRM) will be carried out with the following parent to daughter ion 
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transitions for NTX m/z 341.8→323.8. The plasma concentration vs. time data obtained 
will be modeled by fitting data to a non-compartmental model with extravascular input 
(WinNonlin Professional, version 4.0, Pharsight Corporation, Mountain View, California) 
to obtain pharmacokinetic parameters, including area under the curve (AUC), maximum 
concentration (Cmax), and time to maximum concentration (Tmax).  
3.7 Evaluation of the irritation potential and recovery of the skin following 
treatment with MN and FLU 
 FLU is a biochemical enhancer which inhibits or down regulates 
cholesterol synthesis. Since cholesterol is an important lipid of the SC barrier, down 
regulation leads to malformation of the SC barrier. Transepidermal water loss (TEWL) 
and colorimetry will be used in a HGP model to assess the recovery of the skin and 
irritation potential respectively, following FLU treatment. Five different treatments will be 
compared:  MN+NTXgel+FLU (200 proof ethanol), MN+NTX gel+200 proof ethanol, 
MN+placebo gel, no MN treatment + placebo gel and occlusion only. TEWL and 
colorimeter readings will be obtained before and immediately following treatment. The 
concentration and amount of NTX gel and FLU will be consistent with the PK studies. All 
sites will be occluded for 7 days, TEWL and colorimetry measurements will be obtained 
for 30-45 min at all sites or until values return to baseline (pretreatment values) following 
patch removal.  
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Chapter 4 
Background and literature review 
Human skin is one of the most formidable barriers that protects human beings 
from a vast array of physical and chemical insults on a day to day basis. It is also the 
largest organ of the body and transport of molecules across the skin delivers them 
directly into the systemic circulation. 1 Thus on one hand while the skin is very important 
in protecting the internal homeostasis of the body, on the other hand it can be very 
effective for delivery of xenobiotics/drugs into the body. Depending on the intended site 
of action, drug delivery across the skin is divided into two categories. When drug is 
applied to the skin for local therapy it is known as topical drug delivery whereas when 
drug is intended for systemic effects it is known as transdermal drug delivery. 1 Both of 
the mechanisms are equally effective. Topical delivery is useful when the disease is 
restricted to the outer layers of the skin and deep penetration of drug is not desired 
because it might lead to unwanted side effects. Transdermal drug delivery (TDD) on the 
other hand is a potential alternative route for a host of drug molecules that cannot be 
delivered via the oral or injectable route. Drug is delivered directly into the systemic 
circulation via the transdermal route thus metabolism in the liver (first pass effects) is no 
longer an issue. TDD also results in zero order drug release and steady state plasma 
concentrations over the entire length of the treatment or patch wear time, compared to 
the peaks and troughs of oral delivery dosing. Transdermal drug delivery is also known 
to result in better patient compliance. 23 
4.1 The evolution of transdermal drug delivery  
 The basic principle behind TDD has been utilized for a long time in the form of 
ointments and plasters with reports of mustard plasters for chest congestion and 
belladonna plasters as analgesics. 26 The basic mechanism remains the same where 
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drug is transported across a barrier, the skin in this case, from a region of higher 
concentration on the surface of the skin to a region of lower concentration or pseudo-
sink conditions inside the body. 26 Transdermal drugs were formally introduced onto the 
market in 1979 with the approval of the scopolamine patch for motion sickness. 
Subsequently the transdermal market was revolutionized in the 1990’s with the 
introduction of the nicotine patch for smoking cessation. 27 The nicotine patch had a 
significant positive impact in an addict population that suffered from compliance issues 
and side effects from alternative nicotine delivery systems. 28 Since then a number of 
molecules have been introduced into the transdermal market. A wide range of 
therapeutic areas from hormones like estradiol and testosterone, to pain medications like 
fentanyl, and attention deficit hyperactivity disorder treatment like methylphenidate, etc 
are now delivered transdermally. 29 Figure 4.1 shows the total number of drug molecules 
or combinations approved over the years. A complete list of all transdermal and topical 
dosage forms indicates that 26 active ingredient/ active ingredient combinations are 
currently available on the market. 29 
 
 
16 
 
 
Figure 4.1 Cumulative number of transdermal drugs approved by the FDA since 
the first approval in 1979. There are currently 19 drugs and drug combinations 
administered by various delivery methods that are approved in the United States. Data 
were obtained from the FDA Orange Book. 
Reprinted with permission from Nat Biotech 2008;26(11):1261-1268. 
 
In the last few years, there has been a decline in the number of new active 
pharmaceutical ingredients (API’s) being introduced into the transdermal market due to 
the limited permeability of most molecules across the SC barrier. Physical or chemical 
enhancement techniques are now being developed to facilitate the permeation of drug 
molecules across the SC. These techniques disrupt the SC barrier via 
mechanical/electrical force or chemical modulation and provide an additional advantage 
over passive transdermal delivery because molecular size is no longer a restriction for 
delivery across the skin. This was further established with the introduction of Fluzone®, 
a microneedle (MN) assisted vaccine delivery system, into the transdermal vaccine 
market in 2012.29, 30 
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4.2 Structure of the skin 
  The skin is the largest organ of the body and carries out a wide array of 
functions. 1 It is a formidable barrier to infiltration of chemicals, microbes and is 
responsible for containment of body heat and water. It is a very sensitive organ due to 
the presence of a wide array of pressure and tactile receptors. Knowledge of the basic 
structure of the skin helps to better understand skin function. For drug delivery purposes 
the structure of the skin is best described using a three layer model. From top down, 
they are stratum corneum (SC), epidermis and the dermis. 
4.2.1 Stratum corneum 
The SC is the most important barrier to delivery of drugs across the skin. It is 
around 10µm in thickness with slight variability across different regions on the body. The 
SC is 15—20 layers deep and undergoes continuous renewal with an average timeframe 
of 14 days for complete turnover. This layer is mainly composed of dead keratinized 
remains of rapidly dividing epidermal cells bound together by a lipid matrix.  The major 
SC lipids are ceramide (50%), cholesterol (25%) and fatty acids (10-20%) by weight. 24 
The well-knit cell structure of the SC, with keratinocytes bound in place by the lipid 
matrix gives it a “brick and mortar” structure. The structure minimizes the excessive loss 
of water or heat from the body. However, the skin continuously loses water due to 
insensible perspiration at the rate of 0.5mg/cm2/h. Under occlusive dressing this leads to 
excessive water retention or hydration of the skin. 1, 31 
4.2.2 Epidermis 
The epidermis is the next layer of the skin after SC, although from a skin 
physiology perspective the SC is considered a part of the epidermis itself. This layer is 
around 100µm thick, avascular and is primarily composed of live keratinocytes and a 
wide array of lipid synthesizing precursors and enzymes. It can be divided into four 
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layers under a microscope. From outer surface down they are stratum lucidum, stratum 
granulosum, stratum spinosum and stratum germinatavam. The stratum lucidum forms a 
flat interface with the SC, whereas the stratum germinatavam forms a papillose interface 
with the dermis, a characteristic feature of the human skin. 1The epidermal layer is 
responsible for self-healing with the help of formation of new cells in the lower layers and 
progressive maturation ultimately leading to death and integration in the SC. Lipids 
responsible for formation of the SC are synthesized and undergo differentiation during 
the epidermal transit of live keratinocytes. 25 Apart from the keratinocytes, the epidermis 
is also rich in Langerhans cells making it immunologically active, and melanocytes giving 
individuals their characteristic skin color. 1 Hair follicles and eccrine glands have an 
epidermal origin thus forming an additional pathway for drug transport across the skin. 
The epidermis is more hydrophilic and diffusivity of molecules across the viable 
epidermis is 4 fold higher compared to SC. As a result the epidermis sometimes acts as 
a barrier to extremely lipophilic molecules.  
4.2.3 Dermis 
The dermis is about 1000µm thick and is responsible for providing support and 
nutrition to the top layers of the skin. It is mostly composed of collagen, elastin and 
reticulum which give the skin its characteristic elasticity and structure. The 
microcirculatory system serving the skin is located in the dermal region of the skin. In 
addition to the systemic circulation the skin also possesses an extensive lymphatic 
system and a network of sensory nerves. The circulatory system of the skin is important 
for transdermal delivery because it picks up molecules that cross the SC/ epidermal 
barrier and transfers them directly into the systemic circulation. The major arteries/veins 
are located in the subcutaneous connective tissue below the dermis but they form a 
subpapillary network in the dermis and fine branched loops act as a circulatory system at 
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the interface of the dermis and the epidermis. Blood circulation reaches to within about 
150µm of the skin surface and the normal bold flow is about 0.05ml/min/g of skin tissue.1 
4.2.4 Skin appendages 
 Hair follicles, sebaceous glands, eccrine glands and apocrine glands form the 
skin’s appendages. Hair is present all over the skin surfaces except for high friction 
surfaces like the palms of the hands or soles of the feet. The appendages roughly 
occupies about 0.1% of the total surface area of the body. Hair, like the SC, is also made 
up of keratin and originates from a hair follicle. Each hair follicle has one or more 
sebaceous glands responsible for sebum production.  Eccrine or sweat glands are also 
present throughout the skin and are mainly responsible for maintaining the temperature 
of the internal environment. Apocrine glands are localized to the axilla and anogenital 
regions. Secretion from the glands mixes with the sebum and leads to the characteristic 
body odor on bacterial decomposition. 1 
4.2.5 Enzymes in the skin 
The epidermal layer of the skin is avascular but metabolically active. The 
enzymatic activity in the epidermis is very important for drug bioconversion/metabolism. 
Most enzymes found in the body are also found in the skin, however the amount of each 
enzyme found in the skin is different from their proportions in the body. Examples 
include phase I enzymes like cytochrome P450 (CYP), Non-P450, cyclooxygenases 
(COX), alcohol dehydrogenase (ADH), esterases/ amidases and phase II enzymes like 
glutathione S-transferase (GST), UDP-Glucoronosyltransferase (UGT) and n-
Acetyltransferase (NAT). 32 Distribution studies reveal that xenobiotic metabolizing 
enzymes like CYP exhibit similar qualitative presence in mouse and human cells. 33 
Hydrolytic enzymes like esterase, oxidase and reductase are found 40-120µm from the 
surface of the skin indicating that these enzymes are present in the basal layer of the 
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epidermis, and drugs will be potentially metabolized before reaching the systemic 
circulation.34-36  
 
Figure 4.2 Crosssection of skin and epidermis  
Reprinted with permission from Mayo Clin. Proc. 1995 70; 6:581-586. 
 
4.3 Passive delivery and the mathematics of passive diffusion 
Most transdermal drugs currently on the market are delivered via passive 
diffusion, i.e. they move across the skin barrier due to a concentration gradient. Such 
diffusion across the skin can be attributed to three distinct pathways across the skin. 37 
The intercellular route is the most important route of drug delivery across the SC. Drug 
molecules are transported through a tortuous pathway across the lipid matrix of the S  
and finally partitions into the more hydrophillic layers of the viable epidermis and 
subsequently the dermis. This is the preferred route for molecules having a log P  0.5-
3.5. For extremely lipophilic molecules (log P> 5), however this poses a problem since 
molecules partition into the SC but cannot partition back into the hydrophilic environment 
of the lower layers. The second route is the transcellular pathway where drug molecules 
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move through the different layers of the skin by partitioning repeatedly between the 
hydrophobic lipids in the SC and the relatively hydrophilic keratinocytes. The third route 
is the transfollicular route or the transport of drug molecules through the appendages in 
the skin, mainly the hair follicles. This is hypothesized as the primary route for transport 
of polar molecules across the skin. Thus, in spite of the advantages of transdermal 
delivery, drug delivery across this route is limited to a handful of molecules. 1 
 
Figure 4.3 Simplified diagram of stratum corneum and two microroutes of drug 
penetration 
 
Reprinted with permission from European Journal of Pharmaceutical Sciences 2001 9; 
14(2):101-114. 
 
Diffusion across the skin barrier is mathematically quantified using Fick’s laws of 
diffusion. 38 For mathematical purposes, the skin barrier in most cases is considered as 
a single diffusional barrier, with the formulation as donor on the top of the skin and blood 
as the receiver in the dermis. Depending on the nature of analysis, transport is modeled 
either as a one dimensional or a multi-dimensional phenomenon. For ease of solution, 
steady state flux is usually quantified in order to compare formulations. Cumulative 
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amount of the drug permeated is plotted as a function of time. Steady state flux is 
estimated using the slope of the steady state portion of the graph 
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)       
Where Jss is the steady state flux, A is the active surface area of diffusion, M is the mass 
transport across the skin, P is the permeability of the molecule and Δ  is the 
concentration difference between the donor and the receiver. The flow of the receiver 
can be adjusted to maintain sink conditions at all times so that Δ  is the concentration of 
the drug in the donor. Therefore, permeability can be calculated for a molecule using the 
above equation by experimentally determining the steady state flux and donor 
concentration. 
   
   
 
 
The permeability constant P, can be further analyzed using the above equation. D is the 
diffusivity of the molecule, h is the thickness of the skin barrier and K is the partition 
coefficient of the molecule between the SC lipid and the vehicle which in case of 
transdermal delivery is often estimated using the octanol-water partition coefficient. 
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Figure 4.4 Steady state flux and lag time calculation from cumulative amount vs. 
time plot 
4.4 Enhancement techniques 
The passive delivery of drugs via the transdermal route is limited by the 
therapeutic dosage and physicochemical properties of the API.  Limitations of passive 
transdermal delivery have led to the use of physical and chemical enhancement 
techniques. These techniques employ an additional physical/chemical mechanism to 
enhance the permeability of the skin for most drugs. Physical enhancement techniques 
employ a mechanical/electrical force to permeablize the skin while chemical enhancers 
modify the structure of the skin to enhance permeability.  
4.4.1 Physical enhancement techniques 
Physical enhancement techniques are employed in order to deliver polar/large 
molecules, since SC removal shows higher permeation enhancement, or to reduce the 
lag time following application of a transdermal patch. Some examples of physical 
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enhancement techniques that have been widely explored include iontophoresis, 
sonophoresis, electroporation and microneedles (MN).  
4.4.1. A Iontophoresis 
Iontophoresis uses continuous application of low voltage current for transport of 
drug molecules across the skin. Molecules move either via electrophoresis or electro- 
osmosis and the method is most applicable for small charged molecules or larger 
molecules up to a few thousand Daltons. Compared to passive transdermal delivery 
where the concentration of the drug in the donor is the driving force, the potential drop 
across the skin acts as the driving force in iontophoretic delivery. Saturated donor 
solutions are not used since they lead to a bottleneck effect and flux is optimized using 
the current applied. 39 There are several advantages of using iontophoresis over other 
methods of active delivery. At low voltage, it does not change the structure of the 
stratum corneum for short durations of treatment, thus the skin irritation potential of the 
method is low and the rate of delivery can be controlled by modulating the potential drop 
across the skin (microprocessor/ self-control). 2 A current at the rate of 0.05-0.12 
mA/cm2 has been shown to not cause any significant skin irritation for the duration of 
30minutes. 40 A few iontophoretic delivery systems have been approved by the FDA in 
the past. Examples include Iontocaine® and Lidosite® systems with lidocaine, a local 
anesthetic and epinephrine for topical delivery. However both systems have been 
discontinued since 2006.27 Zecuity®, a sumatriptan iontophoretic transdermal system 
was approved by the FDA in 2013 for acute treatment of migrane. The approval was 
based on phase III clinical trial data indicating effectiveness of the iontophoretic device 
containing drug compared to the placebo at 2 hour following treatment. The product will 
be available in late 2013 from NuPathe. The main disadvantage of the method, however, 
is if higher voltages are required to achieve therapeutic concentrations, it could lead to 
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disruption of the lipid structure of the SC, thus leading to irritation and sensitization. Cost 
associated with the device is significant and commercial failure has resulted in 
withdrawal of a number of iontophoretic systems in the past.  
4.4.1. B Sonophoresis 
Sonophoresis employs low frequency ultrasonic waves to enhance the 
permeability of the skin. Several mechanisms have been investigated to understand the 
working principle, including thermal effects due to the ultrasound, acoustic streaming 
and cavitation. It has been concluded that low frequency ultrasound works better for SC 
disruption and transdermal drug delivery due to higher incidence of cavitation events as 
well as formation of larger bubbles. Since the effect is not transient, this helps in drug 
delivery for a number of hours following application of ultrasound to the skin. 27 This 
system has been primarily investigated for large molecules/biomolecules. Sonophoresis 
has been shown to be effective for a host of molecules, namely insulin, erythropoietin 
and heparin in vitro, as well as insulin in vivo in diabetic rats. 37, 41 Traditionally, high 
frequency (>1mHz) waves have also been used for local/topical delivery of 
hydrocortisone for joint pain, but the mechanism of action of high frequency ultrasound is 
predominantly by thermal ablation and is associated with heating. This can lead to deep 
tissue damage. 2 The major disadvantages of using sonophoresis is the long recovery 
time of the SC following treatment, which can lead to infection at the site of treatment 
and deep tissue damage on incorrect administration of the ultrasonic wave. Further 
improvement is also required in reducing the cost of manufacturing as well as usage to 
make it more cost effective and user friendly. 27 
4.4.1. C Electroporation 
 Electroporation utilizes an electric field to permeablize the skin. High voltage 
pulses are used over short periods (microseconds to milliseconds) of time to disrupt the 
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highly ordered lipid bilayer. 27 Unlike iontophoresis, where current is applied continuously 
for transport of the drug molecules, in electroporation the current is just used to 
permeablize the skin. The technique has been investigated for large molecules like 
insulin, lidocaine, vaccines, oligonucleotides as well as DNA. 2 The main advantage of 
the method is that current is not required for drug transport, thus stability of 
macromolecules is not affected by the application of the current. Reversibility of 
treatment i.e. complete regeneration of barrier function following treatment takes 
anywhere between few second to hours, thus long term effects and infection issues are 
limited.  
4.4.1. D Microneedles 
MN assisted transdermal delivery employs small micron-scale needles to 
permeablize the skin for drug transport in a minimally invasive manner. 42 Small needles 
are used to create pores or channels across the stratum corneum, the main barrier to 
passive delivery. 43 The delivery characteristics depend on the nature of the microneedle 
(solid, hollow, coated or biodegradable) geometry, as well as on the biomechanics of 
skin penetration, and the density of needles on an array. 42 
MN’s were first introduced onto the market in the late 1970’s, but the MN’s true 
potential in the drug delivery market was not evident until the development of the 
microelectronics industry. With the advent and development of the 
microelectromechanical system (MEMS) industry, the synthesis of MN’s became rather 
inexpensive.  For MN fabrication using solid stainless steel, (the MN array used in this 
project) the array is drafted into AUTOCAD, cut with a laser from a stainless steel sheet, 
cleaned with detergent and electropolished with glycerin, orthophosphoric acid, and 
water (6:3:1). The MN array is then cleaned in nitric acid and deionized water to get rid 
of any loose metal from synthesis. 6 Hollow, coated or biodegradable MN’s are usually 
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synthesized using polymer or glass. The basic mechanism involves synthesis of a 
master mold of metal and then using polymer or glass to cast the MN itself. For coated 
MN, the coating is done using a dip coater or individual coating. 44 For biodegradable 
MN, the polymer mixture used for MN synthesis is premixed with drug and the rate of 
drug delivery is then controlled by the rate of polymer degradation. The rate of delivery 
can be optimized by altering the polymer composition. 45 Hollow MN employs an infusion 
pump to facilitate transport of drug across the skin. Therefore, in this case the MN acts 
like a normal hypodermic needle but much shorter, such that it does not reach the pain 
receptors in the dermal layer and therefore does not cause pain. 46, 47 
MN enhanced drug delivery has been studied in detail over the last decade and a 
half. The physical structure and design of MN has a significant effect on transport across 
MN treated skin. MN can range from anywhere between 200-1000µm in length. The 
length of the MN can directly influence the rate of drug delivery. The length of MN can be 
directly correlated to drug delivery in case of solid MN. However in case of hollow MN 
complete insertion of MN has been shown to decrease transport. This is due to 
compaction of underlying tissue. 48 The rate of drug delivery is also influenced by the 
needle geometry, as well as the needle density. The amount of drug delivered is 
proportional to the number of MN pores, if the application pressure is constant. 49 
However, the “bed of nails” effect plays a role if the needle density is too high. 50 The 
pressure applied on application in that case is shared over a large number of needles 
and thus each needle is applied with a lower pressure. The depth and accuracy of 
microporation is no longer consistent throughout the application area leading to 
variability in results. The application efficacy of MN can be monitored using dyeing 
techniques like gentian violet, India ink or calcein staining. The dyes stain the viable 
epidermis, thus staining is only observed in presence of micropores in the skin.10, 12. 
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Impedance spectroscopy and Transepidermal waterloss (TEWL) measurements can 
also be utilized to verify the efficacy and reproducibility of MN treatment. Impedance 
spectroscopy measures the resistance drop across the skin following MN treatment and 
TEWL measures the increase in water loss across MN treated skin. 10, 51 
Mechanistic understanding of the formulation characteristics for MN enhanced 
transdermal drug delivery systems has helped in identification of parameters that are 
important for active delivery systems, as opposed to passive delivery. The first important 
parameter is the route of movement. It has been hypothesized that since MN treatment 
removes the SC barrier, drug molecules directly permeate into the interstitial fluid. Thus 
lipid-vehicle partition coefficient of the molecule no longer plays an important role in the 
movement across the skin since drug permeates into the interstitial fluid in the 
micropores instead of the SC lipids.  However, since the total movement is a contribution 
of the MN treated skin as well as the intact skin surrounding it, for highly lipophilic 
molecules that tend to form a depot in the skin, lipophilicity could still affect total flux 
across MN treated skin. 52 The molecular weight of the drug molecule is no longer a rate 
limiting step for MN enhanced drug delivery. The diameter of the micropores is 
significantly higher than the molecular size of macromolecules. Both small molecules like 
calcein as well as marcromolecules like insulin and vaccines have been successfully 
delivered across MN treated skin both in vitro and in vivo. The mechanism of diffusion 
across the skin has also been investigated for MN treated skin compared to intact skin. 
Intact skin diffusion takes place following free volume theory in the lipid matrix. Dynamic 
exchange of drug molecules occurs with regions of free volumes or “holes” within the 
membrane and diffusivity can be calculated using 
       (     ) 
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Where D is the diffusivity of the molecule, MV is molar volume, D0 is diffusivity of 
hypothetical molecule having zero molar volume and β is constant. However, for MN 
treated skin, transport in the interstitial fluid occurs following the Stokes Einstein 
equation.  
   
  
    
 
Where k is the Boltzman constant, T is the absolute temperature; r is the hydrodynamic 
radius of the solute. This was established using the same drug molecule and varying the 
viscosity of the formulation to show a linear relationship between permeability and 
concentration could only be established if the diffusivity across the MN treated skin from 
the different formulations were normalized for viscosity effects. It was concluded that 
drug from lower viscosity, aqueous formulations have higher flux across MN treated skin 
as compared to intact skin. 22 The effect of charge on the molecule has also been 
studied for MN enhanced delivery. It has been shown that a formulation containing a 
charged molecule having higher aqueous solubility translated into higher flux across MN 
treated skin. In intact skin it is known that charged molecules exhibit a lower flux due to 
binding in the SC, the permeability of charged molecules can be correlated to the 
hydrogen bonding capability of the molecule. 53  A lower solubility of charged molecules 
in a lipophilic medium that is typically used for intact skin delivery further decreases the 
flux of charged molecules across intact skin. 54 Drug loading both in case of solid and 
hollow MN is an additional parameter that requires optimization for MN enhanced 
delivery. Typically a saturated solution of the drug is used to maximize activity and thus 
flux across intact skin. However, for MN treatment, a saturated solution has been shown 
to cause clogging of the micropores or the MN itself for hollow MN. For solid coated MN 
the maximum dose is limited by the drug loading on the coated MN array. Thus 
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optimization of drug loading is an important and additional step in case of MN enhanced 
delivery instead of using saturated solution for maximum drug transport. 55 Lastly, effect 
of the lymphatic system on drug uptake in addition to the systemic circulation has been 
studied for MN enhanced drug delivery. For intact skin, the movement across the SC 
limits the size of the molecules that can be delivered transdermally. However, when MN 
is used to remove the SC barrier, macromolecules can be delivered across the skin. 
Recent studies show the importance of the lymphatic system in uptake of 
macromolecules following MN enhanced delivery and its effect on both lag time as well 
as therapeutic efficacy. 56 
Microneedles are already in clinical trials for delivery of large molecules like 
parathyroid hormone (PTH) and HINI vaccine. It has been established as a efficacious 
and cost effective way of delivering a wide range of molecules across the skin.57 Two 
major concerns with use of this technique in a clinical setting are infection following 
treatment and pain associated with the MN application. Infection following MN treatment 
has been studied for a few different MN geometries. All studies indicated that there was 
no significant risk of infection following MN treatment. 58 Infection, irritation and 
sensitization were also monitored in all the clinical trials. The results indicated that 
although mild erythema was noted following MN treatment in some cases, it disappeared 
within a day or two in most cases (similar changes in the skin was observed for patch 
application without MN treatment), and infection was not observed in any of the patients 
due to MN treatment. 59 Several studies were conducted to compare pain due to MN 
treatment compared to a hypodermic needle. One of the major advantages of using MN 
is the fact that it is minimally invasive and pain free since the needles are not long 
enough to reach the free nerve endings in the skin. Visual analog scoring techniques 
were used to quantify pain in several human studies, using a number of different types 
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and geometry of MN. 60-62 The studies indicated that in all cases the pain of MN 
application was significantly lower than a corresponding hypodermic needle positive 
control. In some cases the pain associated with MN treatment was not significantly 
different from the negative control and volunteers described the feeling as pressure 
comparable to “pressing an elevator button” rather than pain. 63 The effect of 
microneedle geometry on pain has also been evaluated to show that pain increases with 
increase in length of MN. 64 Thus overall MN’s are a safe, efficient and cost-effective way 
of enhancing drug transport across the skin.  
4.4.2 Chemical/Biochemical enhancement technique 
 Chemical/ biochemical enhancement techniques utilize an additional or modified 
chemical moiety to permeablize the skin instead of a physical force. The most important 
characteristics of chemical enhancers used for transdermal delivery are that they should 
be pharmacologically inert, nontoxic, rapid onset upon application, fast recovery on 
removal, and chemically and physically compatible with the drug of interest. 65 
4.4.2.A Chemical enhancers 
Conventional chemical enhancers can be subdivided into different groups based 
on the permeation enhancement mechanisms. There are three major mechanisms by 
which chemical enhancers permeablize the skin. Lipid disruption/ fluidization of SC, 
keratin interaction in the SC, increased partitioning and solubility of drug in the SC or a 
combination of the above.66 From a chemical standpoint, the enhancers can be broadly 
divided into surfactants, fatty acids and solvents. 67 
 Small molecule solvent enhancers like Azone, dimethyl sulfoxide (DMSO), 
alcohols and fatty acids fluidize the lipid structure by intercalating into the SC bilayer and 
increasing the free volume fraction of the SC matrix. Diffusivity of drug increases 
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following the free volume theory equation and thus leads to flux enhancement. 68 
Ethanol, a commonly used penetration enhancer works via this mechanism. Ethanol 
molecules replace water molecules in the lipid polar head groups as well as the protein 
regions of the SC, thus increasing the free volume. 69 In addition to SC lipids, DMSO, 
urea and surfactants interact with the keratin filaments in the SC. This results in 
alteration of the order of the corneocytes and leads to enhanced transdermal transport. 
68  Propylene glycol (PG) is an example of a widely used transdermal excipient that acts 
as a permeation enhancer by interacting with keratin and decreasing drug tissue binding, 
thus enhancing flux. 66 An alternative mechanism for solvents like ethanol and PG is by 
enhancing the solubility of the drug in the SC itself. Drugs for passive transdermal 
delivery typically have a higher solubility in cosolvent systems of water and PG/ethanol, 
and since PG/ethanol themselves interact with the SC barrier they enhance the solubility 
of the drug in the SC. Higher drug concentration in the SC leads to a higher driving force 
and transdermal flux following Fick’s law of diffusion. 68 
 One of the major disadvantages of using transdermal penetration enhancers is 
the irritation potential of these compounds. All of the penetration enhancers work by 
altering the SC barrier and thus in some cases lead to irreversible damage to the skin. 
Toxicity is also an issue with use of chemical enhancers, and chemicals that fall into 
FDA’s generally recognized as safe (GRAS) classification are now being investigated as 
chemical enhancers.  
4.4.2.B Biochemical enhancers 
 Metabolic or biochemical enhancers are chemical moieties that alter biochemical 
pathways in the skin. They act either by inhibiting enzymes that are responsible for 
biosynthesis and modifications of the SC lipids or by metabolism of SC lipids and 
alteration of the barrier function of the skin. 65  
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 Enzymes of the lipid biosynthesis pathway have also been used as biochemical 
enhancers. Proper formation of the SC lipids and their integration into bilayers are 
imperative to the barrier function of the skin. 70 Apart from the regular maintenance and 
turnover of the SC, lipid biosynthesis is enhanced during repair of the skin following 
insult. The SC is primarily composed of 3 different lipids, cholesterol, fatty acids and 
ceramides. 71 A 1:1:1 molar ratio of the SC lipids is imperative to the barrier function of 
the SC. 72 An important aspect of the SC lipids is that they do not contain significant 
amounts of phospholipids in the final structure, unlike other bilayers present in the body. 
Phospholipids are present during lipid biosynthesis; however they are converted into 
nonpolar species during extracellular processing. 24, 73 The lipid content of the SC is also 
independent of the lipid composition of the body and only a very small percentage of 
systemic lipids are incorporated into the SC. The SC lipids are synthesized in the 
keratinocytes in the basal layer of the epidermis. Following synthesis the lipids migrate 
through the different layers of the epidermis in trilaminar membrane structures known as 
lamellar bodies (LB). The LB first appears in the stratum spinosum as ovoid structures 
and gradually moves towards the interface of the stratum corneum and the stratum 
granulosum. Once the lamellar body reaches the SC interface, release of lamellar body 
contents takes place by a mechanism known as lamellar body secretion. Under baseline 
conditions the amount of lamellar body secretion is regulated by the amount of lipids 
required for maintenance of the barrier function of the skin. Following secretion, lamellar 
body lipids undergo extracellular processing with the help of hydrolytic enzymes 
secreted by the lamellar body. This step converts the lamellar body contents into 
nonpolar lipids that get incorporated into the SC as shown in the Figure 4.5. 73 
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Figure 4.5 Formation of permeability barrier 
Reprinted with permission from J Lipid Res 2009 Apr;50 Suppl:S417-22 
 
 
A host of enzymes are responsible for synthesis and post translational 
modification of the lipids. When the skin undergoes insult such as normal wear and 
tear or tape stripping/acetone treatment an up regulation of the mRNA and the 
enzymes are observed for all the lipid biosynthesis pathways in the skin. 74 Changes 
in the expression of all the enzymes, HMGCoA synthase, HMGCoA reductase, 
farnesol pyrophosphate synthase, squalene synthase, acetyl CoA carboxylase, fatty 
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acid synthase and serine palmitoyl transferase, have been studied in a barrier 
disruption model via tape stripping. It has been shown that all the enzymes are 
upregulated following tape stripping. Thus, formation or regeneration of the SC can 
be altered by inhibiting one or more enzyme of the above pathway as well as by 
altering lamellar body release. Inhibitors of the enzyme targets have been explored 
to evaluate their role in skin healing and recovery. Some of the molecules used for 
inhibiting the lipid biosynthetic pathways are fluvastatin and lovastatin for the 
HMGCoA reductase, TOFA for acetyl  oA carboxylase and β-chloroalanine for 
serine palmitoyl transferase. Use of the inhibitors has prolonged the time required for 
return of barrier properties or proper formation of the SC barrier, evaluated using 
transepidermal water loss (TEWL) and transdermal delivery of lidocaine HCl and 
caffeine. 75 
 
Figure 4.6 Metabolic pathways leading to synthesis of cholesterol, fatty acids, and 
ceramides 
Reprinted with permission from Journal of General Internal Medicine 2005 May: 20(5): 
183-200 
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  Trypsin and magainin peptide have also been investigated and reported in the 
literature recently as potential biochemical enhancers. Trypsin is a serine protease, 
typically used in a transdermal research laboratory for separation of the stratum 
corneum from the viable epidermis. Trypsin has been used to increase permeation of 
large molecules like insulin and dextran across the human skin.76, 77 The mechanism of 
action of trypsin has been characterized using infrared spectroscopy to show that trypsin 
alters keratin in the SC. The transformation of alpha to beta keratin results in decreased 
barrier properties of the skin and enhanced permeation of drugs. 77 Magainin, a 23 
residue naturally occurring pore forming peptide, has been investigated as a biochemical 
enhancer for transdermal delivery of fluorescein and granisetron. The mechanism of 
action of magainin is via electrostatic interaction between the charges on the drug 
molecule and the peptide. 78 This has been confirmed using spectroscopy and changing 
the pH of the formulation to alter charges on the magainin peptide and thus the 
interaction potential with drugs.  
 The major advantage of using a biochemical enhancer is that they are typically 
required in very small quantities for enzyme inhibition or alteration of chemical structure, 
and the effects can be easily reversed. The biochemical enhancers lead to a change in 
the expression pattern of the enzymes responsible for proper formation of the SC 
barrier. On removal of treatment, the normal turnover processes in the skin lead to 
regeneration of the SC which can take up to a maximum of 14 days. During drug 
delivery under occlusion, the changes observed in the expression pattern of the 
enzymes are smaller and on removal of treatment the increase in TEWL acts as a signal 
for rapid release of LB contents. Release of preformed LB contents lead to regeneration 
of the barrier function within 30 minutes and complete recovery occurs within 24hours.  
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4.2.C Prodrugs and codrugs 
The third mechanism for chemical enhancement involves modification of the 
chemical structure of the drug itself. Prodrugs or codrugs are modified chemical 
structures of the API that undergo conversion to one or more active drugs within a 
biological system, such conversion usually involving metabolism. These new chemical 
moieties are known as prodrugs when the additional moiety/promoiety used for structural 
modification is pharmacologically inactive. They are known as codrugs when two API’s 
are linked together using a covalent linkage for enhancing delivery. 79 Codrugs and 
prodrugs are pharmacologically inactive and can be cleaved back to parent drugs 
efficiently in the body by chemical and enzymatic hydrolysis. The structure modification 
helps in solving drug delivery issues like chemical instability in formulation, low solubility, 
and metabolism of the parent drugs leading to toxicity issues. It also helps in better 
permeation and absorption across biological membranes. Codrugs have an additional 
advantage in some cases where they can be used as combination therapy with 
synergistic activity. 23, 80 
Five to seven percentage of drugs approved worldwide can be classified as 
prodrugs. 81 A functional group on the drug molecule is usually used to link a pro-moiety 
or a second molecule to form a codrug or prodrug. Some examples of functional groups 
commonly used are shown in the following Figure 4.7.  
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Figure 4.7 Common functional groups on parent drugs that are amenable to 
prodrug design (shown in green). Most prodrug approaches require a 'synthetic handle' 
on the drug, which are typically heteroatomic groups.  
Reprinted with permission from Nature Reviews Drug Discovery 7, 255-270 (February 
2008) 
 
Some examples of blockbuster prodrugs currently on the market include 
simvastatin, lovastatin, omeprazole and enalapril. 80  Ester prodrugs are the most 
common and are used to enhance permeability by masking charged groups on the API. 
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They are preferred due to well documented presence of a number of esterases such as 
carboxylesterases, acetylcholinesterases, butyrylcholinesterases, paraoxonases and 
arylesterases in different organs of the body. In addition, chemical modification of 
carboxylate or hydroxyl group utilized for ester prodrugs are comparatively easy 81 
Prodrugs and codrugs have also been investigated for the topical (ocular and dermal) 
and transdermal market, in addition to the oral route although there are no transdermal 
prodrugs on the market yet. In addition to solving problems of stability and solubility, 
dermal prodrugs/codrugs can be designed to deal with skin irritation and sensitization 
issues. Steroids, NSAID’s, opioid antagonists and anticancer agents are some of the 
therapeutic areas where this strategy has been studied. 23 For passive delivery, prodrug/ 
codrug structures were optimized for lipophilicity and enhanced permeation. Since most 
of the new moieties need to undergo bioconversion for activation, esters, carbamate, 
carbonate and amide linkages are preferentially chosen. The presence of esterase, 
amidase and protease enzymes is well documented in the epidermal layer of the skin. 82-
85  Codrugs for topical delivery are designed with the dual role of enhancing permeation 
of one or both molecules and synergistic activity. A few examples of topical/transdermal 
codrugs that have been evaluated include NTX and bupropion for smoking cessation 
and alcohol addiction 86, retinyl ascorbate and ascorbic acid for oxidative stress, and 5-
fluorouracil and triamcinolone acetonide for actinic keratosis. 87, 88 One limitation of the 
prodrug/ codrug approach via the transdermal route is the increase in molecular weight 
which limits permeability across intact skin. As a result, prodrugs have been studied in 
addition to a physical enhancement technique (MN). Since drugs move directly into the 
interstitial fluid following MN treatment, the prodrugs were optimized for high aqueous 
solubility and showed higher permeation compared to parent drugs across intact skin in 
vitro. 21 Thus the prodrug/codrug approach is an efficient method for drug delivery 
enhancement.  
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4.5 Recovery of the skin following insult/micropore lifetime 
Physical and chemical enhancement techniques lead to damage of the SC 
barrier. Understanding the recovery mechanism following such insult is important for 
optimizing transdermal drug delivery systems using enhancement techniques. The skin 
is a self-regenerating organ and the SC undergoes complete renewal every 2 weeks. In 
addition to the basal level of SC turnover, a defense mechanism is in place following 
insult or injury to the skin. Depending upon the extent of the insult, the mechanism of 
skin recovery can be classified into different phases: the inflammatory phase, tissue 
formation and tissue remodeling.  89 The inflammatory response is the first phase for any 
wound healing model. This phase lasts for 3-4 days following initial insult and enzymes 
responsible for SC turnover are up regulated and immunological response takes place 
during this phase. It is marked by infiltration of platelets and platelet derived growth 
factors, vascular endothelial growth factors, vasoactive mediators and chemotactic 
factors. A series of cytokines are also released from the macrophages and 
keratinocytes, and are responsible for transforming growth factors required for initiation 
and propagation of wound healing. 90 The next phase is the proliferative phase where 
migration and proliferation of epidermal cells take place to regenerate back the barrier, 
lasting for 10-14 days. This phase is marked by proliferation of fibroblasts and other cells 
responsible for wound healing. The last phase is remodeling and lasts for 6-12 months 
during which collagen formation and remodeling of the barrier takes place. 91 
4.5.1 Timeframe of SC recovery 
Depending on the depth and extent of the wound, all or some of the above 
phases might lead to full recovery of the barrier function of the skin. Influence of a 
number of external and internal factors on the rate of recovery have been investigated in 
SC disruption models via acetone or surfactant treatment or tape stripping. Lamellar 
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body secretion plays an important role in the recovery of the SC. Within the first 15-30 
minutes following SC disruption, lamellar body contents are released from a pool of 
preformed lamellar bodies. Over the next 30 minutes to 6h, synthesis and release of new 
lamellar bodies and formation of an organized bilayer structure takes place. Full 
recovery of the SC takes place within 24h of initial insult. 92 Lipogenesis plays a very 
important role in the formation of the lamellar body contents. Synthesis and incorporation 
of the SC lipids are an important step in formation of the lamellar bodies and key 
enzymes of the lipid biosynthetic pathway act as important modulators of barrier 
homeostasis. 
 
Figure 4.8 Three phases of barrier recovery with distinct metabolic activities 
occurring after acute barrier disruption. A = Secretion of preformed pool of lamellar 
bodies (0 to 30 minutes). B = Increased lipid synthesis (free fatty acids, ceramide, and 
cholesterol) (30 minutes to 6 hours), accelerated lamellar body formation and secretion 
(2 to 6 hours). C = Increased glucosylceramide processing (9 to 24 hours), increased 
keratinocyte proliferation and differentiation (16 to 24 hours) 
Reprinted with permission from Fitzpatrick's Dermatology in General Medicine, 7th 
Edition, Chapter 45, Page 390, Copyright © McGraw-Hill Education  
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4.5.2 Role of occlusion 
Occlusion plays a very important role in recovery of the barrier function of the SC 
following insult. 93 Transepidermal water loss (TEWL) is a very important signal for 
recovery of the skin. When the SC barrier is intact, water loss across the skin is minimal 
due to insensible perspiration, however when the SC barrier is disrupted the TEWL goes 
up instantaneously and ac as a signal for immediate release of lamellar body contents 
for regeneration of the barrier. The role of TEWL in the regulation of epidermal 
lipogenesis has been investigated using occlusive, semi-occlusive dressing and 
uncovered controls to show that following acetone treatment for barrier perturbation, SC 
recovers much faster when exposed to air as compared to under occlusion. 94 Barrier 
recovery following removal of occlusion occurs at the same rate as unoccluded control 
sites. Thus occlusion does not alter the mechanism of barrier recovery of the skin but the 
decreased TEWL in case of occlusion slows down the rate of recovery significantly.  
4.5.3 Micropore re-sealing 
The nature of barrier disruption following MN treatment is not well understood. 
However, understanding the rate of micropore closure or re-sealing is an important 
aspect of MN enhanced drug delivery. The rate of micropore closure controls the 
timeframe of drug delivery across MN treated skin. Several techniques have been 
employed to monitor the rate of micropore closure in animal models and humans. 95, 96 
The techniques range from staining studies using methylene blue and India ink, to 
calcein imaging and immunohistochemistry.8, 12, 97 Visualization techniques such as laser 
scanning microscopy, 98 confocal microscopy, 12 and optical coherence tomography are 
utilized to look at dye or drug permeation. 99 Surrogate markers like TEWL 
measurements, impedance spectroscopy and more direct measurements using 
pharmacokinetic studies are also employed. 4, 9-11, 14, 51  
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A number of factors play an important role in micropore closure. Occlusion plays 
a very important role in micropore re-sealing, comparable to wound healing indicating 
that TEWL is an important signal for closure of micropores. 10, 12 It has been shown that 
while under occlusion microchannels remain open for a period of 48-72h, they close 
within 30 minutes to 4hours when exposed to air. 4, 8, 9, 12  Rate of healing is dependent 
on the animal model used and the microneedle geometry as well. Sensitivity of the 
method of detection used to monitor micropore re-sealing also contributes significantly to 
the variability in the reported timeframe. For example, the TEWL measurements in HGP 
following treatment with solid stainless steel MN resulted in micropore closure in 15-30 
minutes, whereas it took 3-4 hours in rat skin using maltose microneedles. The needle 
geometry has also been shown to affect the time required for micropore healing 10, 12 
Impedance spectroscopy was used to demonstrate that MN length, geometry, and 
number of MN per array had an effect on the observed timeframe of micropore closure 
under occlusion. The differences were however not observed using TEWL or impedance 
spectroscopy when all sites were exposed to air. The results suggest that hydration of 
the skin following occlusion also plays a role in micropore lifetime in addition to the 
observed TEWL values. 11 An exhaustive list of all pore lifetime monitoring techniques 
and time frame of micropore closure has been reported. 14 
Pharmacokinetic studies provide a more direct approach for measurement of 
micropore lifetime since the drug delivery window is the most important aspect of 
micropore closure. Studies in HGP and humans with NTX as the model compound have 
shown that drug can be delivered for 48-72 hours following MN application. 4, 8 
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4.6 Pore-lifetime enhancement strategies 
 Multiple factors are responsible for barrier recovery following SC disruption. 
Since the exact nature or extent of insult following MN treatment is not very well 
understood, a number of strategies can be employed to enhance micropore lifetime and 
allow transdermal delivery of drugs across skin beyond 48h. The goal is to optimize 
enhancement strategies to extend the transdermal drug delivery window to 7 days 
following one time application of MN.  
4.6.1 Formulation pH  
 The pH of the formulation can be used to optimize drug delivery. Stability, 
solubility, and irritation issues are pH dependent. The outer surface of the skin has a pH 
of 4.5-5.5, due to the presence of free fatty acids, lactic acid in the sweat, as well as 
microbial colonization.  The “acid mantle” of the skin is very important for maintenance of 
normal physiological functions of the skin including the barrier properties. A pH gradient 
of pH 5 to pH 7.4 is observed as one proceeds from the surface of the skin to the dermal 
layer. 100 The pH of the skin is also very important in restoration of barrier function 
following injury. The role of pH has been studied in both surface and full thickness 
wounds. It has been shown that SC barrier disruption using acetone treatment has a rate 
of barrier recovery that is faster at an acidic pH as compared to pH 7.4. 18 The role of β-
glucocerebrosidase, an important enzyme of the ceramide synthesis pathway, has been 
investigated (refer to Figure 4.5) and it has been shown that the enzyme has an acidic 
pH optimum. Therefore, decreased activity of the enzyme at pH 7.4 is responsible for 
decreased or malformation of SC lipids/lamellar body contents leading to slower barrier 
recovery. 101, 102 The effect of pH on barrier recovery was only observed when the “acid 
mantle” of the skin was destroyed. Once the initial recovery processes restored the 
normal pH of the skin elevated formulation pH no longer played a role in barrier 
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recovery. Since the actual nature of disruption following MN treatment has not been well 
studied, the state of the acid mantle is not known. The role of pH 7.4 in micropore 
healing will therefore provide a better understanding of the nature of the insult and effect 
on the “acid mantle” following MN treatment.  
4.6.2 Inhibition of the cyclooxygenase (COX) pathway 
 The arachidonic acid (AA) pathway or the COX pathway is responsible for the 
formation of both pro-inflammatory and anti-inflammatory cytokines. Since inflammation 
is the first phase of wound healing, inhibition or alteration of the pathway might lead to 
changes in the rate and extent of wound healing. The COX enzymes act on AA to form 
the downstream products, prostaglandins and thromboxanes. Two different isoforms of 
the COX enzymes are primarily found in the body, COX-1 and COX-2. 103 COX-1 is a 
housekeeping enzyme. It is constitutively expressed and is responsible for maintaining 
homeostasis and normal function of the body. COX-2 on the other hand is an inducible 
enzyme and COX-2 mediated prostaglandin synthesis is usually related to non-
physiological conditions like fever, pain, inflammation, cancer, etc. 104 The enzyme also 
plays a role in cellular repair and proliferation. Inhibition of the COX enzymes either 
selectively or using non-steroidal anti-inflammatory drugs (NSAID) leads to a decrease 
in formation of prostaglandins and thromboxanes. Some of the most commonly used 
NSAID’s include ibuprofen, diclofenac and aspirin for pain and inflammation. Specific 
inhibition of the isozymes is desired in some cases to reduce side effects associated 
with NSAID therapy. Celecoxib is one of the most commonly used COX-2 specific 
inhibitors.  
 The role and effect of COX enzymes have been extensively studied in a skin 
tumor model. It has been shown that both COX 1 and COX 2 expression are altered in a 
skin cancer model. Diclofenac is an NSAID used in the treatment of skin cancer. The 
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mechanism of action is by reducing proliferation through induction of apoptosis via a 
prostaglandin (PGE2) mediated pathway. 104 In other tumor models, however, the COX-2 
inhibitor celecoxib has been shown to act in a COX-2 independent mechanism to 
prevent tumor growth. 105, 106 The role of COX enzymes has also been investigated in a 
skin wound healing model, and up regulation of both COX 1 and COX 2, or specifically 
COX 2 have been shown in the literature. 107-110 Wound healing studies also show that 
intraperitonial injection of COX inhibitors affects the rate of wound healing in cutaneous 
tissue. 108  
 
Figure 4.9 COX-1/2-mediated synthesis of prostaglandins. The initial step in 
prostaglandin synthesis is the formation of arachidonic acid (AA) from membrane 
phospholipids by phospholipase A2 (PLA2).Cyclooxygenase-1 (COX-1) and inducible 
COX-2 mediate the synthesis of prostaglandin H2 (PGH2) from AA, which itself gives rise 
to several other prostaglandins (TXA2, PGI2, PGE2, PGD2, PGF2a), due to the activities of 
specific prostaglandin synthases (PGES). PGE2 exerts important functions in 
inflammation and tumour growth. Inactivation of PGE2 occurs via conversion to 15-keto 
PGE2 by the enzyme15-prostaglandin dehydrogenase (PGDH) 
Reprinted with permission from British Journal of Dermatology 2007, 156(s3), 25-33 
47 
 
With regard to drug therapy, the COX enzymes are important because this is 
where the NSAIDs exert their pharmacological effects, through specific and non-specific 
inhibition of the COX enzymes. Diclofenac sodium is used for the treatment of actinic 
keratosis, the premalignant stage of squamous cell carcinoma. It is available in oral as 
well as topical formulations. Three different topical formulations are available  Voltaren® 
gel (1% diclofenac sodium), Solaraze® gel (3% diclofenac sodium, 2.5% hyaluronic acid 
and Pennsaid® (1.5% diclofenac sodium solution). 
 The effect of Solaraze on micropore lifetime enhancement was evaluated in both 
hairless guinea pigs (HGP) and humans. In both cases it was shown that daily or 
alternate day application of topical diclofenac allowed 7 day drug delivery of NTX across 
MN treated skin. 8, 14 However, the drawbacks were decreased NTX flux across the 
micropores due to application of diclofenac, as well as requirement for frequent 
administration. Therefore, to solve the drug delivery problem the codrug approach has 
been evaluated. Transdermal penetration of a series of NSAID’s show that diclofenac 
has the highest penetration at 0% ionization, however a number of different NSAID’s and 
specific COX 1/ COX 2 inhibitors can be used once the codrug approach is validated. 111 
4.6.3 Lipid biosynthesis inhibitors 
 Lamellar body formation and secretion is one of the most important steps in 
barrier recovery. Both mRNA and protein levels of key enzymes of the lipid biosynthesis 
pathway like cholesterol (HMG CoA reductase), fatty acid (acetyl CoA carboxylase) and 
ceramide (serine palmitoyltransferase) are up regulated following skin insult. 74 It has 
been shown that local applications of  inhibitors of the above enzymes, fluvastatin (FLU), 
5-(tetradecycloxy)-2-furancarboxylic acid (TOFA) and β-chloroalanine (BCA) respectively 
lead to a decreased rate of barrier recovery and increased drug absorption following 
acetone treatment. 75 Topical application of a 1:1:1 molar ratio of cholesterol, fatty acid 
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and ceramide leads to complete recovery indicating that the mechanism of action is by 
decreasing the free availability of SC lipids for lamellar body synthesis and barrier 
formation. 73 The role of occlusion in neutralizing the effects of these changes has also 
been investigated to show that although the extent of upregulation of the key enzymes 
are lower, significant changes in levels of the enzymes are still observed. Thus for a 
system under occlusion, inhibitors of the lipid biosynthetic pathways might still work to 
delay barrier recovery and extend the drug delivery window. Since most transdermal 
drug delivery systems utilize occlusive or semi-occlusive patches this strategy can be 
utilized for delivering drugs. 
FLU is a competitive inhibitor of HMG CoA reductase. It is available in an oral 
dosage form and is prescribed for lowering of blood cholesterol levels. The dosage of 
FLU ranges from 20-80mg/day and the oral bioavaibility ranges from 9-50%. 16 Local 
applications of significantly lower amounts of FLU should not lead to any unwanted 
systemic effects. A host of other inhibitors of both the cholesterol synthesis pathway and 
the other lipid synthesis pathways can also be used to extend micropore lifetime.  
4.6.4 Alternate strategies 
 The role of ions in barrier recovery and proper formation of the SC barrier has 
been investigated. Local extracellular Ca+2 ion concentration is an important regulator of 
lamellar body secretion. A calcium ion gradient is maintained in the skin with high local 
concentration of calcium ions at the SC-SG interface. Disruption of the barrier leads to 
loss of the epidermal calcium gradient and faster release of lamellar body contents. It 
has been shown that barrier recovery can be inhibited following disruption by increasing 
the local concentration of calcium and potassium ions. 112 This mechanism has been 
evaluated in a HGP model for micropore lifetime enhancement. It has been shown that 
local application of different salt forms of calcium, in addition to NTX didn’t lead to 
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significant enhancement of micropore lifetime. The results can be explained in terms of 
the local concentrations of calcium and the duration of the studies. In all previous 
studies, the effect of barrier recovery was monitored for a few hours. Following MN 
treatment the local concentration of calcium can change faster over time due to diffusion, 
and maintenance of a high enough concentration to decrease the rate of barrier recovery 
for 7 days is thus difficult. 14 
Additionally, cytokine mediated pathways play a very important role in barrier 
regeneration since a host of cytokines are released from keratinocytes as well as via 
activation PGE2/ PGD2 in the COX pathway. 113 
4.7 The disease state and model drug 
 Alcoholism or alcohol dependence is defined as "a primary, chronic disease with 
genetic, psychosocial, and environmental factors influencing its development and 
manifestations" by the American Medical Association (AMA). 114 It is responsible for 
approximately 80,000 deaths per year and is the third leading cause of lifestyle related 
deaths in the country. 115 Alcohol users can be classified into three groups based on the 
degree of usage. The classifications are: current use is 1 drink, binge use is 5 or more 
drinks at least once and heavy use is 5 or more drinks on 5 or more occasions during a 
30 day period. 116 The groups are not mutually exclusive but binge or heavy drinking 
individuals can qualify for alcohol use disorder (AUD) if it adversely affects physical, 
mental, personal, social or occupational function.  
The main problem with alcoholism lies in the fact that it is a chronic relapsing 
disorder and although therapies are available, compliance is an issue for this patient 
population. The pharmacology of alcohol/ethanol induced addiction is not very well 
understood, but it affects a number of different pathways in the brain. Some of the 
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neurotransmitters that are of importance include dopamine, serotonin and opioid 
peptides. Release of these neurotransmitters or activation of their receptors lead to the 
rewarding effects of alcohol. 117 An ideal treatment would be something that lowers 
craving, blocks reinforcing properties and is free of adverse effects.  
4.7.1 Current treatment options 
Different treatments have been developed over the years for alcohol addiction. 
Pharmacotherapy or behavioral therapy or combinations of both are used for treatment 
of AUD. 118 Some of the behavioral approaches used are cognitive-behavioral therapy, 
motivational enhancement therapy and Alcoholics Anonymous and 12-step facilitation 
therapy. 119 Among pharmacotherapies, the oldest drug for alcoholism is an aversive 
medication known as disulfiram. The drug acts by blocking the metabolism of alcohol at 
the acetaldehyde stage, leading to increased acetaldehyde plasma concentration on 
consumption of alcohol in the presence of disulfiram in the system. This leads to severe 
nausea, pain and vomiting on alcohol ingestion. Clinical trials show that disulfiram only 
prevents consumption due to the side effects, but is not beneficial in decreasing craving 
or the rate of relapse. 16 Another medication used for alcoholism treatment is 
acamprosate.. The mechanism of action is not completely understood but it is known to 
interact with the N-methyl-D-aspartate (NMDA) receptor system. 120 Acamprosate has 
been shown to be effective in numerous clinical trials in recently detoxified alcoholic 
individuals. 121 One advantage of acamprosate is it does not interfere with the 
reinforcement pathway of alcohol. 122 The third drug used for treatment of alcoholism is 
NTX. NTX is the most widely used alcohol dependence pharmacotherapy.  
NTX is a µ-opioid receptor antagonist, used for alcohol and opioid addiction. It 
was FDA approved in 1994 for alcohol addiction.  It works by attenuating the reward 
associated with the ethanol induced mesolimbic dopaminergic pathway for alcohol 
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addiction. 123 In the presence of NTX, the increase in levels of tyrosine hydroxylase 
mRNA in the ventral tegmental area associated with ethanol use is not observed. 123 
From a physicochemical standpoint NTX is a free base (pKa-7.5, 9.2 and log P -2) 19 It is 
currently available in the United States in two different dosage forms. ReVia® (NTX 
hydrochloride) is a 50mg oral tablet and once daily dosing is recommended for most 
patients. 124 NTX is also available as an extended release intramuscular injection form. 
The 30 day dosage form contains 380mg of NTX and the drug is incorporated into 75:25 
biodegradable polylactide-co-glycolide microspheres. 125  For patients to be eligible for 
treatment with NTX they need to be opioid free for 7-10 days before the beginning of 
treatment and be willing to take the medication on a regular basis. Both of the dosage 
forms currently on the market have limitations. The oral dosage form has oral 
bioavaibility ranging from 5-40%, leading to extensive and variable first pass effects, 
causes gastric irritation and hepatotoxicity. 16 According to Vereby et al, a 2ng/ml plasma 
concentration of NTX is required for 85.6% narcotic blockade following a 25mg IV 
injection of heroin. 15 Peaks and troughs ranging from 10ng/ml to 1 ng/ml are observed 
in the plasma concentration following oral dosing requiring a once daily treatment 
regimen. The IM injectable NTX was approved to solve some of the issues related to the 
oral formulation. However, Vivitrol® has extensive injection site reaction issues leading to 
the issuance of a FDA alert. 126 Dose dumping and difficulty of removal of the IM dosage 
form in case of emergency opiate requirement are some of the other issues. 
Consumption of opioid in presence of Vivitrol in the system can lead to accidental 
overdose and has been associated with death in some cases. Vivitrol also has a 25ng/ml 
peak plasma concentration following administration, and gradually decreases to around 
3ng/ml at 4 weeks. 
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Further analysis of the metabolism and pharmacokinetics of NTX in humans 
reveals that NTX is metabolized by dihydrodiol dehydrogenase to form 6β-naltrexol 
(NTXol), the major active metabolite. 127. Both NTX and NTXol plasma levels can be 
correlated to alcohol consumption levels. 128 NTXol has a longer half-life in the plasma 
as compared to NTX, but a significantly higher plasma concentration of NTXol is 
required for therapeutic efficacy as  compared to NTX. 15  
 
Figure 4.10 Structure of NTX and NTXol 
 
4.7.2 Issues with NTX therapy 
NTX is typically prescribed for highly motivated patients since opioid 
consumption during treatment can lead to overdose and death. It works very well in a 
compliant population, however subject compliance is one of the major issues with NTX 
therapy. It has been shown that NTX treatment efficacy increases in compliant subjects 
receiving additional behavioral therapy. 129 NTX satisfies almost all the characteristics of 
a good addiction medication. The drug reduced relapse to 23% in NTX treated group 
compared to 54.3% in a placebo treated group, where relapse was defined as 
consumption of alcohol on 5 or more days within a week during the 4 week study period 
130, 131 blocks reinforcing properties and the “high” associated with alcohol use is lower on 
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treatment with NTX 132, and most of the side effects are associated with the route of 
delivery.  
 Transdermal drug delivery could be a potential alternate route for NTX. Variable 
bioavaibility and hepatotoxicity issues can be resolved via transdermal delivery, steady 
state plasma concentrations are seen with transdermal delivery compared to the peaks 
and troughs of oral and IM delivery, compliance is higher in an addict population 28, and 
patches can be removed very easily in case there is a need for emergency opiate 
treatment. However, NTX cannot be delivered in the therapeutic plasma level range by 
passive transdermal delivery. 4 Prodrugs and codrugs of NTX have been synthesized to 
enhance permeability, and although some of them enhanced flux, the enhancement was 
not enough for therapeutic efficacy in humans. 82-86 MN were used as a physical 
enhancement technique and it was shown that NTX can be delivered at a rate to provide 
low therapeutic plasma concentrations by using 4 MN patches 4. Recently Vivitrol® has 
been shown approved for opioid dependence and NTX has shown efficacy in treatment 
of tobacco addiction and amphetamine addiction as well. 133  
 Thus NTX is an excellent model compound for optimization of pore lifetime 
enhancement strategies and development of a 7 day transdermal drug delivery system. 
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Chapter 5 
Effect of formulation pH on transport of naltrexone species and pore closure in 
microneedle-enhanced transdermal drug delivery 
5.1 Introduction 
The contents of this chapter have been published in Molecular Pharmaceutics 
(April 2013) except figure 5.1. Skin is the largest and the most accessible organ of the 
body. The extensive vasculature in the dermal region of the skin ensures rapid uptake of 
any compound that permeates across the skin barrier into the systemic circulation, thus 
making the skin a very attractive drug delivery target. 1, 2 However, in order to protect an 
individual’s internal environment from infiltration of xenobiotics as well as excessive 
water loss, the stratum corneum (SC), the topmost layer of the skin is specifically 
designed to protect the human body. 134 A very small subset of pharmacologically active 
molecules can successfully cross the SC (passive delivery) in therapeutically relevant 
concentrations. 2, 37 Research in the field of passive transdermal delivery has focused 
primarily on small molecular weight (<500Da) unionized compounds with a octanol/water 
partition coefficient (log P)~2 to help in transport and partitioning across the SC, the 
most important barrier to passive transport. 1, 135 Active transdermal drug delivery 
systems on the other hand employ some kind of physical enhancement technique to 
permeablize the SC or reduce the barrier effect of the SC. Research and development in 
the field of active drug delivery systems over the past two decades have greatly 
enhanced the number of molecules that can be delivered transdermally. It has also 
opened up a whole new area of research since active transdermal systems focus on 
transport across the lower epidermal and dermal layers, which are more hydrophilic than 
the SC and could benefit from water-soluble drug candidates. 2, 27, 136 
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  The current study focuses on microneedle (MN) enhanced transdermal drug 
delivery as a model of active drug delivery systems. Other active drug delivery systems 
may include iontophoresis, ultrasound, microdermabrasion, or electroporation. MN’s are 
small micron-scale needles that are used to permeablize the skin by creating micropores 
or microchannels across the SC. 42 Once the SC barrier is removed, drug can directly 
pass into the interstitial fluid and the lower layers of the skin. MN can vary in length 
anywhere from 200µm to a few millimeters. There are four different methods of MN 
application, “poke/press and patch” where solid MN are used to permeablize the skin 
followed by application of a drug patch, coated MN where drug is coated onto the 
surface of the MN and used as the drug delivery medium, dissolving MN where drug is 
loaded into the polymer used for MN synthesis, and hollow MN where drug is pushed 
through micron-scale needles with the help of an infusion pump. Several researchers 
have looked at the effects of needle length, needle shape, material, etc. on the 
mechanical/structural integrity of MN. 64, 137 Additional studies have focused on transport 
and drug delivery across MN treated skin both in vitro as well as in vivo. It has been 
shown that a large number of molecules can be successfully delivered using a MN 
system. Some examples include naltrexone, calcein, insulin, parathyroid hormone, etc. 
44, 54, 59 
Formulation and pore closure kinetics for MN enhanced drug delivery had not 
been investigated in great depth until recently. The effect of charge/ionization state was 
investigated by Banks et al. to show that an ionized form of the drug exhibited a higher 
flux using naltrexone (NTX) and naltrexol. For intact skin, it is known that unionized 
molecules generally exhibit faster transport, but in MN treated skin the primary 
permeation route is completely different and the faster transport of ionized molecules 
was an important finding. In the Banks study it was concluded that the faster transport of 
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ionized molecules could be attributed to enhanced solubility. 54 Another aspect of MN 
formulation that has been investigated is the effect of formulation viscosity. Milewski et 
al. showed that a lower viscosity formulation translated into faster flux compared to a 
higher viscosity propylene glycol (PG) rich formulation utilizing the same concentration of 
drug in the donor. The results in that study could be explained by assuming a Stokes-
Einstein equation for diffusivity of drug through the MN pores instead of the free volume 
theory that is used for intact skin. 22 The third aspect of donor formulation investigated 
was the effect of saturation on transport across MN pores. For intact skin, delivery from 
a saturated solution translates into the maximum driving force and hence the fastest flux. 
However, in MN enhanced delivery it has been shown that the highest flux is achieved 
using a sub-saturated solution due to pore clogging and viscosity effects. 22, 138, 139 
MN enhanced delivery maximizes drug transport by creating micropores (or 
microchannels) across the skin. However, these micropores begin to close under the 
influence of normal physiological functions. Thus the efficacy of sustained-release MN 
enhanced delivery is greatly limited by the lifetime of the micropores. Recent literature 
reports have shown the effects of MN geometry, occlusion, and skin type on the rate of 
pore closure. Several direct and surrogate markers have been used by different groups 
for closure rate comparison, such as transepidermal water loss (TEWL), impedance 
spectroscopy, dye imaging, and pharmacokinetics. 9-12, 54 By and large, a pore closure 
timeframe of 48-72 hours under occlusion and around 10-15 minutes without occlusion 
has been observed. Several factors may contribute to the closure of micropores. The 
formation of the SC depends on the availability of SC lipids, their processing and release 
from lamellar bodies. 70 Deeper tissue wound healing is a multi-step process which 
involves inflammation, proliferation and remodeling. 140 The role of pH in healing of 
superficial wounds due to tape stripping or acetone treatment has been previously 
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studied using TEWL in rat skin. The results from those studies showed that healing of 
the skin is delayed at a higher pH of 7.4.18 The results can be explained in terms of 
activity of β-glucocerebrosidase across the pH range of the study from 5.5-7.4. β-
glucocerebrosidase is an important enzyme in the ceramide synthesis pathway, 101 and 
exhibits an activity maximum around pH 5, with substantially decreased activity at pH 7.4 
102. Since ceramides constitute 50% of the SC structure by weight, and a molar ratio of 
1:1:1 of ceramides: cholesterol: fatty acids is an important factor for proper formation of 
the SC barrier, at a higher pH the rate of healing is significantly slower over a 6 hour 
timeframe. 24, 73 The effect of surface pH in chronic wounds has also been studied. 141, 142 
There are several factors that can contribute to transport and pore closure during 
MN enhanced delivery. The effect of formulation pH was examined in this study. The 
model compound of choice was NTX (molecular weight- 341.4, log P- 2.0, pKa- 7.5, 
9.16). 143 It is a µ-opioid receptor antagonist used in alcohol and opioid addiction 144. 
ReVia®, the original daily oral formulation has bioavaibility issues as well as 
gastrointestinal side effects. 145 Vivitrol®, the extended release 28-day formulation has 
injection site reactions, and it is difficult to remove if emergency opioid treatment is 
required. 17 Hence, NTX is a good model compound for a sustained release transdermal 
patch formulation. NTX does not reach a therapeutically relevant plasma concentration 
via passive transdermal delivery, so MN enhanced drug delivery was used for 
development of an active transdermal patch. The first human study with NTX and MN 
showed that while utilizing MN, drug could be delivered in the lower therapeutic plasma 
level range for 48-72h, no detectable level of the drug was obtained in plasma for the 
control non-MN treated subjects. 4 Subsequent efforts were directed towards improving 
the NTX formulation for better transport, as well as enhancement of pore lifetime by 
using diclofenac sodium towards the development of a 7 day transdermal system, the 
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ideal transdermal drug delivery goal. 8, 9, 14, 21, 22, 139, 146, 147  In this study the effect of 
formulation pH will be evaluated for transport and in depth analysis of permeability via 
the microchannel pathway and intact skin pathway. A mechanistic understanding of the 
relation between ionization state and transdermal flux will help in development of active 
transdermal systems for a host of different molecules that can potentially benefit from a 
multiday sustained release dosage form. Since the factors contributing to micropore 
closure are not very well understood yet, studying the effect of formulation pH on 
micropore closure kinetics will help determine if this can be used as a possible 
mechanism for pore lifetime enhancement for development of 7-day drug delivery 
systems. The current study was carried out to fulfill research goal 3.1 and 3.2.  
5.2 Experimental section 
5.2.1 Chemicals 
Naltrexone base was purchased from Mallinckrodt (St. Louis, MO). Citric acid 
monohydrate was purchased from Fisher chemicals (Fairlawn, NJ). Water was purified using a 
NANO pure DiamondTM, Barnstead water filtration system. 1-Octanesulfonate, sodium salt was 
obtained from Regis Technologies, Inc. (Morton Grove, IL). Trifluroacetic acid (TFA), 
triethylamine (TEA) and acetonitrile (ACN) were obtained from EMD chemicals (Gibbstown, 
NJ). Sodium hydroxide was obtained from Sigma (Saint Louis, MO). Natrosol® 
(hydroxyethlycellulose) was obtained from Ashland (Wilmington, DE). Seventy percent ethanol 
was obtained from Ricca chemicals (Arlington, TX) 
5.2.2 Donor solution preparation 
All donor solutions for in vitro permeation studies were prepared in citrate buffer (0.3M). 
Citric acid monohydrate was mixed with nanopure water to obtain a base solution. The pH was 
then adjusted with sodium hydroxide to obtain solutions at 6 different pH values. NTX base was 
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added to 3ml of each solution in excess, vortexed, sonicated for 10 minutes, and were left in a 
shaker water bath at 32°C overnight. The pH adjusted saturated drug solutions were used as 
donor solutions for all studies. (pH 5.76, pH 6.30, pH 6.43, pH 6.72, pH 7.56, and pH 8.26) 
All donor gels for in vivo pig studies were prepared in citrate buffer (0.1M). Citric acid 
monohydrate was used to prepare a base solution. The pH was adjusted to pH 5.5, pH 6.5 and 
pH 7.4 using NaOH (3M). The solutions were left overnight and the pH was also measured on 
the next day to make sure changes did not occur. Three percent hydroxyethlycellulose (HEC) 
was added to each solution as a gelling agent. The gels were stored at 32°C for the entire 
length on the study. 
5.2.3 pH measurements  
The pH of all in vitro donor solutions were measured using a VWR® sympHony® 
(SB70P) pH meter and VWR® sympHony® Glass Combination pH Electrode. All 
solutions were measured following pH adjustment, after overnight incubation with drug, 
and immediately before dosing. 
5.2.4 Solubility determination 
The apparent solubility of NTX base in solutions with different pH values was 
determined immediately prior to dosing. Five hundred µl of each donor solution was 
filtered using a 0.2µm, 500µl centrifugal filter. Ten µl of the filtered solutions was used to 
spike 10ml of ACN. Concentration of drug was analyzed using a HPLC (method reported 
in quantitative analysis section) after appropriate dilutions. All solubility determination 
experiments were carried out in triplicate.   
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5.2.5 Viscosity measurements 
Viscosity was measured using a Brookfield DV-III LV programmable cone/plate 
rheometer and a CPE-40 spindle. Each filtered donor solution viscosity was measured at three 
different torque values within the range of 10-100% torque. The temperature was maintained at 
32°C using a circulating water bath throughout the study. 
5.2.6 In vitro diffusion studies 
Full thickness Yucatan miniature pig skin was used for all in vitro experiments. 
The skin was removed from euthanized animals under a University of Kentucky IACUC 
approved protocol. The skin was obtained from the dorsal region of euthanized animals, 
dermatomed to a thickness of 1.4-1.8mm after removal of all subcutaneous fat and 
frozen (at -20°C) until use. Skin samples were thawed on the day of the study. For MN 
treatment, the skin was placed on a wafer of Sylguard® 184 silicone elastomer to mimic 
the underlying tissue. MNs for this study were obtained from Dr. Mark Prausnitz’s 
laboratory at the Georgia Institute of Technology. A 5 MN in plane MN array was used 
for in vitro studies.  Each MN (triangular in shape) was 750 µm long, 200µm wide (at the 
base) and 75 µm thick (thickness of metal used) and the inter needle spacing was 
1.35µm. Each square piece of skin was pierced 20 times to create a total of 100 MN 
pores (Skin was rotated by 90° following 10 MN insertions so as to create non-
overlapping pores). The skin was then placed in a horizontal flow through diffusion cell 
with an active diffusion area of 0.95cm2. Untreated skin was placed directly onto the 
diffusion cells. Three to four cells were used per treatment group for all experiments. A 
PermeGear flow through (In-line, Riegelsville, PA) cell was used for in vitro diffusion 
studies. Water adjusted to pH 7.4 containing 20% ethanol was used as the receiver 
solution. The flow rate of the receiver solution was adjusted to 1.5ml/h to maintain sink 
conditions. The temperature of the cells was maintained at 32°C, the temperature of the 
61 
 
outer surface of the skin. Transepidermal water loss (TEWL) measurements were 
obtained to make sure that untreated skin had values <5g/m2/h indicating no damage. 
Each cell was charged with 250µl of saturated donor solution and receiver solution was 
collected in 6h increments for a total of 48h. Drug concentration was quantified using a 
HPLC assay for NTX. A cumulative amount vs. time plot was generated and flux was 
determined from the steady state portion of the curve using Fick’s first law of diffusion. 
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)         
JTOT or JSS is the steady state flux or total flux, A is the diffusional surface area (0.95cm
2), 
M is the total mass transport across a membrane (skin in this case) and t is time. P is the 
apparent permeability coefficient and STOT is the saturation solubility of the donor. The 
driving force for diffusion is the concentration gradient across the barrier. However, in 
this case since the receiver solution is maintained at sink conditions throughout the 
experiment, the driving force is the solubility of the drug in the donor. Flux enhancement 
is the ratio of flux across MN treated skin to flux across non treated skin for the same 
formulation. At the end of the experiment, the skin was removed and dissected into small 
pieces. Skin concentration of drug was measured by extracting drug from the tissue into 
ACN overnight at 32°C and analyzing the solution by HPLC after appropriate dilutions. 
5.2.7 Quantitative analysis 
The drug concentration in the receiver solution was measured using a HPLC 
assay. The HPLC system consisted of Waters 2695 separation module, Waters 2489 
dual wavelength absorbance detector and Waters Empower™ software. A Perkin Elmer 
Spheri5 VL C18 column (5µ, 220 x 4.6mm), C18 guard column (15 x 3.2mm) was used. 
The mobile phase consisted of 70:30(v/v) of ACN: 0.1% TFA containing 0.065% 1-
octane sulfonic acid sodium salt, adjusted to pH 3.0 with TEA aqueous phase. The 
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wavelength used for quantification was 280nm. The injection volume for all samples was 
100 μl and the retention time for NTX was 2.1 ± 0.1 min. Samples were analyzed within 
a 100–10000 ng/ml linear range of standard curve (r2≥0.99) 
5.2.8 In vivo studies with impedance spectroscopy 
Impedance spectroscopy was used to look at pore closure kinetics in the 
Yucatan miniature pig. All animal experiments were approved by the University of 
Kentucky IACUC. The pig skin was cleaned with soap and water a day before the 
treatment. On the day of the treatment, all sites were marked, 3 sites for MN treatment 
and 1 site for intact skin control for each formulation. The site for the reference electrode 
was in the center and equidistant from all measurement sites. The impedance setup 
consisted of an impedance meter (EIM-105 Prep- heck), 200 kΩ resistor in parallel (IET 
labs, Inc.), reference and measurement electrodes. A large electrode (70mm diameter) 
with conductive gel (Superior StarBurst® electrode with PermaGel) was used as the 
reference electrode. A Ag/AgCl gel electrode (S & W Healthcare Corp. Series 800, 
50mm diameter total area, 10 mm active electrode diameter) was used as the 
measurement electrode. Baseline measurements were obtained in duplicate at all 12 
sites 51. Active sites were cleaned with an ethanol swab, allowed to dry and treated twice 
with a 50 MN array (to give a total of 100MN insertions). The sites were measured again 
for post-MN treatment value; 200µl of gel was then applied to each site and covered with 
an occlusive patch. 148 The non-treated control sites were occluded after application of 
gel as well. All patches were secured using Bioclusive dressing (Systagenix Wound 
Management, Quincy, MA). For each subsequent measurement the patch was removed 
and the active site was cleaned with gauze, measurements were obtained followed by 
reapplication of gel and patch. Single measurements were obtained for all post treatment 
measurements to minimize the exposure of the active site to air and gel on the 
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measurement electrode. Data was analyzed using the following equation for calculation 
of Zpores (impedance of pores),  
       
 
 
    
 
 
     
 
    
      
 
Where Zskin was obtained from the intact skin value under the same treatment condition 
at each time point, Zbox=200kΩ resistance box and Ztotal is the raw value obtained on the 
meter. Admittance (1/Impedance) values were used to compare pore closure kinetics 
among formulations. All data were reported as mean ± SD. 
5.2.9 Statistical analysis  
Data for all experiments are reported as mean ± standard deviation. Statistical 
analysis of data was carried out with Students’ t-test and one way ANOVA with Tukey’s 
posthoc pairwise tests, if required, using GraphPad Prism® software. P<0.05 was 
considered to be statistically significant. 
5.3 Results  
5.3.1 pH and viscosity measurements 
The pH of all in vitro donor formulations was measured before and after addition 
of drug. Changes in formulation pH were observed for all solutions following the addition 
of the drug. The change was more significant for formulations at the lower end of the pH 
spectrum. The viscosity was also measured for all formulations to account for the effect 
of viscosity on MN enhanced transdermal flux. The lower pH formulations were more 
viscous, which can be attributed to the higher concentration of drug in those 
formulations. Viscosity decreased significantly with increase in formulation pH (p<0.05), 
except at pH 6.72 and pH 7.56 (p>0.05). Table 5.1 lists the changes in pH and viscosity 
64 
 
for all formulations. The pH of each solution at dosing was used for all subsequent 
results and calculations.  
5.3.2 Solubility measurements 
The solubility of NTX was quantified in all in vitro donor solutions. Figure 5.2 
shows the measured experimental values of solubility at 32°C for the 6 different pH 
conditions compared to the predicted values from Scifinder® at 25°C. The measured 
values were higher compared to the predicted values across the pH range. 
5.3.3 In vitro diffusion studies 
Flux was determined across MN treated skin as well as non-treated control for 
each of the 6 formulations (Figure 5.3). The flux values indicated that there was a 
significant difference in flux across MN treated skin among the formulations (p<0.05), 
except for pH 5.76 compared to pH 6.3, and pH 7.56 compared to pH 8.26. Flux values 
across non-treated control skin were not significantly different from each other among 
the formulations (p>0.05). Significant flux enhancement was obtained due to MN 
treatment at pH 5.76, pH 6.30, pH 6.43 and pH 6.72 as compared to intact skin control 
(p<0.05). 
Skin concentration and lag time were calculated from the in vitro studies. Table 
5.2 lists the flux enhancement, skin concentration, and lag time of NTX across MN 
treated and non-treated skin. Flux enhancement was higher in lower pH/higher solubility 
formulations compared to the higher pH/lower solubility formulations. Skin concentration 
data for MN treated skin mimicked the flux profiles; formulations exhibiting higher flux 
had higher concentration of the drug in the skin. Skin concentrations for MN treated 
samples were significantly different from each other for all formulations (p<0.05) except 
between pH 5.76 and pH 6.3, and pH 7.56 compared to pH 8.26. Skin concentrations for 
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non-treated skin were not significantly different from each other (p>0.05). The lag time 
calculations showed that MN treatment significantly reduced the lag time compared to 
non-treated control for all formulations except pH 7.56. Lag time also increased with 
increase in pH for MN treated skin (p<0.05). 
5.3.4 In vivo studies for pore closure kinetics 
 In vivo studies were conducted in a Yucatan miniature pig model to look at the 
effect of formulation pH on closure of micropores. Three different pH values were 
evaluated for impedance studies. The average raw values for pre and post MN treatment 
were 84.59 ± 17.82 and 25.87 ± 0.88, respectively. Significant differences between pre 
and post MN treatment impedance values were obtained for all sites (data not shown) 
(p<0.05). Figure 5.4 shows a plot of admittance values vs. time. The admittance values 
were significantly different between pH 5.5 and pH 6.5, and pH 5.5 compared to pH 7.4 
at 24h (p<0.05). There was no significant difference in admittance values between pH 
5.5 and pH 7.4 beyond the 24h time point (p>0.05). 
5.4 Discussion 
The current study was designed to look at the effect of formulation pH on 
transport and pore closure across MN treated skin. Formulation plays a significant role in 
any drug delivery system by having an effect on stability and solubility from the 
physicochemical standpoint, to ease of use from a clinical standpoint. Since this study 
focuses on effect of pH, the choice of the buffer was important and it was based on 
previous publications that studied the effect of pH on wound healing. 18 The 3 pKa 
values associated with citrate buffer are 3.13, 4.76 and 6.4 and it is widely used in the 
pH range of 3-7. A single buffer species was chosen for all pH values to reduce 
variability in the data due to formation of a second NTX species following overnight 
incubation in saturated buffer solutions. In vivo studies were conducted at a buffer 
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concentration of 0.1M, comparable to previous literature. Higher buffer strength of 0.3M 
was used for in vitro studies since the buffer strength of 0.1M was not suitable in the 
presence of high concentrations of NTX base in solution. Changes in the final pH of the 
formulations following incubation with drug were noted and used for all subsequent 
calculations. Solubility of NTX base in the donor formulation was higher, compared to 
predicted values from Scifinder®. The difference in solubility can be explained in terms of 
the temperature difference. The predicted values were at 25°C, while the experimental 
values were at 32°C. The solubility could also be higher due to formation of NTX citrate 
following overnight incubation. The data reported in this paper is in agreement with 
previously published literature on solubility of NTX salts at 32°C 139. Previous 
researchers also reported that saturation solubility is reached around pH 5.0; therefore 
the range of data in the current study is sufficient to explore the effect of formulation pH 
on flux and permeability for NTX. 
The in vitro results showed that MN enhancement translated into significant flux 
enhancement at pH 5.76, pH 6.3, pH 6.43 and pH 6.72. The flux across MN treated skin 
was not significantly different from non-treated control for pH 7.56 and pH 8.26. Thus it 
can be concluded that formulation pH had an effect on flux enhancement across MN 
treated skin. The enhancement ratio of 11.24±2.9 at pH 5.76 indicated that using a lower 
pH formulation is advantageous in terms of flux enhancement across MN treated skin. 
Since flux enhancement directly translates into higher plasma concentration, this will 
lead to smaller patch sizes or fewer numbers of MN treatments in an individual.  
MN enhanced drug delivery employs two distinctly different routes for drug 
movement, the microchannel pathway through the micropores created across the 
skin/SC barrier and passive diffusion through the intact skin pathway around the 
microchannels. However, since the SC is the most important barrier to movement for a 
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large number of molecules, removing the SC barrier theoretically enhances permeability 
by 100-1000 times. 1 The only exceptions to this rule are highly lipophilic molecules that 
form a depot in the SC and release slowly over time. Thus, the total flux (JTOT) can be 
considered to be a sum of the flux values across two parallel routes, relative contribution 
of the MN pathway (JMCP) and intact skin pathway (JISP) flux values towards the total flux 
can be obtained using the following equation. 22  
               
JISP is obtained from the intact skin (non-treated) control cells for each pH value. 
Subtracting the JISP from the total flux of MN treated cells at each pH value gives JMCP. 
Figure 5.5 shows the relative contribution of the two different pathways towards the total 
flux across the pH range. At formulation pH 5.76 NTX is 98% ionized (pKa 7.5), while at 
pH 7.56 NTX is 50% ionized. Figure 5.5 shows that JMCP is 91% of total flux at pH 5.76 
and decreases to 13% at pH 7.56. As the percentage of ionized molecules decreased in 
formulation, the contribution of the JMCP towards the total flux decreased. This can be 
explained in terms of the movement of ionized and unionized molecules across the skin. 
The MN treated skin drug permeates directly into the interstitial fluid in the microchannel 
pathway, a hydrophilic environment that facilitates permeation of hydrophilic molecules. 
Since solubility of the ionized form of the drug is significantly higher in an aqueous 
formulation, it translates into faster flux across MN treated skin at a lower pH. On the 
other hand, unionized molecules move faster through intact SC since charge on the 
surface of the molecule hinders its movement and partitioning. 1 Skin concentration data 
exhibited a similar profile to flux for MN treated and non-treated skin. Thus, the higher 
flux at lower pH values is not an effect of saturation of the skin with NTX. Lag time 
measurements were obtained from the steady state profiles to compare formulations. 
The average lag time for non-treated skin was around 20h, while the lag time for the pH 
68 
 
5.76 condition in MN treated skin was 5h.  Significantly shorter lag times of low pH 
formulations in MN treated skin would be beneficial for development of a drug delivery 
system, since shorter lag times translate into shorter time to steady state plasma 
concentrations.  
 Permeability of drug across the skin barrier via the two different pathways would 
provide a better understanding of movement by eliminating the effect of solubility. 
Therefore, total permeability (PTOT), microchannel pathway permeability (PMCP), and 
intact skin pathway permeability (PISP) were calculated using the following equations. 
               
     (              ) 
     (              ) 
JTOT, JMCP and JISP were previously calculated values from Figure 5.5. The values of fMCP 
and fISP were the fractional area of the treated skin exposed to active MN delivery and 
passive delivery, respectively. fMCP has been estimated to be 0.02 or 2% of the total area 
and fISP~1, based on prior literature. 
146 The total permeability of NTX across Yucatan pig 
skin as well as permeability via the two different routes was calculated. Figure 5.6 shows 
permeability values of NTX from each of the 6 different formulations. PMCP was not 
calculated for pH 8.26 since the JMCP calculation model does not allow for MN pathway 
flux calculation for that particular data point. The data showed that PMCP was not 
significantly different among the formulations across the pH range (p>0.05). On the other 
hand, PISP values for the higher pH formulation at pH 7.56 and pH 8.26 were significantly 
higher (p<0.05), compared to the rest of the formulations. Thus PISP is affected by the 
change in ionization state of the molecule in formulation, and permeability of the 
unionized form of NTX is higher across intact skin compared to the ionized form. PMCP is 
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not influenced by the change in ionization state of the molecule indicating that transport 
across the MN pathway is independent of the ionization state. The flux enhancement 
observed at the lower pH formulations is solely a function of the higher solubility of the 
ionized form of the drug. At the higher pH values the flux/permeability is solely a function 
of the unionized species of the drug. This is evident from the fact that at pH 7.56 and pH 
8.26 there is no significant difference between the PTOT and PISP. The effect of charged 
and uncharged species on flux had already been studied before for MN treated skin. 
However, the current study looks at the role of speciation across the pH range to 
evaluate the effects in MN treated and non-treated skin, while controlling for important 
factors like viscosity of formulation, thickness of skin, etc. 
 Modeling the data in terms of permeability of the ionized and the unionized form 
of NTX would help in the mechanistic understanding of drug transport across MN treated 
and non-treated skin. 149  The following model is used for calculating PMCP and PISP. The 
total solubility of any molecule in solution is a function of the intrinsic solubility (Sun) and 
the solubility of the ionized form (Si) of the molecule which is pH dependent. This 
assumes that only one pKa of NTX (pKa 7.5, associated with the protonation of the 
tertiary amine) is relevant for solubility calculations in the range of the experimental data. 
Sun (0.48mg/ml) was obtained from Scifinder
® and Si was calculated using the pKa and 
the pH values. 
              
          (    
  
  
) 
The Sun and Si can then be used to calculate PMCP and PISP utilizing the following 
equations.  
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Model 1 
     (              ) 
            (        )        (          )   
     (         ) 
      (        )  (          )  
Model 2 
     (              ) 
            (        )  
     (         ) 
     (          )  
The permeability of the ionized (PMCPi) and unionized (PMCPun) form of NTX across 
the microchannel pathway, and ionized (PISPi) and unionized (PISPun) form across the 
intact skin pathway were estimated using the experimental data. The permeability at pH 
5.76 was used for the completely ionized form of the drug, and pH 8.26 was used for the 
completely unionized form of the drug. Since the PMCP could not be calculated for pH 
8.26, PISP at pH 8.26 was used for the PMCPun and PISPun values. The model assumes that 
the products of ionized permeability and unionized solubility and vice versa are 
negligible for both equations. Flux values calculated using the above equations were 
divided by the total calculated solubility to get calculated permeability values. Model 
fitting was done using Scientist® version 3.0 and least squares fitting to experimental 
data. From the fitted data, goodness of fit was r2>0.8 for estimation of microchannel 
pathway permeability and r2>0.9 for estimation of intact skin pathway permeability. The 
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results indicated that the model can be used to predict permeability of a molecule both 
across MN treated and non-treated skin. In Figure 5.7 the black dashed line is the 
calculated permeability from model 1. The black solid line is the calculated permeability 
considering only the ionized species for microchannel pathway and unionized species 
for intact skin pathway (model 2). From the model, the permeability across MN treated 
skin is best predicted using the completely ionized form of the drug. Total permeability 
across the MN pathway is better predicted by model 1 indicating that it is a function of 
both the ionized and the unionized form of the drug. For model 2, the predicted 
permeability at pH 7.26 due to the ionized component alone is much lower compared to 
the experimental values indicating that at the higher pH values unionized molecules 
have a significant contribution towards the MN pathway flux. The intact skin permeability 
value can be predicted by estimating permeability for the ionized and unionized form of 
the drug, or only the unionized form of the drug. There is no significant difference in the 
predicted values with/without taking the ionized species into consideration i.e. between 
model 1 and model 2. PISPi values at the lower end of the pH range estimated to be 
negative by model 1 were forced to zero in Figure 5.7. From Table 5.3 it can also be 
seen that permeability of the completely ionized species (PISPi) for the intact skin 
pathway is estimated to be negative, indicating that negligible permeation of the ionized 
species takes place via the intact skin pathway for this particular molecule. Thus model 
prediction of flux based on pH of formulation can be used for a whole range of molecules 
by estimating the permeability of the ionized and unionized species for the particular 
molecule experimentally. For the intact skin pathway, different equations can be used to 
predict permeability of the unionized species, such as the Potts and Guy equation, etc. 
150, 151 Once permeability is known flux can be calculated using total solubility values 
since the model shows that there is no significant difference between model 1 and model 
2 for intact skin. For MN treated skin, a single experiment will be required to determine 
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the permeability of the completely ionized component across the membrane of choice. 
Using a combination of the PMCPi and the intact skin permeability, flux can then be 
predicted across the pH range using the above model. Thus the data can be used to 
minimize wet lab experiments and facilitate selection of candidates for MN enhanced 
and passive transdermal delivery based on their solubility and estimated permeability 
across the pH range.  
Barrier recovery is one of the most important aspects of enhanced transdermal 
delivery systems like MN. The rate of healing of the skin determines the rate of delivery 
across the skin. Previously published reports have investigated the role of various 
factors in skin wound healing in different wound models ranging from acetone treatment 
to tape stripping and full thickness wounds. The role of pH was investigated in an 
acetone treated model of acute barrier perturbations and it was reported that barrier 
recovery was slower at pH 7.4 over a 6h period. The slower rate of recovery was 
attributed to lower activity of β-glucocerebrosidase and post secretory processing of 
lipids into lamellar membrane structures. 18 However, this is only true when the SC 
barrier is completely destroyed and the skin loses its acidic environment. As the skin 
starts to recover and the acid mantle is reinstated the effects of external formulation pH 
are no longer observed. MN barrier disruptions are not well understood in terms of the 
pH environment of the wounds or barrier recovery. Thus the in vivo experiments in this 
paper were important to determine whether an external pH would have an effect on the 
rate of healing by affecting enzyme activity or post secretory processing over a 
prolonged period of time (7 days), thus extending the micropore lifetime. Impedance 
spectroscopy is a fairly new technique developed to look at wound healing or pore 
closure for MN channels, compared to TEWL. It has been used extensively to look at 
pore closure in rat models and humans. 11 Method development studies for impedance 
spectroscopy were also conducted to look at use of different electrodes, pressure of 
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application, etc. in hairless guinea pigs, Yucatan miniature pigs, and humans. 51 The 
current results showed that there was a significant difference between pH 5.5 and pH 
7.4 at the 24 hour time point, but there were no significant differences in admittance 
values at 54h and 72h. Thus using a pH 7.4 formulation would not be beneficial for 
multiday pore lifetime enhancement in the current MN treatment model. The presence of 
certain cations, like calcium and potassium, has also been shown to have an effect on 
the rate of recovery indicating that ionic strength may also have an effect. 112 In the 
current study citrate buffer was used and the pH of the buffer was adjusted with NaOH to 
eliminate effects of the different ions on barrier recovery. Interestingly the counter ion did 
not play a role in barrier recovery following iontophoresis. 152 
5.5 Conclusion 
The aim of the current study was to investigate the role of formulation pH on 
transport and recovery of MN treated skin. The in vitro results indicated that there is a 
significant flux advantage of using a lower pH, higher solubility (for a weak base) 
formulation for the development of a 7-day patch system. Modeling the data based on 
permeability gives an in depth understanding of the relative movement of the ionized and 
unionized form of the drug across MN treated and non-treated skin. The model can be 
further used for other drugs by obtaining permeability coefficients for the ionized and the 
unionized forms. The in vivo impedance spectroscopy data showed that there was no 
significant effect on barrier recovery/pore closure kinetics when using a higher pH 
formulation over the span of 4 days.  
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Table 5.1 Formulation characteristics of 6 different formulations (n=3 for all 
viscosity measurements)  
pH of buffer 
pH of formulation 
(after addition of drug) 
Viscosity (cP) 
2.3 5.76 4.01 ± 0.03 
3.5 6.30 3.47 ± 0.02 
4.5 6.43 2.57 ± 0.01 
5.5 6.72 2.20 ± 0.02 
6.5 7.56 2.22 ± 0.07 
7.4 8.26 1.98 ± 0.0 
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Table 5.2 Diffusion parameters for 6 different formulations across MN treated and 
non-treated pig skin. (n=3-4)  
 
 
pH of 
buffer 
pH of 
formulation 
(after 
addition of 
drug) 
Flux 
enhancement 
Skin 
concentration 
(µmol/g) 
Lag time 
(h) 
   
MN 
treated 
Non 
treated 
MN 
treated 
Non 
treated 
2.3 5.76 11.24 ± 2.90 
5.15 ± 
0.48 
2.11 ± 
1.14 
5.01 ± 
2.76 
21.26 ± 
0.16 
3.5 6.30 6.11 ± 1.87 
5.22 ± 
0.46 
2.12 ± 
0.15 
6.41 ± 
0.80 
16.27 ± 
0.68 
4.5 6.43 3.55 ± 1.07 
3.99 ± 
0.54 
2.98 ± 
1.31 
6.09 ± 
3.12 
18.24 ± 
3.76 
5.5 6.72 4.24 ± 0.59 
2.96 ± 
0.38 
1.09 ± 
0.18 
10.89 ± 
0.67 
21.64 ± 
1.34 
6.5 7.56 1.15 ± 0.46 
1.44 ± 
0.29 
1.43 ± 
0.12 
19.24 ± 
2.21 
22.59 ± 
0.26 
7.4 8.26 0.96 ± 0.37 
0.79 ± 
0.22 
0.96 ± 
0.15 
20.85 ± 
2.32 
24.76 ± 
1.12 
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Table 5.3 Experimental and calculated permeability values from Model 1 and 
Model 2 
 
 
Experimental Model 1 Model 2 
PMCPi 
(cm/h) 
3.10 x 10-3 ± 3.25 x 10-4 3.92 x 10-3 ± 1.18 x 10-3 4.75 x 10-3 ± 1.18 x 10-3 
PMCPun 
(cm/h) 
1.66 x 10-3 ± 2.70 x 10-4 5.89 x 10-3 ± 4.0 x 10-3 -------- 
PISPi 
(cm/h) 
6.06 x 10-6 ± 1.51 x 10-6 
-(1.45 x 10-4) ± 1.05 x 
10-4 
--------- 
PISPun 
(cm/h) 
1.66 x 10-3 ± 2.70 x 10-4 1.75 x 10-3 ± 1.96 x 10-4 1.66 x 10-3 ± 2.02 x 10-4 
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Figure 5.1 Impedance setup used for all human and animal studies. (a) Prep-Check 
impedance meter, (b) 200 kΩ resistor in parallel, (c) dry Ag/AgCl measurement 
electrodes, (d): gel Ag/AgCl measurement electrodes, (e) reference electrode for 
Yucatan miniature pig and human studies, and (f) reference electrode used for hairless 
guinea pig studies  
Reprinted with permission from Journal of Pharm. Sci 2013; 102(6):1948-1956. 
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Figure 5.2 Solubility of NTX base in citrate buffer (0.3M) at 6 different values at 
32°C. The dashed line represents the predicted values from Scifinder® in the pH 
range of 4-10 at 25°C. (n=3 for solubility determinations) 
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Figure 5.3NTX flux across MN treated and non-treated pig skin from 6 different 
formulations (n=3-4). MN treated flux was significantly higher compared to non-treated 
skin for pH 5.76, pH 6.3, pH 6.43 and pH 6.72 (p<0.05) 
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Figure 5.4 Admittance values vs. time for 3 different pH values. Admittance values 
were not significantly different from each other between the formulations (p>0.05) except 
for the 24h time point (pH 5.5 and pH 7.4; pH 5.5 and pH 6.5 p<0.05) 
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Figure 5.5 Relative contributions of microchannel pathway and intact skin 
pathway towards total flux from 5 different formulations 
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Figure 5.6 Calculated permeability of NTX across microchannel pathway and 
intact skin pathway from experimental data 
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Figure 5.7 Permeability estimation of NTX species through the microchannel 
pathway (a) and intact skin pathway (b). The dashed line is the calculated value of 
permeability based on Model 1. The solid line is calculated permeability based on Model 
2. The points are the experimental parameters. Model selection criteria's for model 1 and 
model 2 respectively, MN treated skin -0.74 and -0.88, intact skin 2.05 and 2.00 
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Chapter 6 
Development of a codrug approach for sustained drug delivery across 
microneedle-treated skin 
6.1 Introduction 
The contents of this chapter have been published in Journal of Pharmaceutical 
Sciences. 147 Transdermal drug delivery is a potential alternative route for a host of drug 
molecules that are difficult to deliver via the oral or parenteral route. It avoids first pass 
effects, hepatotoxicity, gastric irritation issues, as well as needle phobia. However, only 
small, lipophilic molecules can be delivered by passive diffusion alone across the stratum 
corneum (SC), the main barrier to transdermal drug delivery. Hence, physical and 
chemical enhancement techniques are used to enhance the variety of molecules that can 
be delivered via this route. Physical enhancement techniques include iontophoresis, 
electroporation, low frequency ultrasound, and microneedle (MN) enhanced delivery. 
Chemical enhancement techniques include chemical enhancers and the prodrug/codrug 
approach. 2, 27 A codrug or a mutual prodrug is a new chemical entity formed when two 
pharmacologically active molecules are linked together via a covalent linkage. The 
structural modification is usually utilized to enhance drug delivery properties like stability, 
solubility or permeability of one or both drugs. 23 In this study MN enhanced delivery was 
combined with a codrug approach to develop a seven day sustained release patch 
system. MN delivery is a minimally invasive physical enhancement technique. The pain-
free method used in this research was the “poke (press) and patch” approach 42 where 
solid stainless steel MN arrays are used to create micropores (also referred to as 
microchannels) across the SC. The MN array is then removed and a matrix/reservoir type 
patch is applied to deliver drugs through the micropores. Pain associated with the 
application of these MNs is negligible when compared to a hypodermic needle, 60, 64 
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which could potentially lead to better patient compliance, one of the major drawbacks of 
addiction therapy. 131 Naltrexone (NTX), the model compound (M.W of 341.41, log P of 
2.0), is one of the leading FDA-approved pharmacotherapies for alcohol addiction. It is a 
µ-opioid receptor antagonist and is known to decrease alcohol craving in recovering 
addicts. 153 The drug exerts its mechanism of action by attenuating the ethanol induced 
stimulation of the mesolimbic-dopaminergic pathway. 123, 154 Currently, NTX is marketed 
as a 50-100 mg once daily oral formulation, ReVia® (Naltrexone Hydrochloride). The oral 
therapy has compliance issues in addicts. 129, 155 It also has an oral bioavaibility ranging 
from 5-40% and is associated with side effects like hepatotoxicity, nausea, and vomiting 
145. The intramuscular injectable 28 day controlled release formulation of NTX; Vivitrol™ 
was approved by the FDA in 2006. Injection site reactions and difficulty of depot removal 
in case of emergency opiate treatment, in addition to the aforementioned issues are 
some of the major drawbacks of this dosage form. 17, 156 6-β naltrexol is the major 
metabolite of NTX in humans and has a longer half-life of 13 hours in plasma compared 
to that of 4 hours for NTX. It has been shown to be an effective therapy for alcohol abuse 
as well. 128 Recent clinical data suggests that NTX might be a treatment option for 
smoking cessation as well as amphetamine and methamphetamine abuse. 133 
NTX cannot be delivered in relevant therapeutic concentrations transdermally by 
passive diffusion alone. Some of the earlier efforts in this area of research have looked at 
delivery of NTX via the prodrug and codrug approach. The results indicated that although 
significant flux enhancement was achieved in some cases, it was not enough to deliver 
the molecule in therapeutically relevant concentrations. 83, 84, 86 Using MN it has been 
shown both in vitro as well as in humans in vivo that NTX can be delivered at the lower 
end of the therapeutic plasma level range of 2 ng/ml. 4, 15, 54 However, one of the issues 
with this approach is that the micropores begin to close between 48-72 hour under 
occlusion.  4, 10, 12 When exposed to air following one time application of the MN the 
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micropores heal within a 30 minute timeframe. Therefore, in order to develop a 7 day 
patch system, pore lifetime enhancement techniques need to be employed along with MN 
for successful therapy.  
 Different techniques can be used to delay barrier recovery after MN treatment. 
The skin is a self-regulating organ and employs different methods for recovery after 
insult. Cutaneous wound healing itself consists of multiple phases, inflammatory 
response being the first step. Increased synthesis and secretion of lamellar body contents 
and transformation into bilayers are also a part of the recovery process. 92, 113, 157 
Occlusion alone can also delay the recovery process by decreasing the water flux across 
the barrier, one of the major signals for recovery of structure and function. 94  
There are several literature reports indicating the increase in expression of both 
COX-1 and COX-2 following damage to the skin and the role of both enzymes in 
cutaneous repair. 104, 107-109 Diclofenac (DIC) is a potent non-steroidal anti-inflammatory 
drug (NSAID) that nonselectively inhibits both COX-1 and COX-2 thereby preventing 
formation of downstream products like prostaglandins and thromboxane, thus decreasing 
inflammation. 158 It is currently available on the market as an oral as well as a topical 
formulation, and is the first choice of NSAID for this project. Previous experiments 
showed that daily application of Solaraze gel® (3% diclofenac sodium, 2.5% hyaluronic 
acid) after one time application of MN was able to allow delivery of NTX over the seven 
day time period in hairless guinea pigs (HGP).8 Daily application is irrational for a 
proposed 7-day patch system and coformulating the drugs at high concentration at a pH 
optimum of 5 (pH of the outer layer of the skin is 4.5-5.5) 20 is difficult because the drugs 
have different physicochemical properties. Naltrexone is positively charged at pH 5 since 
the most acidic pKa associated with the amine group is 7.5. Diclofenac on the other hand 
is neutral or negatively charged with a pKa of 4.2 associated with the carboxylic acid 
group.  Solubilities of both compounds are also different by orders of magnitude in the pH 
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5 range as shown in Figure 6.1. These incompatibilities lead to the codrug approach. 
Combining the two molecules via a covalent linkage helps in formulating them together in 
a single formulation. Separate application of the two pharmacologically active 
components leads to precipitation of diclofenac on top of the skin and affects the flux of 
naltrexone across MN treated skin significantly. The 3-O-ester-codrug (Figure 6.2) 
contains a biolabile ester linkage that can be cleaved by hydrolytic enzymes (e.g. 
esterase) as soon as it reaches the viable epidermal region of the skin; in order to release 
the parent compounds. 32, 82, 159 Once in the skin the more lipophilic DIC will act locally to 
keep the pores open while NTX is delivered systemically. The overall objective of this 
research is to show that the codrug approach can be used to reduce the inflammatory 
response in combination with occlusion for delayed barrier recovery following MN 
treatment, so that the ultimate goal of a seven day patch system can be achieved. The 
study was carried out to evaluate research goal 3.3. The codrug was synthesized by Dr. 
Raghotham Reddy Pinninti from Dr. Audra Stinchcomb’s laboratory at the University of 
Kentucky.  
6.2 Materials and methods 
6.2.1 Chemicals 
Naltrexone HCl was purchased from Mallinckrodt (St. Louis, MO), diclofenac acid 
from AK Scientific, Inc. (Mountain View, CA) and diclofenac sodium salt from TCI America 
(Portland, OR). Water was purified using a NANOpure DIamondTM, Barnstead water 
filtration system. Hanks’ balanced salts modified powder; propylene glycol and ethanol 
(200 proof) were purchased from Sigma (St. Louis, MO). 4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), sodium bicarbonate, sodium acetate, acetic acid 
and gentamicin sulfate were obtained from Fisher Scientific (Fair Lawn, NJ). 1-
Octanesulfonate, sodium salt was obtained from Regis Technologies, Inc (Morton Grove, 
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IL). Trifluroacetic acid (TFA), triethylamine (TEA) and acetonitrile (ACN) were obtained 
from EMD chemicals (Gibbstown, NJ). Natrosol® (hydroxyethlycellulose) was obtained 
from Hercules. Chemicals for codrug synthesis were purchased from Alfa Aessar (Ward 
Hill, MA) 
6.2.2 Synthetic procedure for codrug  
The synthesis of naltrexone-diclofenac codrug in the current study was carried out 
by Raghotham Reddy Pinninti from Dr. Audra Stinchcomb’s lab group. Diclofenac sodium 
salt was dissolved in a 1:1 (ethyl acetate: water) mixture and acidified with concentrated 
hydrochloric acid. The organic layer was separated and the aqueous layer was treated 
with ethyl acetate twice. The combined organic layer was dried on anhydrous sodium 
sulfate and rotary evaporated to remove reaction solvents. Diclofenac free acid was 
activated with D   (N, N’-Dicyclohexyl carbodiimide) and DMAP (4-
Dimethylaminopyridine) in anhydrous tetrahydrofuran. After two hours, an equivalent 
amount of NTX was added in dry tetrahydrofuran. Combined reactants were allowed to 
stir over night under nitrogen atmosphere. After completion of the reaction, solvents were 
removed under reduced pressure and the reaction crude mixture purified by flash silica 
gel column chromatography eluting with 80% ethyl acetate and 20% cyclohexane. The 
codrug was obtained in 56% yield. The codrug was dissolved in 1, 4-dioxane and an 
equimolar amount of 2M hydrochloric acid in dioxane was added and refluxed for 1.5 
hours, and precipitated with hexanes to get the hydrochloride salt of the codrug. 
6.2.3 Quantitative analysis 
NTX, DIC and the codrug concentrations in all samples were quantified using a 
high pressure liquid chromatography (HPLC) assay, which is a modified version of the 
previously reported NTX assay. 22 The HPLC system consisted of a Waters 717 plus 
auto-sampler, a Waters 600 quaternary pump, and a Waters 2487 dual wavelength 
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absorbance detector with Waters Empower™ software. A Perkin Elmer Brownlee™ 
Spheri 5 VL C18 column (5 µ, 220 x 4.6 mm) and a C18 guard column (15 x 3.2 mm) 
were used with the UV detector set at a wavelength of 280 nm. The mobile phase 
consisted of 70:30 (v/v) ACN: (0.1% TFA with 0.065% 1-octane sulfonic acid sodium salt, 
adjusted to pH 3.0 with TEA aqueous phase). Samples were run at a flow rate of 1.5 
ml/min with a run time of 8.5 min. The injection volume used was 25µl for receiver 
samples and 100µl for the skin disposition samples. For the plasma samples the mobile 
phase consisted of 50:50 (v/v) ACN: (0.1% TFA with 0.065% 1-octane sulfonic acid 
sodium salt, adjusted to pH 3.0 with TEA aqueous phase). Samples were run at a flow 
rate of 1.0 ml/min with a run time of 37 minutes and injection volume of 25 µl.  
6.2.4 Chemical and enzymatic stability 
Chemical and enzymatic stability was determined for the codrugs. For chemical 
stability studies, the codrug was put in prewarmed 0.3M acetate buffer (pH 5.0) after 
solubilization in <5% ACN, if required, at 32ºC in an incubator. Samples were withdrawn 
at regular intervals and injected into the HPLC after appropriate dilutions. Enzymatic 
stability studies are important for estimation of conversion of codrugs in the plasma. For 
plasma stability studies prewarmed HGP plasma at 37°C was spiked with codrug solution 
and samples were withdrawn at regular intervals. One-hundred μl of plasma sample was 
extracted with 1ml of 1:1 ACN: ethyl acetate, vortexed, and then centrifuged at 10,000 X 
g for 20 minutes on a bench top Eppendorf Mini Spin®. The supernatant was decanted 
into a glass test tube and evaporated to dryness under nitrogen. Samples were 
reconstituted in 100μl ACN and injected onto the HPLC. All stability data was analyzed 
using pseudo-first order kinetics (r2≥0.99). All stability studies were carried out in 
triplicate, at a minimum. 
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6.2.5 In vitro diffusion studies 
The in vitro permeation experiments were carried out to determine the 
transdermal flux of the parent drugs and the codrug, the permeability coefficients, as well 
as the concentration of the drug molecules in the skin at the end of the study. For all in 
vitro experiments Yucatan miniature pig (YP) skin was used. YP skin is one of the most 
relevant models for transdermal studies due to physiological, morphological and 
biochemical similarities with the human skin.160 Full thickness skin was obtained by 
removing the subcutaneous fatty tissue by scalpel dissection, and stored at -20°C.  All pig 
tissue harvesting experiments were done under IACUC approved protocols at the 
University of Kentucky.  A PermeGear flow-through (In-Line, Hellertown, PA,) diffusion 
cell system was used for the skin permeation studies. Skin for MN treatment was placed 
on a wafer of polydimethylsiloxane polymer, which mimics the underlying mechanical 
support of tissue because of its comparable structural flexibility and elasticity. The skin 
was pierced 20 times with a 5 MN in-plane stainless steel array (each needle being 
750µm long, 200µm wide, 75µm thick and the distance between two needles 1.35mm), 
making a total of 100 individual and non-overlapping piercings before mounting the skin 
in the diffusion cell. The needles were manufactured by Dr. Mark Prausnitz’s lab group at 
the Georgia Institute of Technology. MN pores were distributed evenly within the 0.95cm2 
area of skin. Untreated skin samples were mounted directly onto the diffusion cells. The 
setup was maintained at 32°C using a circulating water bath. Data was collected using a 
minimum of 3-4 cells per treatment group. The receiver solution was water adjusted to pH 
7.4 containing 20% ethanol at 37ºC. Gentamicin sulfate (50mg/L) was also added to the 
receiver for 7 day studies as an antimicrobial agent. The receiver flow rate was adjusted 
to 1.5ml/h to maintain sink conditions. Each cell was charged with 0.25 ml of the donor 
solution and the diffusion cells were covered with a stopper to prevent evaporation of 
formulation. Samples were collected at regular increments over 48 hours or for the length 
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of the treatment. Drug was concentrated 10 fold by evaporating 1ml of the collected 
receiver sample under nitrogen and reconstituting in 100 µl of ACN for quantification. All 
samples were stored at 4°C until analyzed by HPLC. The skin was removed at the end of 
the study and the treatment area was minced into small pieces using a scalpel after 
removing all excess drug formulation from the surface of the skin. Drug was extracted 
from the samples by immersing the skin pieces in ACN overnight in a shaker water bath 
at 32°C. Samples were injected into the HPLC after appropriate dilution for quantitative 
analysis. The donor was also removed and quantified at the end of the study by direct 
injection onto the HPLC after suitable dilution using ACN. All data was analyzed using 
Fick’s first law of diffusion. Jss=P*Δ  where Jss is the steady state flux, P is the 
permeability coefficient and Δ  is the concentration difference between the donor and the 
receiver. Since the receiver is maintained at sink conditions Δ  is essentially the 
concentration of the donor. Steady state flux is obtained from the linear portion of the plot 
of cumulative amount permeated over time.  
6.2.6 In vivo studies 
Fabrication of transdermal patches 
The transdermal patches were fabricated by sandwiching a buna nitrile rubber ring 
barrier to create a reservoir between the skin and the impermeable backing membrane 
(Scotchpak™ #1109 SPAK 1.34 MIL Heat Sealable Polyester Film). This was done to 
prevent evaporation of formulation and maintain occlusion of treated sites over the period 
of treatment. 3M™ double sided tape was used on either side of the spacer to attach the 
backing on one side and to maintain contact with the skin on the other side. 
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Dose preparation and application 
All animal experiments were approved by the University of Kentucky IACUC. A 
proof of concept in vivo experiment was carried out using 4 % w/w gels of the 
hydrochloride salt form of the codrug. Gels were formulated by dissolving 4% codrug salt 
in PG: buffer at pH 5.0(10:90) and 3.0% hydroxyethylcellulose (HEC) polymer (to have a 
viscous gel formulation). Polymer was dissolved over a 30 minute period to obtain a 
homogenous gel. The solution was stirred until a viscous gel resulted and then left at 
room temperature for about 2 hours to remove bubbles and ensure completion of 
reaction. .  The gel was saturated with excess drug solid and therefore was cloudy. MN 
treated animals were first cleaned topically with isopropyl alcohol, and a 50 MN array was 
applied twice mutually perpendicular to each other to give a total of 100 pores at each 
site. Gel doses (0.3 ml) were applied to the dorsal region of the HGP. Bioclusive dressing 
(Systagenix Wound Management, Quincy, MA) was applied to hold the patch in place 
and prevent evaporation of the formulation. The patch was re-applied using new 
formulation at 3.5 days such that more than 54% of intact codrug was always present in 
formulation. A control experiment was also carried out to look at the effect of NTX HCl 
alone in the same vehicle on pore closure kinetics. A 9% solution of NTX HCl was used 
to prepare a 3% HEC gel and all other methods of application were consistent with the 
codrug gel.  
Staining 
The patches were removed at predetermined time points and the site was cleaned 
with sterile gauze. Gentian violet/ India ink was applied as the dye at the MN treated sites 
and allowed to dry before excess was removed with ethanol and gauze. Both the dyes 
stain the viable epidermis but not the intact SC. Hence, a grid is observed only in the 
presence of micropores in the skin, no staining is observed in its absence. 
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6.2.7 Statistical analysis 
Data for all experiments are reported as mean ± standard deviation. Statistical 
analysis of data was carried out with Students’ t-test and one way ANOVA with post hoc 
Tukey’s pairwise tests, if required, using GraphPad Prism® software, version 5.04 
software. P<0.05 was considered to be statistically significant. 
6.3 Results and Discussion 
6.3.1 Synthesis 
The codrug and its hydrochloride salt were synthesized successfully. The 
structures were verified using 1HNMR, 13CNMR and HRMS 
Codrug 
1HNMR (CDCl3, 300 MHz): δ 7.29(m, 2H), 7.19(t, 1H), 6.93(m, 2H), 6.75(d, 1H), 6.60(d, 
2H), 6.57(d, 1H), 4. 78(s, 1H), 3.67(s, 2H), 3.12(m, 2H), 2.79(m, 1H), 2.32(t, 2H), 2.27 (m, 
2H), 2.05 (m, 2H), 1.69(m, 2H), 1.62, (m, 2H), 0.46(m, 1H), 0.31(m, 2H), 0.30 (m, 2H) 
13CNMR(CDCl3,(300 MHz): δ 4.22, 4.41, 9.77, 23.31, 31.09, 31.59, 36.45, 38.50, 43.75, 
51.01, 59.48, 62.15, 70.28, 90.93, 118.75, 119.52, 122.45, 123.05, 124.19, 124.31, 
128.30, 128.97, 129.73, 130.38, 130.64, 131.31, 132.63, 138.09, 142.92, 147.77, 169.98, 
207.67 
HRMS: Calculated for C34H32O5N2Cl2 618.1688 and found 618.1697 
Hydrochloride salt of codrug 
1HNMR (CDCl3, 300 MHz): δ9.98 (bs,NH
+) 7.33(m, 2H), 7.13(t, 1H), 6.99(m, 3H), 6.61(d, 
1H), 6.57(d, 1H), 4.97(s, 1H), 4.73(s, 1H), 4.10(s, 2H), 3.60(m, 2H), 3.14(m, 4H), 2.92(m, 
1H), 2.65(m, 2H), 2.41(d,1H), 1.82(m, 3H), 1.25(m, 2H), 0.84(m, 4H), 0.62(m, 1H) 
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6.3.2 HPLC method development 
HPLC assay development for the parent drugs and the codrug was the first step 
towards quantification of the data. The retention time of NTX was 2.3 minutes, DIC was 
3.5 minutes and codrug was 6.5 minutes. The retention times for the same compounds in 
plasma samples were 3.3 minutes, 16.0 minutes and 33.0 minutes, respectively. All 
retention times reported are value ± 0.1 minute. Samples were analyzed within the linear 
range of the standard curve for all the three compounds from 100 – 10,000ng/mL. The 
standard solutions exhibited excellent linearity over the entire concentration range 
employed in the assays, r2 >=0.99.  
6.3.3 Stability studies 
Prodrugs and codrugs are traditionally used to enhance solubility, stability or 
permeability of parent drug molecules. Naltrexone and diclofenac have a 
physicochemical incompatibility when co-formulated; therefore the codrug approach was 
employed to enable them to coexist in a single formulation.  Bioconversion of these new 
chemical entities (NCE) to the parent drugs is essential for pharmacological effect. Thus 
one of the most important steps in development of prodrug/codrug molecules is looking at 
stability. Formulation stability of prodrugs/codrugs is used to estimate the conversion in 
the donor medium. The most common mechanism in an aqueous medium is either acid 
or base catalyzed ester hydrolysis. The enzymatic stability in a biological medium 
measures the effect of enzymes in addition to the chemical degradation to indicate how 
fast the parent molecules will be regenerated inside the body. The chemical and 
enzymatic stability data indicated that the chemical half-life of the codrug in the pH 5.0 
buffer was 3.9 ± 0.56 days and the enzymatic half-life in the HGP plasma was 6.4 ± 0.84 
minutes. In both studies regeneration of the parent drugs was observed with the 
degradation of the codrug. The chemical stability indicates that the codrug is not stable 
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enough in an aqueous formulation for the development of a 7-day transdermal drug 
delivery system. However, it could still be utilized as a learning tool for understanding 
permeability, bioconversion of the codrug in the epidermal region of the skin, as well as 
for proof of concept that the codrug methodology could work to enhance the drug delivery 
window following one time application of the MN. The plasma stability study indicates that 
even if intact codrug permeates the skin and reaches the systemic circulation; it would 
cleave back to the parent drugs almost immediately, thus contributing to the NTX flux. 
The systemic concentration of DIC should not be of concern since it would be orders of 
magnitude lower compared to therapeutically relevant systemic doses. The lowest 
systemic dose of DIC sodium is 50mg twice daily and the oral bioavaibility is 0.55. 16 
Therefore, the daily systemic dose is 55mg/day. From a 25cm2 patch, the flux required to 
reach the systemic dose will be 288nmol/cm2/h.  
6.3.4 In vitro experiments 
In vitro permeation experiments were carried out to estimate permeability of the 
codrug, as well as to examine the rate of delivery and the extent of the parent compound 
regeneration in the skin. The goal of the first set of in vitro experiments was to estimate 
flux and skin concentration of the base form of the codrug. A 4.5 mg/ml saturated donor 
solution consisting of codrug in propylene glycol (PG): ethanol: water (43:43:14) was 
used. Four treatment groups each having 3 diffusion cells (MN treated) were dosed and 
then cells were removed every 12 hours to obtain the skin concentration of the parent 
drugs as well as the codrug. An intact skin control was also present for the entire length 
of the study (48 hours). A steady state flux from NTX and DIC of 0.42 ± 0.12 nmol/ 
(cm2/h) and 0.19 ± 0.06 nmol/ (cm2/h), respectively, was obtained (Figure 6.3). The flux of 
NTX was significantly higher compared to the flux of DIC (p<0.05). The skin concentration 
data shows that the codrug degraded in the skin to regenerate back to the parent drugs 
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and the concentration of parent drugs from the codrug increased with time. It also 
showed that the DIC concentration increased in the skin with time and was higher 
compared to the NTX concentration at 48 hours. Thus from the results it can be 
concluded that the codrug cleaved, and NTX flux was obtained from the base form of the 
codrug, although it was not high enough to produce therapeutic efficacy. Significantly, a 
higher amount of NTX was found in the receiver while DIC was retained in the skin in 
higher concentration at 48 hours from this formulation. This difference in flux and skin 
concentration could be attributed to the difference in physicochemical properties of the 
drug molecules. While NTX (pKa 7.5, 9.2) is positively charged at the skin surface pH of 
5, 20, 19 at least 80% of DIC (pKa 4.2) is negatively charged. The skin is known to possess 
a net negative charge due to the presence of negatively charged free carboxylic acid 
groups, which might be responsible for slower migration and higher retention of DIC 
molecules in the skin compared to NTX. Different rates of migration for positively and 
negatively charged molecules have been previously observed in the case of active 
transdermal drug delivery systems utilizing iontophoretic delivery, 161 indicating that 
similar results could be expected in the current system. The hydrophobicity or log P 
values of the parent molecules could also have an effect on the rates of migration. NTX 
having a log P value of 2.0 (optimum log P for transdermal delivery is around 2) should 
permeate much faster through the different layers of the skin compared to DIC with a log 
P of 4.5, which will have a tendency to form a depot in the SC layer instead . The 
hypothesis behind the project is based on the fact that DIC would act locally to enhance 
the drug delivery window while NTX will have a systemic effect. The characteristics of the 
molecules listed above would thus be beneficial for the development of a seven day 
system.  
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The first set of experiments confirmed bioconversion, but further flux 
enhancement was required before the codrug could be tested in vivo for pore closure 
kinetics. From the literature it is known that a charged molecular species has higher flux 
through MN treated skin as compared to a non-treated control.  This property is attributed 
to the enhanced solubility of a charged species in an aqueous donor rather than the 
molecular species itself. 54 Viscosity of the donor formulation also has a predominant 
effect on the flux across MN treated skin, where it has been shown that 17-fold flux 
enhancement was obtained using a low viscosity, aqueous donor compared to a high 
viscosity propylene glycol (PG) rich donor (concentrations for all donor solutions were 
maintained at 110mg/ml). On the other hand, there was no significant difference in flux 
between the low viscosity aqueous donor and the high viscosity PG rich donor across 
untreated skin. Thus it was concluded that donor solution microviscosity has an effect on 
transport across MN treated skin. 22 Hence the hydrochloride salt form of the codrug was 
tested for higher solubility and flux in aqueous donor for subsequent experiments. The 
hydrochloride salt of the codrug (Mol. Wt. 654.15) was used as the donor solution with a 
concentration of 39.3mg/ml in 0.3M acetate buffer at pH 5.0. The flux of NTX from the 
codrug salt was 5.42 ± 1.5 nmol/(cm2/h). A 13-fold flux enhancement was obtained by 
using the salt form over the free base form (p<0.005), which can be attributed to the 
solubility enhancement of the salt form in an aqueous donor.  
Precipitation issues were observed with purely aqueous donor during in vitro 
experiments with the hydrochloride salt form of the drug, so further experiments were 
carried out for formulation development by varying the amount of PG in the donor 
formulation. The different concentrations of PG used were 10%, 25% and 50 % with the 
salt form of the codrug and it was observed that while there was no significant difference 
in flux between the aqueous formulation and 10% PG containing formulation (p<0.05), 
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flux decreased significantly for higher concentrations of PG  (Figure 6.4). All experiments 
were carried out with saturated donor solutions. The data was compared using one way 
ANOVA with Tukey’s posthoc analysis for pairwise multiple comparisons. From these 
results, the 10% PG containing formulation was chosen for in vivo studies since there 
was no significant difference in flux and precipitation issues were much lower. 
6.3.5 In vivo studies 
  The in vitro studies confirmed permeation and bioconversion, but in vivo studies 
were required to elucidate pore closure kinetics. The HGP is the best small animal 
model for transdermal drug delivery. 162 Pore visualization studies were conducted to 
look at the presence/absence of pores under occlusion after one time application of MN. 
The pores can be clearly visualized with gentian violet in Figure 6.5 (A) immediately 
following MN treatment. In panel (B) the pores cannot be visualized at day 4 (96 h) 
following treatment with MN followed by application of NTX HCl gel under occlusion. 
This is in agreement with previously reported data in pharmacokinetic studies where it 
has been shown that the micropores close anywhere between a 48-72 h timeline 
following MN treatment under occlusion, in the absence of additional pharmacological 
moieties for pore lifetime enhancement. 4, 8 Pores can be visualized by India ink staining 
in panel 5 (C) where the hydrochloride salt form of the codrug was used following MN 
treatment indicating that the pores can stay open up to 7 days. Therefore, it can be 
concluded from the studies that the codrug is effective in keeping the pores open 
analogous to our hypothesis. Once the patches are removed, on exposure to air the 
micropores would heal within a 15-30 minute timeframe so that post-treatment infection 
issues are not a major concern with the codrug-MN approach. 
From these studies, it can be concluded that the codrug cleaved back to parent 
drugs both in stability studies, as well as during in vitro studies. The salt form of the 
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codrug improved solubility and flux significantly in in vitro studies. Subsequent in vivo 
studies with the salt form in an optimized 10% PG containing formulation kept the pores 
open for a 7 day target drug delivery window, but the steady state plasma concentration 
of NTX from the codrug was not high enough to quantify in the HGP model. This could be 
predicted from the clearance estimation from previous pharmacokinetic studies with NTX 
in the same animal model based on the size of the treatment area since,  
             
Where Jss is the steady state flux, A is the active treatment area, Css is the steady state 
plasma concentration and Cl is the clearance of the compound in a HGP model. 
In this case with 4 patches, A was 1.8cm2 for each patch (total of 7.2cm2 for 4 
patches, 400 MN treatments, Jss was 6.35 nmol/cm
2/h (0.95cm2,100 MN treatments) from 
the in vitro studies and Cl is 5.6 L/h, 148 which translates to a Css of 1.5 ng/ml based on 
number of MN treatments. The LLOQ on the LC/MS assay was 1ng/ml. Hence reliable 
pharmacokinetic data could not be obtained from this codrug. Physicochemical 
optimization is required to obtain a molecule that would have higher stability and 
permeability in a range that can be clinically applicable, thus making the codrug approach 
applicable for pore lifetime enhancement and delivery. NTX has been used in this 
research as a model compound; further optimization of these codrugs will help in 
development of 7 day transdermal systems for a host of other molecules that can 
potentially benefit from once a week transdermal dosing. 
Future codrug designs will explore a variety of different linking groups of diverse 
susceptibility to hydrolysis including carboxylate ester, carbamate ester and carbonate 
ester. From previous data, it is known that all the aforementioned linkers are bioconverted 
in the skin and that the rate of bioconversion depends on the structure of the molecule 
and type of linker used.  A nontoxic extended linker moiety will be used in between, if 
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required (e.g. polyethylene glycol, alkyl chain). The polyethylene glycol can enhance 
solubility due to the presence of additional groups with hydrogen bonding capabilities. 
The alkyl chain can be used to enhance stability of prodrug/codrug molecules due to 
electron donating effects. 21,146 Different salt forms of the codrug can also be used to 
enhance solubility as shown in the case of NTX. 139  Different positions on the NTX 
molecule will also be explored to look at the 6-O secondary alcohol position in 
comparison to the 3-O phenolic position. Formulation stability could also be enhanced by 
adding PG to the formulation, since the main mechanism of degradation in formulation is 
chemical hydrolysis. However, the viscosity will need to be monitored to balance between 
formulation stability and effect of viscosity on transport across MN pores. Quantitative 
stability studies based on structures using all of the above would help in identification of a 
candidate that can be developed as a 7 day drug delivery system.  
Flux enhancement parameters, like the ionization form of the drug for solubility 
enhancement and lower viscosity formulations would be utilized to develop a quantitative 
structure permeability relationship (QSPR) for compounds that are suitable from a 
stability standpoint for development of the 7 day system. The theoretical flux range 
required for NTX to achieve therapeutically relevant concentrations in humans is 12-
90nmol/ (cm2/h) from a 25cm2 patch, based on the standard oral NTX dosing regimen. 
Comparisons of the codrug salt formulation with that from the human pharmacokinetic 
study 4 carried out previously across YP skin showed that there was no significant 
difference in flux between the two formulations (p>0.05). However, this flux is much lower 
compared to the most optimized low viscosity NTX HCl formulation currently used as a 
prototype (Figure 6.6).  Thus the above flux optimization techniques will be employed to 
reach the final drug delivery goal of a 2 ng/ml plasma concentration in humans. 
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The development of QSPR with NTX and DIC as model compounds will help in 
future development of codrugs for MN enhanced transdermal delivery. Depending on the 
local concentration and permeability, DIC could be substituted with a host of other 
NSAIDS. NTX can be replaced with a series of drug molecules that could potentially 
benefit from 7-day transdermal drug delivery. From a structural standpoint, any drug 
molecule can be used provided they have an accessible –OH group since all the linkages 
proposed for this research, carboxylate, carbamate and carbonate require a functional –
OH or –COOH group for bond formation.  
6.4 Conclusions 
 In conclusion, the possibility of utilizing NTX DIC codrugs for systemic delivery of 
NTX across MN treated skin was explored. The DIC is used as an active pharmacological 
moiety to enhance the drug delivery window. The results indicated that the codrug 
approach can be used for the development of a seven day transdermal system. Drug 
products with two actives are routinely approved by the US FDA, thus this project is not 
limited from a regulatory perspective.  The 3-O-ester codrug used in the current study 
bioconverted back to the parent drugs in the skin and the local concentration of DIC 
regenerated was high enough to keep the pores open, as evidenced by pore visualization 
studies. Stability and solubility enhancement techniques will be used to develop 
molecules that can deliver NTX in therapeutically relevant concentrations. 
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Figure 6.1 Solubility profile of NTX and DIC generated using predicted chemical 
property values from Scifinder®  19 
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Figure 6.2 Structure of parent drugs, (a) NTX, (b) DIC (c) 3-O-ester codrug and (d) 
hydrochloride salt form of 3-O-ester codrug  
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Figure 6.3 In vitro diffusion studies across full thickness Yucatan miniature pig 
skin of the base form of codrug (a) Permeation vs. time profile of NTX and DIC from 
the codrug at 48 hours post MN treatment. (n=3)  (b) Skin concentration over time 
from the base form of the codrug. Both NTX and DIC concentration could be observed 
in the skin indicating the regeneration of the parent molecules. n=3 for 12h, 24h and n=2 
for 36h and 48h 
105 
 
 
 
Figure 6.4 In vitro diffusion studies across full thickness Yucatan miniature pig 
skin comparing the flux of NTX at steady state from different donor formulations. 
Propylene glycol (PG) was used in different concentrations to optimize formulation 
for in vivo studies (n≥3) 
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Figure 6.5 In vivo micropore visualization with different staining techniques. (A) 
Shows presence of micropores immediately following MN treatment, (B) shows 
absence of micropores with India Ink staining at 96h following treatment with NTX 
alone (C) shows presence of micropores with India Ink staining at 7 days following 
treatment with codrug       
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Figure 6.6 In vitro diffusion study across full thickness Yucatan miniature pig skin 
comparing the flux of NTX at steady state from NTX HCl, salt form of the codrug 
and previously studied formulation for in vivo human pharmacokinetic studies 
(n≥3) 
 
 
 
 
 
 
 
 
 
Copyright © Priyanka Ghosh 2013 
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Chapter 7 
Optimization of naltrexone diclofenac codrugs for sustained drug delivery across 
microneedle treated skin  
7.1 Introduction 
The contents of this chapter have been submitted for publication in 
Pharmaceutical Research. (Revisions submitted May 2013) Codrugs or mutual prodrugs 
are two active pharmaceutical ingredients (API) linked via a covalent linkage to form a 
single chemical moiety. 23 They are primarily synthesized to solve drug delivery issues 
like stability and solubility of the parent compounds or to enhance permeation of one or 
both active moieties across biological barriers by modification of the chemical 
structure.79  Codrugs and prodrugs are pharmacologically inactive in their modified form; 
however they are bioconverted back to parent drugs either by chemical or enzymatic 
hydrolysis in formulation, when crossing biological barriers, or in the plasma.23, 79 
The overall goal of the current project was to optimize codrug structures in order 
to develop a sustained release transdermal drug delivery system for alcohol addiction. 
Naltrexone (NTX), the model compound (MW-341.4, log P-2.0) is a µ-opioid receptor 
antagonist approved for alcohol and opioid addiction treatment. 19 6β-Naltrexol (NTXol) 
(MW-343.4, log P-0.68), the active metabolite of NTX, has also been shown to have 
therapeutic efficacy for alcohol addiction. 15, 128 The current available dosage forms for 
NTX are oral and an extended release intramuscular injection. Both forms have their 
own drawbacks. The oral dosage form has compliance issues in an addict population 
due to daily dosing and gastrointestinal side effects. 15, 155 The extended release 
intramuscular dosage form has been associated with serious injection site reactions and 
difficulty with removal in case of emergency opiate requirements. 17, 126  
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NTX can potentially benefit from an alternative delivery route like transdermal 
drug delivery. This noninvasive technique allows delivery of drugs directly into the 
systemic circulation and bypasses gastrointestinal side effects. The transdermal route is 
also known to be patient-friendly and comparatively more effective in an addict 
population with compliance issues. 28 However, NTX doesn’t cross the stratum corneum 
(SC) barrier at a therapeutically relevant rate by passive diffusion alone.4 The SC, the 
topmost layer of the skin is formed of dead keratinized epidermal cells and a lipid matrix, 
and forms the most important barrier to transport of xenobiotics across the skin. 1 
Previous work, in both animal models and humans, has shown that by using 
small micron-scale needles or microneedles (MN), it is possible to deliver NTX at a rate 
that provides plasma concentrations in the lower end of the therapeutic range. 4 MNs are 
a physical enhancement technique used to permeablize the skin by creating micropores. 
The effectiveness of this technique for enhancement of transdermal drug delivery has 
been established in the literature over the past decade and a half. 42, 43 Using the ‘poke 
(press) and patch’ approach for MN treatment drug can be delivered across treated skin 
for 48-72h under occlusion. The drug delivery window can be further enhanced by local 
application of a non-steroidal anti-inflammatory drug, diclofenac sodium (DIC) (MW-
296.1, log P-4.5). 8, 9, 19 Due to physicochemical incompatibility of the two molecules in 
formulation, daily or alternate day application of DIC was required to keep micropores 
open for a 7 day period. 14, 163 The incompatibility in formulation also leads to a significant 
decrease in flux of NTX across micropores in the presence of DIC, as compared to NTX 
alone, due to precipitation issues upon co-administration. 14 
The codrug approach was thereafter used to combine NTX and DIC into a single 
chemical moiety with the goal of solving the formulation issue. The bioconversion of the 
properly designed new chemical entities in the skin or plasma should not be a problem 
since it has been previously shown that prodrugs/codrugs are bioconverted in the skin, 
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both during passive delivery and MN enhanced delivery. 21, 82, 85, 86  The hypothesis was 
that following bioconversion in the skin, DIC would act locally and keep the pores open 
facilitating systemic delivery of NTX. A proof of concept study was conducted using a 
NTX-DIC 3-O-ester linked codrug to look at stability, solubility, transdermal flux and local 
skin concentration of the codrugs and the parent drugs. 147  Although pharmacokinetic 
profiles were not obtained from the study, pore visualization techniques were used to 
verify the presence of micropores in the skin at the end of 7 days, using the codrug 
formulation compared to absence of micropores for the NTX control. These studies 
confirmed that the codrug approach was useful for development of a 7 day system, 
however further optimization was required. The codrug also had a formulation half-life of 
around 4-5 days, and the solubility and transdermal flux were an order of magnitude 
lower compared to the most optimized formulation for NTX delivery across MN treated 
skin. 22, 139  
In the current study, four codrugs of NTX/ NTXol and DIC have been compared 
to look at structure vs. stability, solubility, transdermal flux and bioconversion in the skin. 
The study was carried out to satisfy research goal 3.4. The codrugs for this part of the 
research were synthesized by DoMin Lee from Dr. Kyung Bo Kim’s laboratory at the 
University of Kentucky. 3-OH (phenol position) on NTX or the 6-OH (secondary alcohol) 
position on NTXol were used for the synthesis along with the –COOH group on 
diclofenac.  Ester, carbamate or amide linkers were used to join the two molecules either 
directly, or with the help of a polyethylene glycol (PEG) linker. Furthermore, 
hydrochloride salts of promising codrugs were synthesized and tested to develop a 
formulation for in vivo pharmacokinetic studies.  
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7.2 Materials and Methods 
7.2.1 Chemicals 
NTX HCl and NTX base were purchased from Mallinckrodt (St. Louis, MO), DIC 
acid from AK Scientific, Inc. (Mountain view, CA) and DIC sodium salt from TCI America 
(Portland, OR). Water was purified using a NANOpure DiamondTM, Barnstead water 
filtration system. Propylene glycol was purchased from Sigma (St. Louis, MO). Sodium 
acetate and acetic acid were obtained from Fisher Scientific (Fairlawn, NJ). 1-
Octanesulfonate, sodium salt was obtained from Regis Technologies, Inc (Morton Grove, 
IL). Trifluroacetic acid (TFA), triethylamine (TEA) and acetonitrile (ACN) were obtained 
from EMD chemicals (Gibbstown, NJ). Unless otherwise noted, all other reagents for 
codrug synthesis were obtained from Sigma Aldrich (St. Louis, MO). 
7.2.2 Synthesis of the codrugs 
Codrug I and hydrochloride salt of codrug I were synthesized following previously 
reported procedures. 147 Codrugs II, III and IV were synthesized by DoMin Lee in Dr. 
Kyung Bo Kim’s laboratory at the University of Kentucky. 
Codrug II: Benzyl bromide (0.522 mL, 4.375 mmol) was added to a suspension of 6β-
NTXol (500 mg, 1.458 mmol) and potassium carbonate (1 g, 7.3 mmol) in acetone (10 
mL). The reaction mixture was then refluxed for 2 h before it was concentrated under 
reduced pressure. The resulting crude product was further purified by column 
chromatography on silica gel using dichloromethane-methanol mixture to obtain 
compound 1 as a white solid (500 mg, 79%). A mixture of compound 1 (500 mg, 1.153 
mmol), DIC acid (685 mg, 2.306 mmol), and DMAP (7 mg, 0.06 mmol) were dissolved in 
dichloromethane (50 mL) and  cooled to -78oC in an acetone/ dry ice bath under N2. To 
the reaction mixture, N,N’-dicyclohexylcarbodiimide (685 mg, 2.306 mmol) in 
dichloromethane (20 mL) was then added with vigorous stirring.  After 1h, the reaction 
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mixture was allowed to warm up to room temperature and concentrated under reduced 
pressure. The resulting crude product was purified by column chromatography on silica 
gel using hexane-ethyl acetate mixture to yield compound 2 as a white solid (260 mg, 
32%). Catalytic hydrogenation of compound 2 (100 mg, 0.140 mmol) over a Pd/C catalyst 
provided Codrug II as a solid (80 mg, 92 %). 
Codrug III: Triethylamine (0.123 mL, 0.879 mmol) was added to a suspension of NTXHCl 
(200 mg, 0.586 mmol) and 4-Nitrophenyl chloroformate (130 mg, 0.644 mmol) in 
dichloromethane (5 mL). The resulting solution was stirred for 4h at room temperature, 
and then concentrated under reduced pressure to yield an oilic crude product. The crude 
product was purified by column chromatography on silica gel using dichloromethane-
methanol mixture to provide compound 3 as a light yellow solid (292 mg, 66%). To a 
dichloromethane solution containing compound 3 (61 mg, 0.143 mmol) and DIC-EBE (73 
mg, 0.143 mmol) was added DMAP (35 mg, 0.286 mmol). The reaction mixture was then 
stirred for 1h at room temperature and then concentrated under reduced pressure. The 
resulting crude product was purified by column chromatography on silica gel using 
dichloromethane/methanol solvent systems to obtain codrug III as a light yellow solid (78 
mg, 69%). 
Codrug III hydrochloride salt: To a dichloromethane solution of codrug III (100 mg, 0.126 
mmol), 1M HCl was slowly added and continuously stirred for 10 min. The resulting 
codrug III salt was filtered and dried to yield codrug IIIHCl as a white solid (95 mg, 91%). 
Codrug IV: To a suspension of 6β-NTXol (300 mg, 0.875 mmol) and di-tert-butyl 
dicarbonate (210 g, 0.962 mmol) in acetone (20 mL) was added potassium carbonate 
(604 mg, 4.373 mmol) with vigorous stirring. The reaction mixture was then refluxed for 1 
h and concentrated under reduced pressure. The resulting crude product was further 
purified by column chromatography on silica gel using dichloromethane-methanol solvent 
systems to provide compound 4 as a white solid (340 mg, 88%). To a suspension of 
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compound 4 (340 mg, 0.766 mmol) and 4-Nitrophenyl chloroformate (232 mg, 1.149 
mmol) in dichloromethane (10 mL) was added DMAP (280 mg, 2.298 mmol). The 
resulting mixture was stirred for 1h at room temperature and subsequently concentrated 
under reduced pressure to yield the crude product, which was further purified by column 
chromatography on silica gel using dichloromethane/methanol solvent systems to obtain 
compound 5 as a light yellow solid (445 mg, 95%). Next, N, N-Diisopropylethylamine 
(0.623 mL, 3.58 mmol) was added to a suspension of compound 5 (436 mg, 0.716 mmol) 
and DIC-EBE (458 mg, 1.074 mmol) in dichloromethane (10 mL) and stirred for 1h at 
room temperature. After the reaction mixture was concentrated under reduced pressure, 
the resulting crude product was further purified by column chromatography on silica gel 
using dichloromethane/methanol solvent systems to obtain compound 6 as a white solid 
(455 mg, 71%). %). Trifluoroacetic acid (1 mL) was added to a solution of compound 6 
(300 mg, 0.334 mmol) in dichloromethane (10 mL). The resulting solution was stirred at 
room temperature for 1h. The reaction mixture was concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel using 
dichloromethane-methanol mixture to afford Codrug IV as a semi solid (120 mg, 45%). 
7.2.3 HPLC assay 
All codrugs and parent drugs were quantified using HPLC. The HPLC instrument 
used consisted of a Waters™ e2695 separation module, a 2489 UV/Visible detector and 
Empower™3 software. A Perkin Elmer Spheri5 VL C18 column (5µ, 220 x 4.6mm) and a 
C18 guard column (15 x 3.2mm) were used with the UV detector set at a wavelength of 
280nm/215nm. The mobile phase consisted of 70:30(v/v) ACN: (0.1% TFA with 0.065% 
1-octane sulfonic acid sodium salt, adjusted to pH 3.0 with TEA aqueous phase). 
Samples were run at a flow rate of 1.5 ml/min. All codrugs and parent drugs were 
quantified using standard curves in the range of 100-10,000 ng/ml. 
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7.2.4 Stability studies 
The stabilities of all codrugs were determined in 0.3M acetate buffer pH 5.0 at 
32ºC. For stability studies drug was presolubilized in ACN. The solution was then used to 
spike prewarmed buffer at 32ºC (100µl in 10ml of buffer, <1% total ACN concentration). 
One hundred µl samples were obtained at regular time intervals and the reaction was 
terminated using 900µl of ACN. All samples were stored at -80ºC until analysis using 
HPLC. Samples were stable in -80ºC verified using quality control standards (data not 
shown). Data for all stability studies were analyzed using pseudo first-order kinetics. All 
studies were run in triplicate. 
7.2.5 Donor solution preparation and solubility determination 
Donor solution was prepared for all codrugs in 0.3M acetate buffer pH 5.0 
containing 10% propylene glycol (PG). Excess drug was added to the above mixture, 
vortexed, sonicated for 10 min and left overnight at 32ºC (The only exception, codrug I 
was incubated in donor solution for an hour before dosing due to stability issues). The 
choice of the donor was based on previous studies using codrugs and flux of model 
compounds across MN treated skin.21, 147 For solubility determination, codrug solution 
was removed from the donor, filtered using a 0.2µm, 500µl centrifugal filter and injected 
onto the HPLC after suitable dilution with ACN. Saturation solubility was determined for 
all codrugs except hydrochloride salt of codrug III due to limited availability of codrug. All 
solubility determinations were carried out in triplicate. 
7.2.6 Melting point determination of codrugs 
 Differential scanning calorimetry (DSC) was used to estimate melting point of 
parent drugs and codrugs in the range of 50-300ºC. The apparatus used was a DSC 
2920 with a DSC refrigerated cooling system from Texas Instruments (TA Instruments, 
New Castle, DE). Two to five mg of drug was weighed into hermetic aluminum pans and 
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sealed with a lid. Drug was heated @10ºC/min from 50-300ºC.  Data was collected using 
Thermal Advantage and analyzed using Universal Analysis 2000 softwares from TA 
Instruments. Melting point was determined from the inflection point of the melting curve. 
7.2.7 Diffusion studies 
All diffusion studies were carried out using full thickness Yucatan miniature pig 
skin. Studies were approved by the IACUC protocols at University of Kentucky and 
University of Maryland, Baltimore. The skin was obtained from euthanized animals, 
dermatomed to a thickness of 1.4-1.8mm and stored at -20ºC until the day of the 
experiment. MN’s for this study were obtained from Dr. Mark Prausnitz’s laboratory at 
the Georgia Institute of Technology. A 5 MN in plane array was used for in vitro studies.  
Each MN was 750 µm long, 200µm wide and 75 µm thick and the interneedle spacing 
was 1.35µm. For all experiments skin was cut into small rectangular pieces. They were 
then placed on a wafer of Sylguard® 184 silicone elastomer to mimic the underlying 
tissue and treated with a 5 MN array,  20 times to generate a total of 100 MN pores per 
diffusion cell (within the 0.95cm2 active area). The permeation experiments were carried 
out using a PermeGear® flow through system (In-line, Riegelsville, PA). The receiver 
solution used was water alkalified to pH 7.4 containing 20% ethanol at 37ºC. The flow 
rate was set at 1.5ml/h and the temperature of the diffusion cells was maintained at 32ºC 
to mimic physiological skin surface conditions. Each cell was charged with 250µl of the 
relevant codrug or parent drug for control cells and receiver solution was collected in 6h 
increments for a total of 48h. At the end of the study the cells were removed and drug 
was quantified both in the receiver solution and skin samples using HPLC. For the 
receiver solution, steady state flux values were determined for NTX/NTXol from the 
codrugs using Fick’s first law of diffusion. The cumulative amount permeated was plotted 
as a function of time and the slope of the steady state portion of the curve was used to 
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determine flux. Permeation profiles did not reach steady state in the 48h timeframe for 
DIC and codrug, so cumulative amount of drug permeated was quantified, where 
applicable. Receiver samples were concentrated, if required by evaporating 1ml of the 
receiver solution under nitrogen at 37°C followed by reconstitution in 100µl of ACN.  For 
quantification of the drug concentration in the skin samples, the active permeation area 
was dissected out and cut into small pieces. The concentration of parent drugs and 
codrug in the skin was determined by incubating the skin in 10ml of ACN overnight at 
32ºC and analyzing the solution by HPLC after appropriate dilutions. All permeation 
studies were carried out in triplicate, at a minimum.  
7.2.8 Statistical analysis 
 Data for all experiments were reported as mean ± standard deviation. Statistical 
analysis of data was carried out with Students’t-test and one way ANOVA with post hoc 
Tukey’s pairwise tests, if required, using GraphPad Prism® software, and version 5.04 
software. P<0.05 was considered to be statistically significant. 
7.3 Results 
7.3.1 Synthesis of codrugs 
Structures of all codrugs are provided in Figure 7.2. The synthesis of codrug I, 
base and salt form has been previously reported. 147 Codrugs II, III and IV and 
hydrochloride salt form of codrug III were synthesized successfully. The structures were 
verified using 1HNMR and HRMS 
Codrug II: 1H NMR (CDCl3, 500 MHz)  7.41-7.24 (m, 10 H),7.09 (m, 1H), 6.96-6.92 (m, 
3H), 6.72 (m, 1H), 6.57-6.54 (m, 2H), 5.31 (2H, s), 5.12-5.07 (m, 3H), 4.79-4.71 (m, 2H), 
4.04 (m, 2H), 3.86 (s, 2H), 3.49 (m, 2H), 3.08-2.99 (m, 2H), 2.64-2.56 (m, 2H), 2.39-2.18 
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(m, 4H), 2.09-1.95 (m, 7H), 1.81 (m, 1H), 1.71-1.60 (m, 12H), 1.49-1.43 (m, 2H), 1.37-
1.27 (m, 6H), 1.17-1.11 (m, 7H), 0.84 (m, 1H), 0.52 (m, 2H), 0.12 (m, 2H) 
Codrug III: 1H NMR (CDCl3, 500 MHz)  7.78 (s, 1H), 7.32 (m, 2H), 7.12-7.07 (m, 2H), 
6.97-6.93 (m, 2H), 6.86 (t, 1H, J = 8.5 Hz), 6.71-6.66 (m, 3H), 6.60 (m, 1H), 6.49 (d, 1H, 
J = 8.5 Hz), 5.98 (m, 1H), 4.69 (m, 2H), 3.64-3.44 (m, 13H), 3.19 (s, 2H), 3.10-3.00 (m, 
4H), 2.72-2.56 (m, 4H), 2.44-2.31 (m, 8H),  2.17-2.12 (m, 3H), 1.90-1.26 (m, 8H), 0.86 
(m, 2H), 0.56 (m, 4H), 0.15 (m, 4H) 
Codrug III HCl salt: 1H NMR (DMSO-d6, 500 MHz)  8.66-8.58 (m, 2H), 8.08 (s, 1H), 7.96 
(s, 1H), 7.47 (s, 1H), 7.08 (m, 2H), 6.77-6.74 (m, 2H), 6.61 (m, 1H), 6.63 (d, 1H, J = 7.0 
Hz), 6.41-6.36 (m, 2H), 6.28-6.22 (m, 2H), 5.85 (m, 1H), 4.70 (s, 1H), 4.58 (s, 1H), 3.61-
3.56 (m, 2H), 2.82-2.79 (m, 6H), 2.71-2.50 (m, 11H), 2.30-2.23 (m, 3H), 2.09 (m, 12H), 
1.74-1.59 (m, 4H), 1.09-1.07 (m, 4H), 0.67-0.64 (m, 6H), 0.27 (m, 2H), 0.20 (m, 2H), 
0.10 (m, 2H), 0.00 (m, 2H) 
Codrug IV: 1H NMR (CDCl3, 500 MHz)  7.62 (s, 1H), 7.33-7.31 (m, 2H), 7.17-7.15 (m, 
1H), 7.09-7.08 (m, 1H), 6.96 (t, 1H, J = 8.0 Hz), 6.88-6.86 (m, 1H), 6.76-6.69 (m, 2H), 
6.65 (d, 1H, J = 8.0 Hz), 6.49 (d, 1H, J = 8.0 Hz), 5.28 (m, 1H), 4.51 (m, 2H), 3.76-3.47 
(m, 18H), 3.08-2.97 (m, 3H), 2.59-2.57 (m, 2H), 2.35 (m, 2H), 2.18-1.88 (m, 8H), 1.60-
1.58 (m, 1H), 1.46-1.25 (m, 9H), 0.82 (m, 1H), 0.51 (m, 2H), 0.11 (m, 2H) 
7.3.2 HPLC assay development 
The first step towards analysis of codrugs and parent drugs was development of 
a HPLC method. The same column, mobile phase composition and wavelength (280nm) 
were used for all compounds.  All codrugs and parent drugs had baseline resolution on 
the assay. The retention times (±0.1 min) for all compounds from the HPLC assay are 
reported in table I. Standard curves for both codrugs and parent drugs were prepared in 
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the range of 100-10,000 ng/ml for ACN samples and 100-5000 ng/ml for extracted 
receiver samples. All standard curves were linear (r2>0.999).  
7.3.3 Stability and solubility studies 
 Formulation stability was carried out for all codrugs to determine the relative rate 
of conversion due to chemical hydrolysis. The results indicated that stability was 
significantly enhanced by using the 6-O-secondary alcohol linkage over the 3-O-phenol 
linkage for both codrugs I and II, and codrugs III and IV. Stability was also significantly 
enhanced by using the PEG covalent link and carbamate/ amide linkage compared to 
the ester linkage, both for codrug I and III, and codrug II and IV. (Figure 7.4) 
 The solubility studies were carried out to quantify saturation solubility of codrugs 
in donor formulation and evaluate its effect on flux.  The studies indicated that solubility 
of the NTX-DIC codrugs were significantly higher compared to NTXol-DIC codrugs with 
similar linkage. The PEG linkage enhanced solubility for codrug III and IV, as compared 
to codrug I and II. Solubilities of codrugs were also enhanced by using a hydrochloride 
salt form of the drug compared to a free base form.   
7.3.4 Diffusion studies 
 The diffusion studies were carried out to quantify the permeation of NTX/NTXol 
across the skin and concentration of codrugs and parent drugs in the skin. The diffusion 
studies indicated that flux of NTX from codrugs I salt and III were significantly higher 
compared to flux of NTXol from codrugs II and IV (p< 0.05). The flux of NTX from codrug 
I salt and codrug III, and NTXol from codrug II and codrug IV were not significantly 
different from each other (p>0.05). (Figure 7.5) Permeation of DIC and intact codrug was 
also observed for codrug III from the 10% PG containing formulation. Cumulative 
amount of DIC and codrug present in the receiver solution were 1.09 ± 0.36 nmol and 
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2.89 ± 1.0 nmol, respectively, at the end of the 48hr experiment. NTX flux was further 
enhanced by 2.5 fold on using the salt form of codrug III, over free base form. (Figure 
7.6) Significantly higher permeation of DIC and intact codrug were also observed using 
the salt form of codrug III, they were 3.1±0.86nmol and 24.3 ± 8.8 nmol, respectively.  
 Skin concentration of codrugs and parent drugs were quantified at the end of the 
experiment to evaluate the effect of codrug structure on bioconversion in the skin. The 
skin concentration data indicated that bioconversion was more complete for NTX-DIC 
codrugs compared to the NTXol-DIC codrugs. Intact codrug was present in the skin for 
all codrugs, whereas NTX and DIC were only quantifiable for codrugs I and III. Skin 
concentrations of codrugs were not significantly different among the 4 codrugs. Skin 
concentration of NTX was not significantly different between codrugs I and III (p>0.05). 
Skin concentration of DIC was significantly different between codrugs I and III (p<0.05). 
Skin concentration was also determined for codrug III salt to evaluate the effect of salt 
form on skin concentration. No significant differences were observed for NTX or DIC 
concentration using codrug III base or salt form (p>0.05).  
Flux data from codrug I has been previously reported. 147The salt form of codrug I 
has been used for all comparisons for diffusion experiments in this study since the 
limited solubility of the free base form in 10% PG containing formulation prevented direct 
comparison of results. 
7.4 Discussion 
Prodrugs and codrugs have been explored for drug delivery via different routes 
over the last few decades. The approach is mostly used to solve a drug delivery issue 
and the major advantage lies in the fact that chemical modification renders the new 
chemical entity pharmacologically inactive thus decreasing potential side effects and the 
need for additional pharmacological evaluation. Compared to all other routes of drug 
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delivery, the topical/transdermal field has seen slower progress in terms of the number 
of new API’s approved and on the market over the years. 29 The most important reason 
being the extreme barrier property of the skin/SC. Chemical modification of the API itself 
to form codrugs/prodrugs provides a new approach for flux enhancement, decreasing 
some of the need for excess permeation enhancer supplementation.  Additionally, two 
API can be delivered at the same time in a codrug to have a synergistic effect. A few 
examples of topical/transdermal codrugs that have been evaluated include NTX and 
bupropion for smoking cessation and alcohol addiction, retinyl ascorbate and ascorbic 
acid for oxidative stress, and 5 fluorouracil with triamcinolone acetonide for actinic 
keratosis. 87, 88  
The current study evaluated codrugs for pore lifetime enhancement following MN 
treatment. Unlike previous codrug examples in the literature where both drugs were 
targeted either for systemic delivery or for topical application, the NTX/NTXol codrugs 
are designed for systemic delivery of NTX/NTXol while DIC acts locally in the 
SC/epidermal layer of the skin to enhance micropore lifetime. The physicochemical 
properties of NTX allow systemic permeation, and a higher log P and negative charge 
facilitates retention of DIC in the skin. 147 
Purity and structure of all codrugs were confirmed using NMR and HRMS. 
Quantitative analysis is an important step in the development of any drug delivery 
system. HPLC was used for quantification of codrug and parent drugs in stability, 
solubility and permeation studies. Since all compounds were evaluated using reverse 
phase chromatography and the same assay parameters, retention time on the HPLC 
can be used as a comparative estimate of hydrophobicity or log P of the molecules. 164  
NTX and NTXol were comparable in hydrophobicity with NTXol being slightly more 
hydrophilic due to the presence of an additional hydroxyl group at the 6 position 
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compared to the ketone of NTX. DIC was the most hydrophobic of the parent molecules, 
which is expected from the reported log P values from Scifinder®. Comparing codrugs I 
and II, codrug I with a retention time of 4.9 min was more hydrophobic compared to 
codrug II at 4.4 min. The difference in hydrophobicity can be attributed to more 
significant hydrophilic interactions of a phenolic hydroxyl as compared to a ketone 
functional group substitution. Comparison of codrug III and IV followed the same pattern, 
where the retention time shifted from 3.8 min for codrug III to 3.7 min for codrug IV. 
Although in both cases the codrugs with the free phenolic hydroxyl had less retention on 
the column, the shift was much less significant for the PEG linked codrugs. This can be 
attributed to significant hydrophilic interactions of the PEG chain itself. Effect of PEG 
chain on enhancement of hydrophillicity is also confirmed by the fact that both codrug III 
and IV are eluted significantly earlier than codrug I and II. Since 
hydrophobicity/hydrophilicity plays an important role in permeation of molecules across 
intact and MN treated skin, the comparative analysis provides an estimate of solubility 
and transport. For MN treated skin, it has been shown that lower viscosity aqueous 
formulations lead to higher flux. Higher hydrophillicity would translate into enhanced 
solubility in an aqueous medium; a molecule with lower log P will be beneficial for the 
current delivery system in terms of higher solubility. 
Codrugs/prodrugs are primarily designed to solve a drug delivery problem, but 
since these molecules are pharmacologically inactive chemical/enzymatic hydrolysis is 
imperative for bioconversion and function of these molecules. In the current project, 
codrugs were designed to formulate NTX and DIC in a single formulation so that 
precipitation of one drug on application of the other didn’t lead to reduced NTX flux 
across the micropores. Thus, stability in formulation is a very important criterion for these 
codrugs. The results from the stability studies indicated that codrugs I and III (phenol 
122 
 
linked codrugs) were less stable in formulation compared to codrugs II and IV 
(secondary alcohol linked codrugs). This was expected since the resonance stabilization 
of a phenol makes it a better leaving group compared to a secondary alcohol. Codrug III 
was more stable compared to codrug I, and codrug IV was more stable compared to 
codrug II. This can be attributed to the carbamate/amide linkage in place of the ester 
linkage. It has been shown in the literature that ester linked prodrugs are more 
susceptible to chemical hydrolysis as compared to carbamate prodrugs at a formulation 
pH of 5.0. 21 On the other hand, carbamate linked prodrugs are less stable at 
physiological pH 7.4 at similar buffer concentrations. 21 The change in the rate of 
chemical degradation within the pH range indicates that the primary mechanism for 
hydrolysis of a monosubstituted carbamate in an aqueous formulation is probably via 
proton elimination and not nucleophile attack of hydroxyl groups. 165 Thus employing 
carbamate codrugs enhances formulation stability and could be beneficial because they 
are known to degrade faster under physiological conditions. Since NTX/ NTXol and DIC 
codrugs could not be linked directly with a carbamate linkage, a PEG link was used to 
serve the dual role of linking the molecules and enhancing solubility. PEG is one of the 
most commonly used topical/transdermal excipients, thus irritation, toxicity and side 
effects related to incorporation of PEG in the formulation should be limited or non-
existent. Once inside the body, PEG is metabolized into a series of phase I and II 
metabolites, with no toxicological concern. Molecular weight of the PEG subunit does 
play a role in its metabolism, with PEG’s >5000 showing little or no metabolism. 166 Thus 
from the stability studies it can be concluded that codrugs II, III and IV with more than 
85% intact codrug in formulation at 7 days could be used for the development of a drug 
delivery system. Since the stability studies were conducted in aqueous buffers, the 
codrugs will be expected to be more stable in a 10% PG containing formulation since 
hydrolysis is the primary mechanism for degradation. Once inside the body, the codrugs 
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will be degraded by enzymatic hydrolysis in the skin, in addition to chemical hydrolysis 
for much faster regeneration of parent drugs. Presence of esterase, amidase, and 
protease, in addition to the normal phase I and II enzymes are well documented in the 
skin. 32, 159 
Solubility of drug in the donor is important for transdermal drug delivery. The drug 
concentration in formulation is the main driving force for transport across the skin. As 
stated before, MN-enhanced drug delivery with lower viscosity aqueous formulations has 
demonstrated significantly higher flux compared to viscous PG-rich formulations. Ten 
percent PG containing 0.3M acetate buffer at pH 5.0 was chosen as the formulation 
based on previous studies. 29, 147 The solubility data indicated that the PEG link 
significantly enhanced solubility for both codrug III and IV, compared to codrug I and II. 
Solubility of codrug I and III was higher compared to II and IV, indicating that phenol 
linked codrugs are more soluble compared to secondary alcohol linked codrugs. This 
can be further explained in terms of the melting point (MP) estimates where codrug I has 
a lower melting point compared to codrug II. Lower MP translates into higher aqueous 
solubility for the unionized form of the drug. 167  
Stability and solubility studies provide important information about how well drug 
transport might proceed, however skin permeation studies are required for estimation of 
flux and bioconversion in the skin. Diffusion studies were carried out using dermatomed 
Yucatan miniature pig skin. The choice of the animal model was based on previous 
studies with MN and transdermal drug delivery. 46, 146 The diffusion studies indicated that 
the flux of NTX from codrug I and III was significantly higher compared to NTXol flux 
from codrug II and IV. This can be attributed to the higher formulation stability of the 
NTXol codrugs; significant amounts of intact codrug were found in the skin, and no 
parent drugs were quantified at the end of the study suggesting that NTXol was not 
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released efficiently from the codrug to generate transdermal flux. The difference in 
physicochemical properties of NTX and NTXol could also be responsible for reduced flux 
of NTXol. Since NTXol has an additional hydroxyl group following conversion, H-bonding 
potential of NTXol is higher. It has been shown in the literature that the higher the 
number of hydrogen bonds, the lower the transdermal flux across intact skin. 53 The skin 
concentration study also showed that DIC was only present in the skin for the NTX 
codrugs. Since the presence of DIC in the skin is imperative for its local effect on pore 
lifetime enhancement, the NTXol codrugs would not be able to keep micropores open 
beyond 48-72h in the absence of DIC. Also, significantly lower flux from these codrugs 
as compared to the NTX codrugs is a disadvantage.  The skin concentration of DIC is 
significantly different between codrug I and III. This can be explained with the help of 
mass spectrometry data (not shown) which indicates that DIC is not completely 
bioconverted in the skin from codrug III. A mixture of DIC (MW: 296) and DIC + PEG 
linker conjugate (MW: 452) was found in the receiver and skin samples by mass scan 
and ESI-/ ESI+ ionization. Since an accurate estimate of local skin concentration of DIC 
required for pore lifetime enhancement is not available, it would be beneficial to test 
codrug III in vivo to see if it is efficacious. If not, the linker at the DIC end of the molecule 
will have to be optimized further for faster release of DIC. 
The hydrochloride salt form of codrug I led to a 13-fold enhancement in solubility 
and transdermal flux 147, but direct comparison of the effect of the salt formulation could 
not be evaluated due to changes in donor composition. A hydrochloride salt form of 
codrug III was synthesized and evaluated for further solubility and flux enhancement in 
vitro. Codrug III was chosen because formulation stability and solubility was higher as 
compared to codrug I. Codrugs II and IV were comparatively more stable but 
bioconversion, transdermal flux of NTXol, and skin concentrations of DIC were much 
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lower.  The permeation studies indicated that flux of NTX can be further enhanced using 
a salt form of the codrug over the free base form. A 2.5 fold enhancement in NTX flux 
was obtained using a sub-saturated codrug III salt as donor compared to free base. 
(Saturated donor could not be used due to limited availability of codrug III salt.) The 
permeabilities of NTX from codrug and codrug salt were not significantly different from 
each other, indicating that the flux enhancement was due to enhanced solubility. Skin 
concentrations of codrug or parent drugs were not significantly different between salt 
and free base.  Thus salt form has no significant effect on skin concentration of the 
parent drugs or the codrug, when comparing data from the same donor condition, 
irrespective of the physicochemical properties of the molecule. This will be useful if 
alternate salt forms are used to further enhance solubility, 139 and additional studies for 
determination of local skin concentration of DIC will not be necessary. The salt form also 
led to higher cumulative amounts of DIC and codrug permeation compared to the base. 
Intact codrug diffusing through the skin will convert under physiological conditions to 
regenerate parent drugs, thus further contributing to plasma concentrations of NTX. The 
amount of DIC permeated through the skin is well below therapeutic systemic 
concentrations and thus should not be of any concern.  
Therefore, from the structure permeability evaluation it can be concluded that 
NTX-DIC PEG linked codrug (codrug III) is the best choice for the current project in 
terms of stability, solubility, bioconversion and NTX flux.  NTX requires a flux of 12-
90nmol/cm2/h from a 25cm2 patch for therapeutic efficacy, based on current oral dosing 
and clearance. Codrug III hydrochloride salt has a flux of 10.8 ± 2.1 nmol/cm2/h from the 
currently tested sub-saturated solution; therefore further flux enhancement is expected 
using a saturated solution. From stability data, 85% of codrug III will be intact in 
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formulation over a 7 day patch application period, rendering it to be a suitable molecule 
for in vivo evaluation of the codrug concept via pharmacokinetic studies.  
7.5 Conclusion 
 NTX/NTXol and DIC codrugs were designed and evaluated for development of a 
7 day drug delivery system for alcohol addiction treatment. Stability, solubility, 
transdermal flux of NTX and local skin concentration of DIC were determined to develop 
a structure permeability relationship for the codrugs. A secondary alcohol linker 
enhanced stability of codrug molecules, however solubility, bioconversion, flux of NTX 
and local skin concentration of DIC were higher using phenol linked codrugs. Transport 
was further enhanced by utilizing a hydrochloride salt form of the PEG linked NTX-DIC 
codrug making it the most suitable candidate for further in vivo pharmacokinetic studies.  
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Table 7.1 Physical properties of parent drugs and codrugs 
 
Molecular 
weight (MW) 
Color/Consistency 
Retention 
time 
(min) 
Melting 
point 
(ºC) 
Naltrexone 341.4 White/Solid 2.1 178 
Naltrexol 343.4 
Yellowish 
white/Solid 
2.0 191.5 
Diclofenac 296.15 White/Solid 2.9 184 
Codrug I 
(hydrochloride 
salt) 
619.53 
656.0 
White/Solid 
White/Solid 
4.9 
--- 
152.5 
Codrug II 621.55 Slightly yellow/Solid 4.4 202 
Codrug III 
(hydrochloride 
salt) 
793.73 
830.19 
Yellow/Solid 
Yellow/Solid 
3.8 --- 
Codrug IV 795.75 Cream/Solid 3.7 ---- 
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Table 7.2  Physicochemical characterization of codrugs 
 
Solubility 
(mM) 
Pseudo first order 
rate constant (k) 
(days -1) 
Stability 
(Approx. half-life) 
(days) 
Codrug I 
(hydrochloride 
salt) 
7.23* 
83.8 ± 15.4 
0.0803 8.72 ± 1.05 
Codrug II ----- 0.0052 130.88 ± 4.94 
Codrug III 
(hydrochloride 
salt) 
27.16 ± 0.5 
87.67 ± 1.5┼ 
0.0238 29.14 ± 1.04 
Codrug IV 6.8 ± 0.2 0.0035 187.56 ± 8.55 
 
n≥3 for all estimates except melting point determination 
*Codrug I solubility was determined in 43% PG, 43% ethanol containing solution (data 
previously reported in 147 
┼Saturation solubility could not be reported due to limited codrug 
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Figure 7.1 Microneedle array with 5 MN array for in vitro studies and 50 MN array 
for in vivo studies and applicator for 5 MN array(left panel), Yucatan miniature pig 
skin before treatment and following treatment with gentian violet for visualization 
(right panel) 
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Figure 7.2 Structures of NTX/NTXol and DIC codrugs 
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Figure 7.3 Structures of intermediates for codrug synthesis 
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Figure 7.4 Stability of NTX/DIC codrugs in 0.3M acetate buffer pH 5.0. Data 
analyzed using pseudo first-order kinetics. n=3 for all codrugs 
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Figure 7.5 Flux of NTX/NTXol and skin concentration of parent drugs and codrugs. 
n≥3 for all studies. Flux of NTX from codrug I and codrug III are not significantly 
different (p>0.05) and they are higher than NTXol flux from codrug II and codrug IV 
(p<0.05). Skin concentration of NTX and codrug are not significantly different for I and III 
(p>0.05). Skin concentration of DIC is significantly different (p<0.05) 
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Figure 7.6 Flux and skin concentration from codrug III and codrug III salt. n≥3 for 
all studies. Flux of NTX was significantly higher (p<0.05). No significant difference 
in skin concentration except for codrug (p>0.05) 
Copyright © Priyanka Ghosh 2013 
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Chapter 8 
Fluvastatin as a micropore lifetime enhancer for sustained delivery across 
microneedle treated skin 
8.1 Introduction 
Transdermal drug delivery allows delivery of drugs across the skin. The skin is 
best described as a three layer model for drug delivery purposes. From top down these 
layers are stratum corneum (SC), the epidermis and the dermis. Among these, the SC is 
the major rate limiting step to delivery of most drugs across the skin, due to its rigid 
structure and high lipophilicity. 1 A very small subset of molecules can effectively cross 
the SC barrier in therapeutically relevant amounts29. The structure of the SC is 
composed of dead keratinized remains of once rapidly dividing epidermal cells bound 
tightly by a lipid matrix. 29 The intercellular domain of the SC is composed of three 
different lipid molecules, namely cholesterol, free fatty acids and ceramide in equimolar 
ratio. 73, 75 There is a plethora of literature on the proposed mechanisms of recovery after 
SC disruption using different methods like tape stripping, acetone treatment, surfactants, 
etc. Formation and release of lamellar body contents is a major process in regeneration 
of the SC barrier following disruption or normal wear and tear. There is an initial burst (0-
30 minutes) release of preformed lamellar body contents followed by the up regulation of 
lamellar body synthesis, which includes both lipid precursors and hydrolytic enzymes. 74, 
92  Following release at the interface of the SC and epidermis, the lamellar body contents 
undergo extracellular processing to form comparatively nonpolar SC lipids from their 
polar precursors. Thus a host of enzymes and biochemical pathways are involved in 
proper functioning of the SC barrier. Modulation of a number of the precursors and the 
enzymes involved lead to malformation of the SC barrier following insult. 73, 75  A 
constant molar ratio of the lipids is one of the most important parameters in barrier 
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recovery and a decrease in synthesis of any of the three lipids or their precursors leads 
to a delay due to malformation of lamellar bodies. 24 
 Microneedles (MN) are an alternative technique used to permeablize the SC 
barrier and increase the number of drugs that can be delivered transdermally. It is a 
physical enhancement technique. 42 There are a number of different types of MN and 
application techniques. Solid MN’s are used to permeablize the skin followed by 
application of drug over treated skin, or drug coated onto the MN itself. Polymer MN’s 
are used to load drug into the polymer itself for delivery. Hollow MN’s are used in 
conjunction with an infusion pump to facilitate delivery of hormones and vaccines over 
short periods of time. 2, 27, 42  The effectiveness of MN as a drug delivery vehicle has 
been established in the literature over the past decade. 4, 43, 44, 47, 168 The MN delivery 
system is very useful for short term delivery, over a few hours. 5, 30, 57 However, the 
efficacy of the technique is severely limited due to normal healing processes of the skin 
which lead to re-sealing of the micropores anywhere between a 48-72h timeframe under 
occlusion. 10-12 Thus, drug can only be delivered across MN treated skin for a maximum 
of 3 days under occlusion. 4, 14 Lifetime of the micropore when exposed to air is much 
shorter and ranges from 15 minutes to a few hours depending on the MN geometry, 
animal model and detection method used. 10-12 The shorter timeframe of micropore 
resealing can be explained in terms of enhanced transepidermal water loss (TEWL) in 
absence of occlusion.  TEWL is the most important signal for barrier recovery and 
lamellar body secretion following insult to the skin. 94 
 Biochemical enhancers/lipid biosynthesis inhibitors prevent the synthesis of the 
essential lipids required for lamellar body synthesis and thus the proper formation of the 
SC. Local concentrations of specific inhibitors of the three lipid synthesis pathways 
namely cholesterol, fatty acids and ceramides can be used to alter the molar ratio and 
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thus delay barrier recovery . 75 The inhibitors can be used either as a pretreatment or in 
formulation. Some of the inhibitors that can be used for the above mechanism are 5-
(tetradecycloxy)-2-furancarboxylic acid (TOFA) for fatty acid synthesis, fluvastatin (FLU) 
for cholesterol synthesis, and β-chloroalanine (BCA) for ceramide synthesis. 75 
The goal of the current study was to evaluate the effectiveness of FLU, an 
HMGCoA reductase inhibitor and the most important enzyme of the cholesterol 
synthesis pathway, as a pore lifetime enhancement agent for sustained drug delivery 
across MN treated skin. Solid stainless steel MN’s were used to permeablize the skin. 
This technique is also known as the “poke (press) and patch” approach and is 
advantageous for sustained delivery because the MN is only used to permeablize the 
skin and does not remain in contact with skin thereafter. 42 The current efforts are 
directed towards enhancing the drug delivery window to 7 days, the ideal transdermal 
patch wear time, by using a biochemical enhancement technique in addition to MN. The 
study fulfills research goals 3.5, 3.6 and 3.7. 
The model compound for the drug delivery project was naltrexone (NTX). It is a 
µ-opioid receptor antagonist used for alcohol and opioid addiction. The currently 
approved dosage forms include oral and an extended release intramuscular injection. 16, 
17 The oral dosage form has issues with variable bioavaibility and compliance in its 
treatment population due to daily dosing and side effects. 16, 124 The extended release 
intramuscular injection is difficult to remove if there is a need for emergency opiate 
treatment, and also leads to injection site reactions.17, 126 Thus NTX is a suitable 
candidate for transdermal patch development and an active delivery system in the form 
of MN is used in this project since the drug cannot be delivered in therapeutic 
concentrations via passive delivery. 4 It has been previously shown that by using MN, 
NTX can be delivered at therapeutic levels for 2-3 days in humans.4  
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8.2 Experimental section 
8.2.1 Materials 
Naltrexone HCl was purchased from Mallinckrodt (St. Louis, MO), and fluvastatin 
sodium from Cayman chemical (Ann Arbor, MI). Propylene glycol and ethanol (200 proof) 
were purchased from Sigma (St. Louis, MO). Acetic acid, ammonium acetate and benzyl 
alcohol were obtained from Fisher Scientific (Fair Lawn, NJ). 1-Octanesulfonate, sodium 
salt was obtained from Regis Technologies, Inc (Morton Grove, IL). Trifluroacetic acid 
(TFA), triethylamine (TEA), methanol, ethyl acetate and acetonitrile (ACN) were obtained 
from EMD chemicals (Gibbstown, NJ). Natrosol® (hydroxyethlycellulose) was obtained 
from Ashland (Wilmington, DE). Ethanol (70%) was obtained from Ricca chemical 
(Arlington, TX). Sterile water for injection was from Hospira (Lake Forest, IL) and water 
was purified using a NANOpure DIamondTM, Barnstead water filtration system for all in 
vitro experiments. 
8.2.2 HPLC methods 
NTX and FLU were quantified using high pressure liquid chromatography 
(HPLC). The HPLC system consisted of a Waters 717 plus auto-sampler, a Waters 600 
quaternary pump, and a Waters 2487 dual wavelength absorbance detector with Waters 
Empower™ software. A Perkin Elmer Brownlee™ Spheri 5 VL C18 column (5 µ, 220 x 
4.6 mm) and a C18 guard column (15 x 3.2 mm) were used with the UV detector set at a 
wavelength of 280 nm for NTX and 305nm for FLU. The mobile phase consisted of 
65:35 (v/v) ACN: (0.1% TFA with 0.065% 1-octane sulfonic acid sodium salt, adjusted to 
pH 3.0 with TEA aqueous phase). Samples were run at a flow rate of 1.5 ml/min. The 
injection volume used was 100µl for all samples. 
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8.2.3 In vitro experiments 
The in vitro studies were carried out to look at the flux across MN treated skin 
and the skin concentrations of NTX and FLU in the skin. Full thickness Yucatan 
miniature pig skin was used for all in vitro experiments. All pig tissue harvesting 
experiments were done under IACUC approved protocols at the University of Kentucky.  
Fresh skin was cleaned to remove excess subcutaneous fat, dermatomed and stored at 
-20°C. Skin was thawed and cut into small square pieces on the day of the diffusion 
experiment. The thickness was measured for each individual piece of skin and the 
average thickness of all treatment groups was maintained between 1.4-1.8mm. Skin was 
next treated with a 5 MN in-plane array, 10 times in one direction and 10 times in a 
mutually perpendicular direction to generate a total of 100 MN insertions within the 
active treatment area of 0.95cm2. Five treatment groups were used based on the 4 
different vehicles used for FLU and a control for NTX only; all studies were done in 
triplicate. Saturated NTX gel was prepared by mixing 90mg/ml of NTX HCl (saturated 
solution) with propylene glycol (PG) (10%). A 3% HEC gel of the NTX solution was used 
for the in vitro studies. The 4 different FLU treatments were FLU in 200 proof ethanol, 
acetone, PG: ethanol=7:3 and PG: ethanol: water=1:2:1. All the vehicles for FLU were 
based on previous studies looking at recovery of the skin or commonly used drug 
deposition methods. 72, 75 The concentration of FLU was 1.5% for all the formulations and 
40µl of the formulation was applied to each cell. The receiver solution was water 
alkalified to pH 7.4 containing 20% ethanol at 37ºC to mimic physiological conditions. 
The temperature of the diffusion cell skin surface was maintained at 32ºC. Samples 
were collected every 6h for 48h. All samples were analyzed using HPLC. The steady 
state flux of NTX was calculated using the steady state portion of the cumulative amount 
permeated vs. time plot. The skin concentrations of both drugs were also determined at 
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the end of the study by extracting the drug overnight into 10ml of ACN, and injecting the 
extracted sample onto the HPLC column after appropriate dilutions. 
8.2.4 Pharmacokinetic studies 
Pharmacokinetic (PK) studies were carried out in hairless guinea pigs (HGP) 
using FLU and NTX to evaluate the effectiveness of FLU as a pore lifetime enhancement 
technique. All animal studies were approved by the IACUC at University of Kentucky and 
University of Maryland. All animals used had jugular vein catheters. Catheters were 
either implanted in the laboratory or animals were purchased with catheters from 
Charles River. Three treatment groups were used for the PK studies. Treatment group: 
300µl of NTX gel + 40µl of FLU in ethanol (200 proof), vehicle control group: 300µl of 
NTX gel + 40µl of ethanol (200 proof), MN control group: 200µl of NTX gel. For PK 
studies, preparation of the NTX gel was similar to the in vitro studies except 1% benzyl 
alcohol was added as an antibacterial agent. All sites were treated twice with a 50 MN 
array to generate a total of 100MN pores and there were 2 treatment sites per animal. 
FLU was deposited using the ethanol solution in the active treatment group; only ethanol 
was used in the vehicle control group followed by NTX gel for all three groups. All sites 
were occluded using patches 148 for 7 days following treatment. Two hundred µl blood 
samples were withdrawn from the catheter at regular intervals into collection tubes 
precoated with 500IU/ml heparin. The blood samples were immediately centrifuged at 
10,000 x g for 3 min; plasma was separated and stored at 80C until analysis. All in 
vivo studies were carried out at least in triplicate. Data for control studies were 
previously reported in Nicole Brogden’s thesis at the University of Kentucky.14 
8.2.5 LC/MS-MS analysis of plasma samples 
 All plasma samples were extracted  using a previously validated method. 146 
Five hundred µl of 1:1 ACN: ethyl acetate was added to 100 µl of plasma for protein 
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precipitation. The mixture was vortexed for 15 seconds and centrifuged for 20minutess 
at 12000 x g. The supernatant was removed carefully without disturbing the pellets and 
dried under nitrogen in a glass test tube. The extract was suspended in 100µl ACN, 
vortexed, sonicated for 10 minutes and transferred to HPLC vials with low-volume 
inserts for injection. For plasma standards, the 100µl of the blank plasma was spiked 
with 10µl of ACN standards and extracted following the same method as above.  
The LC/MS-MS system consisted of HPLC Waters Alliance 2695 Separations 
Module, Waters Micromass® Quattro MicroTM API Tandem Mass Spectrometer and 
Masslynx Chromatography software with Waters Quanlynx (V. 4.1) analysis software. A 
Waters Atlantis Silica HILIC column (5µ, 150 x 2.1mm) and guard column (10 x 2.1mm) 
were used for LC separation. The mobile phase composition was methanol with 0.1% 
acetic acid: 20mM ammonium acetate =95:5, the flow rate was 0.5ml/min and positive 
mode atmospheric pressure chemical ionization was used for detection of NTX  (APCI+). 
Multiple reaction monitoring (MRM) was carried out with the following parent to daughter 
ion transitions for NTX•H l m/z 341.8→323.8. The corona voltage was 3.5 μA, cone 
voltage 25 V, extractor 2 V, RF lens 0.3 V, source temp 130 °C, APCI probe temperature 
575 °C. The collision gas was 20 eV. Nitrogen gas was used as a nebulization and 
drying gas at flow rates of 50 and 350 l/h, respectively. Injection volume was 40µl. 
8.2.6 Pharmacokinetic analysis 
The plasma concentration vs. time data obtained using the MS were modeled by 
fitting data to a non-compartmental model with extravascular output (WinNonlin 
Professional, version 4.0, Pharsight Corporation, Mountain View, California) to obtain 
pharmacokinetic parameters like area under the curve (AUC), maximum concentration 
(Cmax) and time to maximum concentration (Tmax).  
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8.2.7 Reversibility/recovery of pores 
The reversibility/recovery of the pores following removal of occlusion was studied 
using transepidermal water loss (TEWL) in a HGP model.  Five different sites were 
chosen on the dorsal region of an animal. The treatment sites were site 1: 
MN+NTXgel+FLU (200 proof ethanol), site 2: MN+NTX gel+200 proof ethanol, site 3: 
MN+placebo gel, site 4: no MN treatment+ placebo gel and site 5: occlusion only. All 
sites were marked and cleaned on the day of the treatment. Sites 1,2 and 3 were treated 
twice, with 50 MN arrays (620µm), (the two treatments being mutually perpendicular to 
each other to give a total of 100 non overlapping insertions) and TEWL readings were 
obtained before and immediately following treatment at all sites using a TEWL 
evaporimeter (cyberDERM, Media, PA). The concentration and amount of NTX gel and 
FLU were consistent with the PK studies. A placebo gel was used for site 3 and site 4. 
The placebo gel was similar in composition to the NTX gel with 10% PG, 1% benzyl 
alcohol and 3% HEC as the gelling agent. Forty µl of the 1.5% FLU in ethanol or 200 
proof ethanol was applied to the treated skin at site 1 and 2, respectively and 300µl of 
NTX/placebo was applied to sites 1-4. All sites were occluded using a transdermal patch 
147 secured in place with Bioclusive™ tape. The occlusive patch was removed after 7 
days and TEWL measurements were obtained for 30-45min at all sites or until values 
returned to baseline (pretreatment values). All experiments were conducted at least in 
triplicate.  
8.2.8 Skin irritation 
 Local skin irritation can be one of the major drawbacks of topical/transdermal 
delivery, so irritation studies were conducted to look at the effect of local FLU treatment 
of the skin in HGP. The studies were conducted using the same treatment groups as the 
recovery studies. Colorimeter (Chroma Meter CR-400, Konica, Minolta, Japan) readings 
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were obtained, in triplicate, at each site before and immediately after the treatment. The 
data was used to record changes in the color of the skin from baseline based on 3 
different color axes, the red-green axis (a*), the black-white axis (L*) and the yellow-blue 
axis (b*). The sites were then occluded for 7 days and readings were obtained after 
removal of occlusion. The degree of redness of the skin or the change in erythema of the 
skin was measured by the change in the red green axis (Δa*) values. Skin irritation 
studies were conducted in triplicate. 
8.2.9 Staining/ pore visualization studies 
 Pore visualization studies were carried out to look at the pores on the skin 
following treatment with FLU. Two sites were used on the same animal for these studies. 
Site 1: MN + NTX gel +FLU (200 proof ethanol) and site 2: MN : NTX gel+ 200 proof 
ethanol. The amount and concentration of all gels were consistent with the other studies. 
The skin was occluded for 7 days following treatment. Gentian violet was used to stain 
the skin after removal of the occlusive patch. The dye stains viable epidermis and not 
SC, so a grid can be clearly visualized for MN treatment/ presence of micropores in the 
skin, whereas no staining can be observed on skin with intact SC. 
8.2.10 Statistical analysis  
 Data for all experiments are reported as mean ± standard deviation. Statistical 
analysis of data was carried out with Students’ t-test and one way ANOVA with post hoc 
Tukey’s pairwise tests, if required, using GraphPad Prism® software, version 5.04 
software. P<0.05 was considered to be statistically significant. 
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8.3 Results  
8.3.1 HPLC assay  
 NTX and FLU were quantified in ACN for skin samples and receiver samples 
from diffusion using HPLC. The retention times were 2.2 minutes and 3.2 minutes for 
NTX and FLU, respectively. All retention times are reported ±0.1 minutes. All standard 
curves were linear in the range of 100-10,000ng/ml, r2>0.99. 
8.3.2 Diffusion studies 
 The in vitro diffusion studies were carried out to optimize the formulations for in 
vivo studies. All formulations for FLU were chosen based on previous publications on 
skin recovery following FLU treatment. The NTX was formulated in 10% PG containing 
formulation because concentrations higher than 10% of PG have been shown to 
decrease flux across MN treated skin significantly. 146 The in vitro results indicated that 
there was no significant difference in flux across MN treated skin among the 5 different 
treatment groups (p>0.05). The skin concentration data indicated that there was no 
significant difference in the concentration of NTX or FLU in the skin irrespective of the 
method of FLU deposition (p>0.05). Ethanol (200 proof) was chosen as the vehicle for 
FLU deposition from these studies. 
8.3.3 Pharmacokinetic studies 
The pharmacokinetic studies were carried out to evaluate the effect of FLU 
treatment on micropore closure in vivo in a HGP model. The three treatment groups 
were evaluated either for 168h for the treatment and vehicle control groups, or for 96h 
for MN control. The results indicated that detectable levels of NTX were present in the 
plasma for 72h for all study groups. The average plasma concentration for the MN only 
control was below 2 ng/ml beyond 58h. The plasma concentrations from vehicle control 
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treatments were below 2 ng/ml beyond 144h, and plasma concentrations for FLU 
treatment group were above 2 ng/ml throughout the range of the study. The WinNonlin 
parameters indicated that the areas under the curves (AUC) for plasma concentration 
vs. time plots were not significantly different from each other for the treatment group and 
the vehicle control group (p>0.05). There was no lag time observed with MN enhanced 
delivery in any of the three groups. There was no significant difference in maximum drug 
concentration (Cmax) among the 3 groups (p>0.05). The average plasma concentration 
was 39.2 ± 15.4 ng/ml.  Tmax or time to maximum plasma concentration was reached 
between 15 minutes and 4 hours for all studies. The standard curves in ACN and plasma 
were linear in the range on 1-75 ng/ml, r2≥0.98. 
8.3.4 Recovery studies 
 The recovery of the skin i.e. regeneration of the barrier function of the SC was 
studies using TEWL were carried out to look at the effect of the local concentration of 
FLU on the recovery/healing of the skin on removal of occlusion. The data (Figure 8.3) is 
represented as a ratio of the post treatment values to the pretreatment intact skin 
/baseline values. Values with an enhancement ratio of less than 1 were not used for the 
calculation since values below baseline indicates complete reversal of treatment. The 
recovery studies indicated that there were no significant differences among the 5 
treatment groups used for the recovery studies (p>0.05) 
8.3.5 Irritation studies 
 The irritation studies were carried out to look at the effect of local FLU treatment 
on the skin at 7 days. The data (Figure 8.4) indicated that there were no significant 
differences among the treatment groups immediately following treatment or following 
removal of the patches at 7 days following treatment (p>0.05). The established positive 
control treatment for irritation studies in HGP is 0.5% sodium lauryl sulfate solution and 
146 
 
the corresponding Δa* value is 12.3. 169 All the experimental values were significantly 
lower (p<0.05)  
8.3.6 Staining studies 
 The staining studies indicated that pores were present in the FLU treated group 
at the end of the 7 day patch application period compared to the absence of pores in the 
ethanol treated vehicle control group. In some of the studies staining was observed in 
the region surrounding the micropores for the treatment group. FLU is a known inhibitor 
of the cholesterol synthesis pathway; therefore it can influence the normal turnover of 
the intact skin in addition to the healing of the micropores. This process can lead to 
staining of the regions around the micropores.  
8.4 Discussion 
 MN enhanced transdermal delivery has been established as a safe, effective and 
pain free method for drug delivery over the last decade. However, the re-sealing of the 
micropores is a rate limiting step in effective delivery of drugs across MN treated skin for 
more than 48 hours. Pore lifetime enhancement methods have been explored in the 
literature to enhance the drug delivery window. One such method is topical application of 
Solaraze® (3% diclofenac sodium, 2.5% hyaluronic acid), a non-steroidal anti-
inflammatory drug. The hypothesis was that inhibition of the cyclooxygenase pathway 
would lead to decreased local subclinical inflammation following MN treatment, thus 
enhancing the drug delivery window. The results from impedance spectroscopy, TEWL 
and PK studies in animal models and humans indicated that daily/alternate day 
application of diclofenac allowed drug delivery for a period of 7 days compared to 2-3 
days in the absence of a pore lifetime enhancement agent in formulation, following MN 
treatment. 8, 9, 14 However, the studies required frequent application of diclofenac, which 
is not ideal for a 7 day transdermal patch system and formulating high concentrations of 
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diclofenac at the skin surface pH of around 5 was difficult due to the physicochemical 
properties of the molecule. 
The current study was designed to evaluate the role of FLU, a lipid biosynthesis 
inhibitor, as a pore lifetime enhancement agent. Expression levels of mRNA of most 
enzymes of the lipid biosynthesis pathway are upregulated following insults to the SC 
barrier. 74 Inhibitors of these enzymes have been shown to delay barrier recovery 
following acetone or surfactant treatment. 75 Since the exact nature of barrier insult 
following MN treatment is not well established, the goal of the current study was to 
evaluate the effect of FLU as a one-time topical application on micropore healing and 
drug delivery using pharmacokinetics and TEWL for evaluation. It was believed that 
frequent reapplication or formulation issues would not arise with the FLU treatment as 
compared to diclofenac, since only very small concentrations of potent lipid biosynthesis 
inhibitors were required for previously published studies,. The hypothesis was that down 
regulation of cholesterol synthesis would lead to delay in barrier recovery and enhance 
the drug delivery window. FLU (M.W. 411.47, log P 4.6, pKa 4.27) was chosen over 
other lipid biosynthesis inhibitors because it is a well-known statin drug and the dosage, 
metabolism, pharmacokinetics and toxicity profile is well established in humans. 16, 19 
The lowest therapeutically relevant oral daily dose is 20 mg and the oral bioavaibility is 
9-50%. 16 Therefore, even if the bioavaibility is 100% from the topical formulation, the 
maximum delivered dose would be 1.2 mg over 7 days, which is significantly below the 
therapeutic dose. In comparison, TOFA and β-chloroalanine are investigational drugs 
with very limited data being available. 
 Optimization of formulation for in vivo studies was required in order to maximize 
FLU skin concentration and NTX flux. Four different methods were chosen for FLU 
deposition. The results indicated that there was no significant difference in NTX flux or 
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skin concentration of FLU using any of the deposition methods. Ethanol (200 proof) was 
chosen for in vivo studies because it is a frequently used topical excipient and most of 
the 40 µl ethanol used was allowed to evaporate before application of the drug gel. 
Acetone is similar in action to ethanol; however it caused irritation in the MN-treated 
animal models (data not shown) and thus was not used for in vivo studies. The other two 
formulations tested contained either 70% or 25% PG. PG has been shown to interact 
with the underlying dermis and microchannels in MN treated skin. 146 The high viscosity 
of PG rich formulations significantly decreased flux across MN treated skin, as compared 
to an aqueous formulation. 22 The formulations also contained large amounts of ethanol, 
a known permeation enhancer, and evaporation of the ethanol from these was not as 
efficient due to the presence of PG. Solubility of FLU was not an issue with any of the 
formulations. Therefore, 40 µl of 1.5% FLU in 200 proof ethanol was chosen as the 
vehicle for FLU deposition for all in vivo studies. Ethanol is a well-known chemical 
enhancer used in the topical/transdermal industry. It acts by replacing the water 
molecules in the lipid polar head groups as well as the protein regions of the SC, thus 
enhancing free volume and permeability of molecules across the skin. 69 Therefore, a 
control was used in PK, recovery and irritation studies to evaluate the effect of ethanol 
alone on micropore lifetime.  
 PK studies are the most direct measure of drug delivery and micropore closure. 
Three different groups were evaluated to look at the effect of FLU in ethanol and MN, 
ethanol only and MN, and MN only in HGP. A non-MN treated control was not evaluated 
for animal studies since it is known that permeation of ionized species like NTX HCl is 
limited across the intact SC. The PK data indicated that for the MN only control, plasma 
concentration dropped below 2 ng/ml beyond 58h. This data is in agreement with 
previously published pharmacokinetic data where the drug delivery window following one 
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time application of MN has been shown to be between 48-72 hours. 4, 8 The treatment 
group showed NTX levels above 2 ng/ml for the entire length of the study, as compared 
to the vehicle control group which showed levels above 2 ng/ml until 144hours. The AUC 
values for the treatment group and the vehicle control group were not significantly 
different from each other indicating that ethanol treatment alone also enhanced the drug 
delivery following MN treatment. As mentioned before, ethanol is a known permeation 
enhancer used in passive transdermal delivery. However, the role of ethanol has never 
been evaluated in MN enhanced delivery. Since an intact skin control with ethanol 
treatment was not evaluated in the current study, it is difficult to assess the exact 
mechanism via which the drug delivery window was enhanced. A direct comparison is 
difficult because evaluations of NTX plasma concentrations resulting from delivery of 
NTX HCl across intact skin are limited by the LLOQ of the LCMS-MS assay. The Cmax 
and Tmax values indicated that treatment of all animals were consistent across the 
treatment groups. Drug was quantified in plasma within 15 minutes of treatment 
indicating that there is no significant lag time associated with the patch system. Such 
profiles are commonly observed for MN treatment and immediate delivery in addition to 
sustained release is one of the advantages of such a delivery system. The shape of the 
plasma concentration time curve is consistent with reported profiles of MN enhanced 
delivery, where a peak is observed immediately following patch application followed by a 
decline in the plasma concentration due to re-sealing of the micropores. Such data can 
be modeled using a 3 compartment model for drug permeation across skin, 
pharmacokinetics of the drug in the body, and healing of the micropores. 146 Rate of 
micropore re-sealing in the presence of an active pore lifetime enhancement agent can 
then be estimated if permeation values are known from in vitro studies and PK estimates 
are obtained from in vivo studies. Thus from the PK studies it can be concluded that both 
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FLU and an ethanol vehicle can be used to enhance the drug delivery window, however 
the exact mechanism of ethanol action is not known. 
 Recovery of the skin i.e regeneration of barrier function and irritation of skin 
following local application of biochemical inhibitors and permeation enhancers are 
important aspects during development of transdermal delivery systems for chemical 
enhancement techniques. 66, 67  Therefore, recovery of the skin following removal of 
treatment at 7 days was monitored using TEWL. Five sites were compared for the 
recovery and irritation studies. In addition to the treatment group and vehicle control, site 
3 was used to evaluate the role of the NTX gel, site 4 was used to evaluate the effect of 
MN treatment, and site 5 was only occlusion used to control for TEWL enhancement at 
all sites due to occlusion alone. There was no significant difference among the sites 
following removal of treatment or at any of the later time points indicating that recovery 
of the skin was not influenced by the presence of FLU or ethanol. Recovery of the skin 
was expected, since removal of occlusion leads to increased TEWL across disrupted 
SC, which in turn acts as one of the major signals for lamellar body release and skin 
healing. 94 Irritation data also indicated that there was no significant difference among 
the sites and Δa* values, and all sites were much lower compared to the positive control 
in HGP, the most sensitive model for skin irritation for transdermal and topical studies. 
 The staining studies were conducted to visualize the micropores at the end of the 
7 day period. The studies were used as a visualization technique for presence of 
micropores for correlation with PK data. The studies indicated that micropores could be 
visualized in FLU treated groups; however they were not present for the ethanol control 
group at 7 days. NTX concentration in the plasma of the ethanol treated group was 
<2ng/ml at 7 days probably indicating that micropores had re-sealed by that time. A time 
dependent study for the ethanol treated group with time points on day 5 and 6 in addition 
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to day 7 would help with better correlation of pore visualization to the PK data. The FLU 
treated group showed additional staining in the regions between the micropores. 
Cholesterol is required for the normal turnover process of the SC in addition to healing. 
Thus it might be possible that local application of the inhibitors decreased cholesterol 
synthesis in the entire treated region leading to malformation of the barrier. However this 
should not be of additional concern for FLU treatment because both recovery and 
irritation studies indicated that there was no significant effect of the treatment following 
removal among the groups. 
 Thus overall the FLU in ethanol treatment was effective in enhancing the drug 
delivery window of NTX but the exact role of ethanol and FLU could not be evaluated in 
this study. Further, pretreatment with MN and FLU before application of the NTX gel is a 
three step process which is not practical outside a clinic setting. Therefore further 
optimization of formulation is required for incorporation of NTX and FLU into a single 
formulation. The other inhibitors of the lipid biosynthetic pathway in addition to FLU could 
be evaluated separately or in combination to understand their role in micropore lifetime 
enhancement. Synergistic effects of enhancement strategies and inhibitors have been 
reported previously.  
8.5 Conclusion 
  The current study was conducted to evaluate the role of FLU as a pore lifetime 
enhancement agent. The data indicated that FLU pretreatment allowed delivery of 
therapeutically relevant NTX for 7 days while treatment with the ethanol vehicle allowed 
delivery upto 5 days. Recovery of the skin following removal of treatment and irritation 
issues due to local application of FLU were not significant with the current drug delivery 
system. Staining studies further confirmed the presence of micropores on the skin at 7 
days for the FLU treatment. Thus in conclusion, FLU in ethanol was effective in 
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enhancing micropore lifetime, however the exact mechanism of enhancement could not 
be clearly evaluated from the current studies, and further evaluation is needed. 
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Table 1:  WinNonlin parameters from pharmacokinetic studies 
 
Treatment group Vehicle control MN control 
C
max
 (ng/ml) 38.1 ± 19.7 39.3 ± 19.2 39.4 ± 11.5 
T
max
 (h) 2.7 ± 3.8 1.4 ± 1.7 2.8 ± 2.0 
AUC (ng*h/ml) 
(time for AUC 
calculation) 
1411.1 ± 1040.5 
(146.7 ± 24.4) 
1696.1 ± 1665.8 
(151.0 ± 25.7) 
613.5 ± 212.9 
(80.0 ± 13.9) 
C
ss
 (ng/ml) 9.3 ± 5.6 11.1 ± 9.7 7.5 ± 1.5 
n 3 4 3 
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Figure 8.1 Formulation optimization for application of FLU along with NTX gel. 
Flux of NTX across MN treated skin (top panel), skin concentration of NTX and DIC 
across MN treated skin (bottom panel). n≥3 for all studies except control NTX. 
p>0.05 for flux and skin concentration data among all groups.  
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Figure 8.2 NTX plasma concentrations in HGP following application of MN and 
FLU, MN and vehicle control or MN only. Full profile (top panel) and later 
timepoints (bottom panel). n≥3 for all studies. The data indicated that there was no 
statistical difference in AUC between the FLU treated group and vehicle control group. 
Plasma concentration was below 2ng/ml for vehicle control group beyond 144 hours. 
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Figure 8.3 Recovery of skin following 7 day treatment with FLU using TEWL. 
Measurements were obtained before, immediately following treatment and after 
removal of patches at 7 days. n=3. Data is presented as a ratio of TEWL enhancement 
over baseline.p>0.05 among all sites 
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Figure 8.4 Change in erythema of the skin following 7 day treatment with FLU 
using colorimetry. Measurements were obtained before, immediately following 
treatment and following patch removal at 7 days. n=3, p> 0.05 among all sites. 
Positive control for skin irritation is from 169 
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Figure 8.5 Gentian violet staining in HGP at 7 days following treatment with 1.5% 
FLU in 200 proof ethanol (A) and (B) or 200 proof ethanol only (C). The images 
show that pores can be visualized at 7 days following FLU treatment in HGP while 
staining of pores cannot be visualized in the ethanol control 
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Chapter 9 
Conclusions and future directions 
 The overall goal of the project was to optimize formulation for sustained drug 
delivery across microneedle (MN) treated skin. Naltrexone (NTX) has been used as the 
model compound to optimize drug delivery following the “poke and patch” method of MN 
treatment. Currently, NTX can be delivered across MN treated skin for 48-72 hours 
under occlusion and up to 7 days using daily/alternate day topical application of 
Solaraze®. NTX is used for alcohol and opioid addiction and a 7 day transdermal patch 
system could be beneficial for such treatment. Since NTX doesn’t permeate at a 
therapeutic rate through intact skin, MN has been used as a physical enhancement 
technique. The project was focused on optimizing formulation for extending the 
micropore lifetime following one time application of MN. 
 Three different strategies were investigated in the current project. The first 
strategy was to utilize the pH of the formulation for extending micropore lifetime and 
enhancing transport across MN treated skin. The effect of pH on micropore healing was 
evaluated using impedance spectroscopy. Although, pharmacokinetic studies provide 
the most direct measurement of drug delivery/ micropore healing, such studies are time 
consuming and expensive. Impedance spectroscopy is an alternative technique where 
resistance drop across the skin or impedance of the skin is used as a surrogate marker 
for measurement of the barrier properties of the skin. Earlier studies have shown that 
when the “acid mantle” of the skin barrier is destroyed following insult, recovery of the 
skin is delayed at pH 7.4 compared to pH 5.5. 18 The results can be explained in terms of 
the reduced activity of β-glucocerebrosidase, an important enzyme of the ceramide 
biosynthetic pathway. However, the exact nature or depth of injury following treatment 
with MN (of the specific geometry) is not very well understood. Thus it is not known 
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whether the “acid mantle” is actually destroyed following MN treatment and the time 
frame associated with the process. Impedance measurements over a period of 100 
hours following MN treatment indicated that there were no significant differences in the 
rate of micropore healing at pH 5.5, pH 6.5 and pH 7.4 after the initial 24 hours. Since 
the goal was to extend micropore lifetime for up to 7 days, formulation pH cannot be 
used to achieve the desired results. There could be several factors influencing the 
results of these studies. In previously reported studies in the literature, the nature of the 
skin insult was different. Tape stripping or acetone treatment was used to destroy the 
barrier properties of the skin, and measurements were obtained up to a maximum of 24 
hours following insult. 18 Thus it is possible that for MN treatment, either the “acid 
mantle” is not destroyed or its properties are recovered within the first few hours due to 
rapid release of the lamellar body contents, and thus no long term effects of formulation 
pH are observed on healing of the micropores. 
 Formulation pH was also used to evaluate the role of ionization state of the 
molecule on transport across MN treated skin compared to intact skin. NTX is a weak 
base and the most acidic pKa of NTX is 7.5.. Flux of NTX base was compared from 6 
different pH values (pH 5.76, pH 6.30, pH 6.43, pH 6.72, pH 7.56, pH 8.26) across MN 
treated skin. The results indicated that a lower pH formulation led to significantly higher 
flux values across MN treated skin; however there was no significant difference in flux 
across intact skin. Thus the rate limiting step for delivery of drugs in MN enhanced 
delivery is the drug concentration in the formulation and not the lower layers of the skin. 
This is different from intact skin delivery where the stratum corneum (SC) is the rate 
limiting step in delivery of most molecules, and the lower layers of the skin are rate 
limiting only for highly lipophilic molecules (generally log P>5). Further analysis of flux 
via the microchannel pathway and the intact skin pathway (skin surrounding the MN 
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pores for MN treatment) indicated that as the unionized component of the drug 
increased in formulation with increase in pH, the contribution of the MN pathway flux 
towards total flux also decreased. This indicates that when a completely ionized 
molecule is used for transport across MN treated skin; transport is mostly via the 
aqueous/porous pathway created in the skin due to MN treatment. However when a 
unionized molecule is used, transport takes place via the intact skin surrounding the MN 
treatment and there is no significant difference in the flux across MN treated skin vs. 
intact skin. This is important for formulation of molecules for MN enhanced drug delivery 
systems since the advantage of MN is only obtained when permeation takes place 
through the MN pathway, in addition to the intact skin pathway to generate the increased 
total flux. Permeability calculation indicated that there were no significant difference in 
permeability across the pH range for MN treated skin, permeability increases with 
increase in pH (decreased ionization) for NTX across intact skin. Thus the enhanced flux 
at lower pH values is due to enhanced solubility of the ionized drug in an aqueous 
formulation. Modeling of the permeability data using permeability of the ionized and 
unionized form of the drug across the microchannel pathway and intact skin pathway 
allows for better understanding of the transport, and contribution of each species 
towards total flux. The models can be further used to calculate permeability of a host of 
drug molecules across the pH range if the pKa, intrinsic solubility, and permeability of 
the ionized form across the MN pathway are known. This would help in reducing wet lab 
experiments and facilitate faster optimization of formulation for MN-enhanced and intact 
skin delivery. 
 The second approach was to use codrugs of NTX/naltrexol (NTXol) and 
diclofenac (DIC). Solaraze® (3% diclofenac sodium, 2.5% hyaluronic acid) has been 
used in previous studies to show that local application of Solaraze® can be used to 
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extend micropore lifetime for up to 7 days following MN treatment. However, DIC is an 
acid with a pKa of 4.2 and solubility of DIC is low around the formulation pH of 5 for 
NTX. Precipitation is observed on top of the skin on co-application of NTX and 
Solaraze®. Such precipitation reduces the permeation of NTX across micropores which 
in turn decreases the plasma concentration of the drug. Additionally, daily/alternate day 
application of Solaraze® was required for therapeutic efficacy which is not ideal for a 7 
day transdermal patch system. In order to solve the drug delivery issue codrugs were 
designed and evaluated for therapeutic efficacy in vitro and in vivo. A NTX-DIC ester 
codrug (codrug I) was used for proof of concept studies to evaluate bioconversion of 
codrug in the skin, permeation of NTX and local skin concentration of DIC. The results 
indicated that the codrug bioconverted in the skin to regenerate parent drugs but the flux 
of NTX from the codrug was not high enough so a hydrochloride salt form was used to 
enhance flux, since it is known that ionized molecules with higher aqueous solubility lead 
to enhanced flux across MN treated skin. A proof of concept hairless guinea pig (HGP) 
staining study was used to show that micropores were present on the skin at the end of 
7 days using the codrug, indicating that the codrug strategy could potentially be used for 
drug delivery. However, the codrug had a short half-life and significantly lower flux 
compared to the most optimized NTX formulation, so structure optimization was required 
for better stability and flux enhancement. 6-β NTXol, the active metabolite of NTX, was 
used along with NTX to design codrugs along with amide and carbamate linkages for 
better stability. A polyethylene glycol (PEG) chain was used to link the molecules where 
direct linkage was not possible, to further enhance solubility. The results from 4 codrugs 
synthesized indicated that all codrugs bioconverted in the skin, and the NTX codrugs 
were less stable due to the phenolic linker compared to the secondary alcohol linker 
used for the NTXol codrugs. However, permeation studies across Yucatan miniature pig 
(YP) skin showed that permeation of NTXol from codrugs was significantly lower 
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compared to NTX codrugs, and parent drugs were not quantified in the skin for the 
NTXol codrugs. Since the presence of diclofenac from the codrug in the epidermal 
region of the skin is imperative to the therapeutic efficacy of codrugs, only NTX codrugs 
from the current design can be used for development of a drug delivery system. Skin 
concentration of DIC was lower from codrug III (amide/carbamate PEG linked codrug) 
compared to codrug I, and subsequent investigation indicated that complete 
bioconversion of the amide linkage did not take place in the skin. Codrug III HCl salt was 
further evaluated to maximize flux and future studies for the project would include in vivo 
pharmacokinetic studies with codrug III HCL salt. Optimization of the linker at the DIC 
end of the codrug molecule might be necessary for faster release of DIC, if the current 
skin concentration is not optimum for keeping the micropores open for a 7 day period 
following one time application of MN. Further modification of formulation might also be 
necessary to retain DIC in the skin longer, since hyaluronic acid (HA), the excipient used 
in Solaraze®, facilitates retention of DIC in the upper layers of the skin. It has been 
shown that HA alone is not responsible for extending micropore lifetime, but the effect of 
HA in the DIC formulation is not clearly understood yet. 9  
The third strategy was development of a topical/transdermal system using small 
quantities of fluvastation (FLU), an inhibitor of the cholesterol synthesis pathway, as a 
topical application followed by transdermal delivery of NTX. A constant molar ratio of the 
essential SC lipids-cholesterol, fatty acid and ceramide is imperative to the proper 
formation of the SC barrier. Inhibitors of the metabolic pathways have been shown to 
decrease synthesis of the SC lipids or inhibit their extracellular processing, thus leading 
to malformation of the SC barrier following insult. 75 The main advantage of this strategy 
over DIC is the fact that very small concentrations (40 µl, 0.5-1.5%) of inhibitors have 
been used to show efficacy in previously reported studies using alternate methods of 
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barrier disruption. Different deposition methods were used to evaluate the effect of 
topical application of FLU on flux of NTX across MN treated skin. Ethanol (200 proof) 
was chosen as the vehicle for FLU deposition for in vivo pharmacokinetic studies, 
irritation and recovery studies. The choice of vehicle was based on ease of application of 
drug in an ethanol based vehicle, PG containing vehicles were not used due to effect of 
PG on flux across MN treated skin.The pharmacokinetic data indicated that local 
application of FLU allowed NTX delivery across MN treated skin for 7 days. Topical 
application of ethanol alone as a vehicle control also enhanced transport of NTX and 
extended micropore lifetime compared to NTX only control animals for up to 5 days, 
however it was not effective in delivery of NTX in therapeutically relevant concentration 
for 7 days. Ethanol is a known permeation enhancer thus increased permeation of NTX 
in presence of ethanol was expected, however the exact mechanism of action could not 
be elucidated from the current study. There was also no significant difference in area 
under the plasma concentration vs. time curve (AUC) between the treatment group and 
the vehicle control group. This can be attributed to the huge variability associated with 
the study and the limited animals per group. Recovery of the skin following removal of 
treatment was monitored to ensure that local application of inhibitors did not lead to a 
permanent effect on skin/micropore healing. The results indicated that there was no 
significant difference in recovery of the barrier function following removal of treatment 
between inhibitor treated sites and controls. Irritation due to inhibitor as well as ethanol 
application was also a concern. Colorimetric studies were used to evaluate the 
redness/irritation potential of the skin. Results indicated that there was no significant 
irritation due to topical application of the inhibitor. Staining studies were conducted to 
visualize micropores following 7 day patch application period. Gentian violet staining 
indicated that ethanol did not keep the pores open for 7 days; however micropores were 
visible for FLU treated sites. The skin around the micropores also exhibited nominal 
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staining in the FLU treated group indicating that presence of topical inhibitors influence 
the normal turnover process of the skin in the region between the micropores, in addition 
to the micropores. However this did not lead to any irritation in HGP, the most sensitive 
model, so should not be of concern for development of a drug delivery system.  
 Inhibitors of the other pathways of lipid synthesis can also be used to enhance 
micropore lifetime. Some examples include TOFA for fatty acid synthesis and β-
chloroalanine for ceramide synthesis. Concentration of the inhibitors as well as the 
application method can be further optimized to enhance the effect. A three-step 
application process for a transdermal patch system is not patient friendly outside a clinic 
setting, thus further optimization of formulation is also required to incorporate NTX and 
the lipid biosynthesis inhibitors in a single formulation. 
 Thus, overall the current research investigated three different mechanisms for 
micropore lifetime enhancement and sustained NTX delivery. Formulation pH can be 
used to maximize NTX transport however a higher pH formulation was not useful for 
enhancement of micropore lifetime. The codrug approach can be used for NTX delivery 
across the MN treated skin for up to 7 days. Future pharmacokinetic studies with codrug 
III salt will further validate the efficacy of the drug delivery system. Topical application of 
lipid biosynthesis inhibitors, such as FLU, can also be used to deliver NTX for 7 days. 
Further optimization of the application process is required to decrease variability in the 
data. 
 The current research was conducted using NTX as the model compound. 
Although development of a 7 day transdermal system for NTX is important, one of the 
major areas where MN delivery can provide a huge advantage is delivery of 
macromolecules, like proteins and peptides. Protein and peptide therapeutics are quickly 
becoming the first line of treatment for a host of diseases. 170,171 One of the major issues 
in development of protein therapeutics is that oral delivery of these compounds is almost 
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impossible due to the fact that the gastrointestinal tract is designed for degradation of 
proteins. The chemical and biochemical challenges involved in oral delivery include acid 
hydrolysis in the stomach, enzymatic degradation in the intestine and bacterial 
fermentation in the colon. 172 The physicochemical characteristics of these 
protein/peptide drugs, including molecular weight and hydrophillicity, prevent effective 
transport across the intact skin by passive delivery. Therefore, several protein drugs 
have been evaluated for transdermal drug delivery using physical enhancement 
techniques like iontophoresis, ultrasound, etc. Some examples include calcitonin, 
vasopressin and insulin. 173,41 MN will thus be an excellent alternative method for delivery 
of macromolecules. Recent studies have evaluated short term macromolecule delivery 
using MN to establish efficacy. Parathyroid hormone (PTH) therapy using MN has been 
shown to be effective in phase 2 clinical trials. 57 Thus translating our current 
understanding of MN enhanced delivery of small molecules to macromolecules will be 
beneficial towards the development of the field. One unique aspect of MN enhanced 
transdermal delivery of the macromolecules is the spike in the plasma concentration 
profile. A steady state plasma profile is usually associated with passive delivery. The 
peak in the plasma concentration has been attributed to lymphatic uptake of 
macromolecules, compared to systemic uptake of small molecules. 56 It will be 
interesting to study the effect of micropore healing in addition to lymphatic uptake on 
plasma concentration for long term delivery of macromolecules across MN treated skin.  
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Appendix I 
Synthetic schemes for codrugs 
Synthetic scheme for codrug I 
 
 
 
 
Synthetic scheme for codrug II 
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Synthetic scheme for codrug III and codrug III HCl salt 
 
Synthetic scheme for codrug IV  
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Appendix II 
Assay development for HPLC and LCMS/MS 
 
HPLC assay for naltrexone, diclofenac and codrugs 
Naltrexone (NTX), diclofenac (DIC) and codrug concentrations in all samples 
were quantified using a high pressure liquid chromatography (HPLC) assay, using a 
modified version of the previously reported NTX assay. 22 The HPLC system consisted 
of a Waters 717 plus auto-sampler, a Waters 600 quaternary pump, and a Waters 2487 
dual wavelength absorbance detector with Waters Empower™ software. A Perkin Elmer 
Brownlee™ Spheri 5 VL C18 column (5 µ, 220 x 4.6 mm) and a C18 guard column (15 x 
3.2 mm) were used with the UV detector set at a wavelength of 280 nm. The mobile 
phase consisted of 70:30 (v/v) ACN: (0.1% TFA with 0.065% 1-octane sulfonic acid 
sodium salt, adjusted to pH 3.0 with TEA aqueous phase). Samples were run at a flow 
rate of 1.5 ml/min. The injection volume used was 25µl for receiver samples and 100µl 
for the skin disposition samples. The retention times for all compounds are reported in 
Table 7.1. All retention times reported are value ± 0.1 minute. Standard curves for both 
codrugs and parent drugs were prepared in the range of 100-10,000 ng/ml for ACN 
samples and 100-5000 ng/ml for extracted receiver samples. The standard solutions 
exhibited excellent linearity over the entire concentration range employed in the assays, 
r2 >=0.99 
LCMS/MS assay for NTX 
Plasma samples were extracted using a previously validated method. 146 Five 
hundred µl of 1:1 ACN: ethyl acetate was added to 100 µl of plasma for protein 
precipitation. The mixture was vortexed for 15 seconds and centrifuged for 20 minutess 
at 12000 x g. The supernatant was removed carefully without disturbing the pellets and 
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dried under nitrogen in a glass test tube. The extract was suspended in 100µl ACN, 
vortexed, sonicated for 10 minutes and transferred to HPLC vials with low-volume 
inserts for injection. For plasma standards, the 100µl of the blank plasma was spiked 
with 10µl of ACN standards and extracted following the same method as above.  
The LC/MS-MS system consisted of HPLC Waters Alliance 2695 Separations 
Module, Waters Micromass® Quattro MicroTM API Tandem Mass Spectrometer and 
Masslynx Chromatography software with Waters Quanlynx (V. 4.1) analysis software. A 
Waters Atlantis Silica HILIC column (5µ, 150 x 2.1mm) and guard column (10 x 2.1mm) 
were used for LC separation. The mobile phase composition was methanol with 0.1% 
acetic acid: 20mM ammonium acetate =95:5, the flow rate was 0.5ml/min and positive 
mode atmospheric pressure chemical ionization was used for detection of NTX  (APCI+). 
Multiple reaction monitoring (MRM) was carried out with the following parent to daughter 
ion transitions for NTX•H l m/z 341.8→323.8. The corona voltage was 3.5 μA, cone 
voltage 25 V, extractor 2 V, RF lens 0.3 V, source temp 130 °C, APCI probe temperature 
575 °C. The collision gas was 20 eV. Nitrogen gas was used as a nebulization and 
drying gas at flow rates of 50 and 350 l/h, respectively. Injection volume was 40µl. 
Standard curves were prepared in the range of 1-50 ng/ml for ACN samples and 
extracted plasma samples. The standard solutions exhibited excellent linearity over the 
entire concentration range employed in the assays, r2 >=0.98 
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Figure II.1 Sample chromatograms for NTX, DIC and codrugs on HPLC 
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Figure II.2 HPLC standard curves of NTX and DIC in ACN. n=3 for all concentrations    
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Figure II.3 Sample HPLC standard curves of codrugs in ACN 
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Figure II.3 Sample LCMS/MS standard curves of NTX in ACN and HGP plasma 
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